US Pat. No. 10,392,578

EXTRACTION OF LIPID FROM CELLS AND PRODUCTS THEREFROM

DSM IP Assets B.V., TE H...

1. An extracted microbial lipid comprising a triglyceride fraction of at least 70% by weight of the lipid fraction, wherein the docosahexaenoic acid content of the triglyceride fraction is at least 50% by weight, wherein the docosapentaenoic acid n-6 content of the triglyceride fraction is from at least 0.5% by weight to 6% by weight, and wherein the oil has an anisidine value of 0.5 to 26, and wherein the lipid has less than 5% by weight of an organic solvent.

US Pat. No. 10,392,576

COATED SLIDING MEMBER

KABUSHIKI KAISHA RIKEN, ...

1. A coated sliding member for use under an environment where it is in contact with lubricant, comprising:a base material; and a hard carbon film formed on a surface of the base material,
the hard carbon film being constituted of
a first hard carbon layer having a thickness of 3 ?m or more formed on a surface of the base material by a vacuum arc method using carbon and consisting of diamond-like carbon, when a total amount of all elements configuring the first hard carbon layer is defined as 100 atom %, a hydrogen content is 2 atom % or less, and a carbon content is 96 atom % or more, and
a second hard carbon layer formed on a surface of the first hard carbon layer by a vacuum arc method using carbon and consisting of diamond-like carbon, when a total amount of all elements configuring the second hard carbon layer is defined as 100 atom %, a hydrogen content is 2 atom % or less and a total content of carbon and nitrogen is 96 atom % or more,
the film thickness of the second hard carbon layer being 3 to 35% of the film thickness of the first hard carbon layer, and the percentage of the nitrogen represented by atom % of the second hard carbon layer is 3 to 15% with respect to a total content of carbon and nitrogen.

US Pat. No. 10,392,575

LIGNITE DRYING WITH CLOSED LOOP HEAT PUMP

General Electric Company,...

1. A dryer system for drying lignite coal for use in a power plant, the system comprising:a dryer, adapted to dry lignite coal, having:
an inlet line for direction lignite coal into the dryer;
a first outlet line for removing dried lignite coal from the dryer; and
a second outlet line for removing vapour from the dryer,
a closed loop heat pump circuit, configured and arranged to provide heat energy to the dryer, comprising:
a first working fluid;
a dryer heat exchanger in the dryer;
an expansion device fluidly connected and downstream of the dryer heat exchanger;
an evaporator heat exchanger fluidly connected to and downstream of the expansion device and further connected to the second outline line so as to enable heat energy transfer from the vapour of the second outlet line to the first working fluid; and
a compressor, fluidly connected to and downstream of the evaporator heat exchanger and at an upstream end of the dryer heat exchanger, for compressing the first working fluid; and
a pre-heater connected to the inlet line so as to enable preheating of the lignite coal before entry into the dryer, wherein the pre-heater is connected to the second outlet line downstream of the evaporator heat exchanger so as to enable the use of a remaining heat of the vapour and/or vapour condensate exiting the evaporator heat exchanger thereby preheating of the lignite coal before entry into the dryer.

US Pat. No. 10,392,574

CHARGE CARBON BRIQUETTE FOR ELECTRIC ARC STEELMAKING FURNACE

1. A non-homogeneous material composition comprising between 45 and 96 weight percent of a carbon-containing material, between 2 and 30 weight percent of calcium oxide and magnesium oxide, and between 2 and 25 weight percent of a binder material; and comprising an external surface layer of calcium magnesium silicon oxide surrounding a volume of the material composition.

US Pat. No. 10,392,572

STANDPIPE-FLUID BED HYBRID SYSTEM FOR CHAR COLLECTION, TRANSPORT, AND FLOW CONTROL

Lummus Technology Inc., ...

1. A process for recycling char to a gasification reactor, the process comprising:separating a gasification reactor effluent comprising char and syngas to produce a solids stream comprising the char and a vapor stream comprising the syngas;
feeding the char in the solids stream to a single standpipe and accumulating an amount of char within the standpipe to generate a pressure differential via the weight of the accumulated char;
recycling the char to the gasification reactor;
measuring a flow rate of the char being recycled to the gasification reactor; and
adjusting a flow rate of at least one of steam, air, oxygen, or oxygen-enriched air being fed to the gasification reactor based upon the measured flow rate of the char being recycled to the gasification reactor.

US Pat. No. 10,392,569

VACUUM GAS OIL HYDROTREATING METHODS AND UNITS

UOP LLC, Des Plaines, IL...

1. A hydrotreating process comprising:providing a vacuum gas oil stream;
heating the vacuum gas oil stream;
passing the heated vacuum gas oil stream to a hydrotreating reactor;
hydrotreating the heated vacuum gas oil stream under hydrotreating conditions and at a pressure within the range of approximately 35-50 kg/cm2g to form a hydrotreated effluent, wherein the hydrotreating reactor includes at least one catalyst bed, and further wherein said at least one catalyst bed includes an all metal catalyst in which the metal components, in the form of oxides, constitute between approximately 40-50 wt. % of the catalyst;
passing the hydrotreated effluent to a hot separator to form a gas stream and a liquid stream, wherein a pump around circuit is provided in a top section of the hot separator to remove a pump around liquid stream from an upper portion of the hot separator via a pump around line, and further wherein the pump around liquid stream is cooled to form a cooled stream, which is routed back into the hot separator;
passing the gas stream to a cold separator to form a heavy liquid stream, a light liquid stream and a vapor stream; and
passing the vapor stream to an amine scrubber.

US Pat. No. 10,392,568

SEQUENTIAL MIXING SYSTEM FOR IMPROVED DESALTING

Phillips 66 Company, Hou...

1. A desalting system for desalting crude oil comprising:a mixing valve for mixing crude oil with wash water causing at least a portion of the salt in the crude oil to dissolve into the wash water forming desalted crude oil and salty wash water;
a heater upstream of the mixing valve;
at least one feed conduit for conveying a stream of crude oil and wash water to the mixing valve;
a static mixer;
a first intermediate conduit for delivering crude oil and wash water from the mixing valve to the static mixer;
a desalter vessel for separating desalted crude oil from salty wash water;
a coalesced conduit for delivering crude oil and wash water from the static mixer to the desalter vessel;
a second static mixer spaced from and downstream of the first static mixer and connected by a second intermediate conduit and wherein the second static mixer is arranged to impose less harsh mixing on the crude oil and water mixture than the first static mixer is arranged to impose wherein the coalesced conduit is arranged between the second static mixer and the desalter vessel; and
electric field generators arranged to apply an electric field over crude oil and wash water in said first static mixer, in said second static mixer and over the second intermediate conduit;
further including the electric fields are dual polarity electric fields that include both an AC and a DC field to the crude oil and wash water.

US Pat. No. 10,392,567

CATALYSTS AND METHODS FOR CONVERTING BIOMASS TO LIQUID FUELS

Alliance for Sustainable ...

1. A method comprising:contacting an oxygenated compound and hydrogen (H2) with a solid catalyst, wherein:
the solid catalyst comprises a metal carbide comprising a transition metal and a hydrogen-activating site,
the hydrogen-activating site has a concentration between 8 ?mol/g and 132 ?mol/g, and
the contacting converts at least a portion of the oxygenated compound to a deoxygenated compound.

US Pat. No. 10,392,565

CONVERSION OF BIOMASS BY EFFICIENT BASE-CATALYZED DECARBOXYLATION REACTION

Savannah River Nuclear So...

1. A method for converting a biomass feedstock to a product comprising liquid hydrocarbons, the method comprising:combining a biomass feedstock, a base, and a solvent to form a reaction mixture;
heating the reaction mixture to a decarboxylation reaction temperature, forming a carbon dioxide byproduct and a product comprising liquid hydrocarbons through a decarboxylation reaction, and reacting the base with the carbon dioxide byproduct to form a carbonate through a carbonate formation reaction;
wherein the reaction mixture comprises excess base and over the course of the entire decarboxylation reaction and the entire carbonate formation reaction, the reaction mixture is not completely vaporized and the reaction mixture has a pH of greater than 14.

US Pat. No. 10,392,564

PROCESS FOR PRODUCING BIO-PRODUCTS FROM BIOMASS USING ROTARY COMPRESSION UNIT

Enginuity Woldwide, LLC, ...

1. A method of producing bio-products from starting biomass materials, the method comprising the steps of:providing a starting biomass material comprising a moisture-containing or water-laden material;
producing friction and compression to generate a desired elevated temperature and steam from bound and unbound water within the starting biomass material;
mixing and heating the starting biomass material resulting from the steam that is formed from increased friction and pressure such that the biomass flows evenly onto itself;
removing the bio-product;
cooling the bio-product; and
collecting the bio-product.

US Pat. No. 10,392,563

COKE OVEN WITH IMPROVED EXHAUST GAS CONDUCTION INTO THE SECONDARY HEATING CHAMBERS

THYSSENKRUPP INDUSTRIAL S...

1. A coke oven comprising:an upper oven that comprises
a coking chamber, and
a device for supplying primary air;
a lower oven disposed below the upper oven, the lower oven comprising
an exhaust gas collecting channel,
an outer sole flue and an inner sole flue for conducting gas, the outer sole flue and the inner sole flue being separated by a partition but connected via a transition region, wherein the transition region is divided into a plurality of flow channels, and
secondary air supply openings for supplying secondary air into the outer sole flue and into the inner sole flue; and
a plurality of downwardly-directed downcomer channels with openings that are configured to conduct gas out of the upper oven into the lower oven, wherein the openings are disposed along a main direction of extent of the lower oven, with a first outer opening to a first outer outside edge of the lower oven being at a distance of 0.1 m to 2.5 m as measured along the main direction of extent of the lower oven, with a second outer opening to a second outer outside edge of the lower oven being at a distance of 0.1 m to 2.5 m as measured along the main direction of extent of the lower oven,
wherein the openings in the plurality of downwardly-directed downcomer channels, the outer sole flue, the transition region, and inner sole flue, and the exhaust gas collecting channel are configured such that the gas from the upper oven is directed via the openings in the plurality of downwardly-directed downcomer channels into the outer sole flue of the lower oven, where the gas flows through the outer sole flue, is deflected in the transition region, flows through the inner sole flue, and exits the lower oven via the exhaust gas collecting channel.

US Pat. No. 10,392,562

POLYMERIZABLE LIQUID CRYSTAL COMPOUNDS, POLYMERIZABLE LIQUID CRYSTAL COMPOSITIONS, LIQUID CRYSTALLINE POLYMERS, PHASE DIFFERENCE FILM AND DISPLAY DEVICE

JNC CORPORATION, Tokyo (...

1. A polymerizable liquid crystal compound, represented by formula (1):wherein, in formula (1),W1 is independently hydrogen, fluorine, alkyl having 1 to 5 carbons, alkenyl having 2 to 5 carbons or fluoroalkyl having 1 to 5 carbons,
A1 is independently 1,4-phenylene, 1,4-cyclohexylene or naphthalene-2,6-diyl, and in the rings, at least one hydrogen may be replaced by fluorine, chlorine, trifluoromethyl, alkyl having 1 to 5 carbons, alkoxy having 1 to 5 carbons, alkoxycarbonyl having 1 to 5 carbons or alkanoyl having 1 to 5 carbons,
Z1 is independently —CH2CH2—, —COO—, —OCO—, —CH2O—, —OCH2—, —OCH2CH2O—, —CH?CHCOO—, —OCOCH?CH—, —CH2CH2COO—, —OCOCH2CH2—, —CH2CH2OCO— or —COOCH2CH2—,
m and n are independently an integer from 0 to 7, with the provisio that m+n is greater than or equal to 3 and less than or equal to 8,
Y1 is independently a single bond, —O—, —COO—, —OCO— or —OCOO—,
Q1 is independently an single bond or alkylene having 1 to 20 carbons, and in the alkylene, at least one piece of —CH2— may be replaced by —O—, —COO—, —OCO—, —CH?CH— or —CH?CH—, and
PG is independently a functional group represented by any one of formula (PG-1) to formula (PG-9):
wherein, in formula (PG-1) to formula (PG-9), R1 is independently hydrogen, halogen, methyl, ethyl or trifluoromethyl.

US Pat. No. 10,392,561

BIMESOGENIC COMPOUNDS AND MESOGENIC MEDIA

Merck Patent GmbH, Darms...

1. A bimesogenic compound of formula I
wherein
R11 and R12 are each independently H, F, Cl, CN, NCS or a straight-chain or branched alkyl group with 1 to 25 C atoms, which are unsubstituted, mono- or polysubstituted by halogen or CN, in which one or more non-adjacent CH2 groups are optionally replaced, in each occurrence independently from one another, by —O, S, NH, N(CH3)—, —CO—, —COO—, —OCO—, —O—CO—O—, —S—CO—, —CO—S—, —CH?CH—, —CH?CF—, —CF?CF— or —C?C— in such a manner that oxygen atoms are not linked directly to one another, and
at least one of
R11 and R12 is an alkenyl group or an alkinyl group either straight-chain or branched, with 2 to 25 C atoms, which are unsubstituted, mono- or polysubstituted by halogen or CN, in which one or more non-adjacent CH2 groups are optionally replaced, in each occurrence independently from one another, by —O—, —S—, —NH—, —N(CH3)—, —CO—, —COO—, —OCO—, —O—CO—O—, —S—CO—, —CO—S—, —CH?CH—, —CH?CF—, —CF?CF— or —C?C— in such a manner that oxygen atoms are not linked directly to one another,
MG11 and MG12 are each independently a mesogenic group, and
at least one of
MG11 and MG12 comprises one or more 5-atomic and/or 6-atomic rings, in case of comprising two or more 5- and/or 6-atomic rings at least two of these are optionally linked by a 2-atomic linking group,
Sp1 is a spacer group comprising 1, 3 or 5 to 40 C atoms, wherein one or more non-adjacent and non-terminal CH2 groups are optionally replaced by —O, S, NH, N(CH3)—, —CO—, —O—CO—, —S—CO—, —O—COO—, —CO—S—, —CO—O—, —CH(halogen)-, —CH(CN)—, —CH?CH— or C?C in such a way that no two O-atoms are adjacent to one another, no two —CH?CH— groups are adjacent to each other and no two groups selected from the group consisting of —O—CO—, —S—CO—, —O—COO—, —CO—S—, —CO—O— and —CH?CH— are adjacent to each other,
X11 and X12 are independently from one another a linking group selected from the group consisting of —CO—O—, —O—CO—, —O—, —CH?CH—, —C?C—, —CF2—O—, —O—CF2—, —CF2—CF2, —CH2—O—, —O—CH2—, —CO—S—, —S—CO—, —CS—S—, —S—, and a single bond, and under the condition that in —X11—Sp1—X12— no two O atoms are adjacent to one another, no two —CH?CH— groups are adjacent to each other and no two groups selected from the group consisting of —O—CO—, —S—CO—, —O—COO—, —CO—S—, —CO—O— and —CH?CH— are adjacent to each other.

US Pat. No. 10,392,559

PREPARATION METHOD OF NANOCRYSTALS COATED WITH METAL-SURFACTANT LAYERS

SAMSUNG ELECTRONICS CO., ...

1. A method for preparing nanocrystals, comprisingsynthesizing colloidal semiconductor nanocrystal cores in the presence of palmitic acid, wherein the semiconductor nanocrystal cores consist of InP;
adding zinc acetate to the colloidal semiconductor nanocrystal cores and heating the mixture while maintaining the reaction temperature constant to etch the surfaces of the semiconductor nanocrystal cores; and
forming metal-surfactant layers derived from the zinc acetate and palmitic acid on the etched surface portions of the semiconductor nanocrystal cores.

US Pat. No. 10,392,558

METHOD OF PRODUCING ALUMINATE FLUORESCENT MATERIAL, ALUMINATE FLUORESCENT MATERIAL AND LIGHT EMITTING DEVICE

NICHIA CORPORATION, Anan...

1. An aluminate fluorescent material comprising a composition of an aluminate that comprises at least one alkaline earth metal element selected from the group consisting of Ba, Sr and Ca, at least one alkali metal element selected from the group consisting of Na, K, Rb and Cs, and Mg and Mn,and having a ratio (IB/IA) of a diffraction intensity IB of a peak of a plane (0,0,10) at a diffraction angle 2? of 39.76° in an X-ray diffraction pattern measured with a CuK? ray to a diffraction intensity IA of a peak of a plane (1,0,7) at a diffraction angle 2? of 33.22° in the X-ray diffraction pattern in a range of 0.4 or more and 10 or less.

US Pat. No. 10,392,556

POLYCARBONATE BLOCK COPOLYMERS

Saudi Aramco Technologies...

1. A polymer composition comprising a triblock copolymer having a formula:
wherein:
—Z— is an optionally substituted C1-6 aliphatic group,
—Y is an acyl group;
each Ra, Rb, Rc, and Rd is independently selected from the group consisting of: hydrogen, halogen, —CH2ORz, optionally substituted C1-10 aliphatic, optionally substituted 6- to 14-membered aromatic, optionally substituted 3- to 14-membered heterocyclic, and optionally substituted 5- to 14-membered heteroaryl, and wherein any two or more of Ra, Rb, Rc, and Rd may be taken together to form an optionally substituted 3- to 12-membered ring, optionally containing one or more heteroatoms;
each L is independently a bond or a polyfunctional moiety;
n is an integer between 4 and 100;
m is an integer between about 4 and about 500;
m? is, on average approximately equal to m;
Rz is selected from the group consisting of R10, —C(O)R10, —SO2R10, —Si(R10)3, —C(O)N(R10)2; and
R10 is an optionally substituted moiety selected from the group consisting of: C1-20 aliphatic, C1-12 heteroaliphatic, 6- to 14-membered aryl, and 5- to 14-membered heteroaryl.

US Pat. No. 10,392,555

NANOPARTICLE DESIGN FOR ENHANCED OIL RECOVERY

International Business Ma...

1. A method for selecting a nanoparticle to support oil extraction in a subterranean formation comprising:determining one or more environmental conditions of the subterranean formation;
determining a set of nanoparticle parameters based on the one or more environmental conditions,
wherein a nanoparticle having one or more nanoparticle parameters from the set of nanoparticle parameters displaces a volume of water greater than another volume of oil at equilibrium at an oil-water interface under the one or more environmental conditions;
wherein the set of nanoparticle parameters comprise at least one of composition, size, or shape;
determining a subset of nanoparticle parameters selected from the initial set of nanoparticle parameters, wherein a nanoparticle having the subset of nanoparticle parameters conforms to a performance criteria, wherein the performance criteria comprises one or more of the following:
a contact angle between the nanoparticle and the oil-water interface of a spherical nanoparticle ranging from approximately 70 degrees to approximately 89 degrees,
a free energy profile of the nanoparticle at the oil-water interface indicating an oil in water emulsion,
a nanoparticle arrangement at the oil-water interface,
a nanoparticle diffusion coefficient at the oil-water interface,
a maximum emulsification rate of the oil in the water,
a maximum spreading force or a structural disjoining pressure for displacement of the oil from a solid surface, or
a formation of a wedge film at a three phase contact line at the oil, the water and a rock interface; and
selecting the nanoparticle having the subset of nanoparticle parameters.

US Pat. No. 10,392,553

METHOD FOR ENHANCING PRODUCTIVITY OF HYDROCARBON FORMATIONS USING FLUID CONTAINING ORGANOMETALLIC CROSSLINKING AGENT AND SCALE INHIBITOR

BAKER HUGHES, A GE COMPAN...

1. A method of subjecting a hydrocarbon-bearing calcareous or siliceous formation penetrated by a well to a hydraulic fracturing operation which comprises:(a) pumping into the well at a pressure sufficient to create or enlarge fractures in the hydrocarbon-bearing calcareous or siliceous formation an aqueous fracturing fluid comprising:
(i) a crosslinkable viscosifying polymer;
(ii) an organometallic crosslinking agent containing a polyvalent metal ion;
(iii) a scale inhibitor selected from the group consisting of polyvinyl sulfonates, a polyacrylamidomethylpropane sulfonic acid, carboxymethyl inulin and sulfonated polyacrylates and mixtures thereof; and
(iv) a proppantand creating or enlarging fractures within the hydrocarbon-bearing calcareous or siliceous formation;(b) forming a viscous gel containing the scale inhibitor after step (a) by forming crosslinks between the crosslinkable viscosifying polymer and organometallic crosslinking agent wherein the crosslinkable viscosifying polymer forming the crosslinks with the organometallic crosslinking agent consists essentially of a cellulosic derivative, galactomannan gum, carrageenan, polyacrylamide, alkylpolyacrylamide, partially hydrolyzed polyacrylamide or a copolymer of acrylamide and either an acrylate or acrylamidomethylpropane sulfonic acid or a mixture thereof and further wherein the viscous gel is stable at a temperature in excess of 150° F. and exhibits a viscosity in excess of 500 cP at 100 sec?1 at 150° F.;
(c) transporting the scale inhibitor in the viscous gel into the formation;
(d) preventing and/or inhibiting the formation of scales in the well and/or formation with the transported scale inhibitor; and
(e) exposing the proppant to formation closure stresses.

US Pat. No. 10,392,551

OIL FIELD TREATMENT FLUIDS

Baker Hughes, a GE compan...

1. A surfactant preblend, comprising:a first surfactant chosen from alcohol ethoxylates;
a second surfactant chosen from C4 to C12 primary alcohols; and
a third surfactant chosen from ethoxylated propoxylated alcohols, the first, second, and third surfactants being different from each other.

US Pat. No. 10,392,549

DATE TREE TRUNK-BASED FIBROUS LOSS CIRCULATION MATERIALS

Saudi Arabian Oil Company...

1. A method to control lost circulation in a lost circulation zone in a wellbore, comprising:introducing an altered drilling fluid into the wellbore such that the altered drilling fluid contacts the lost circulation zone and reduces a rate of lost circulation into the lost circulation zone, where the altered drilling fluid comprises a drilling fluid and a lost circulation material (LCM), wherein the LCM comprises a plurality of date tree trunk fibers produced from date tree trunks, wherein the drilling fluid comprises a gel-polymer mud or a volcanic ash-based mud.

US Pat. No. 10,392,548

COMPOSITE MATERIAL PART HAVING A THERMALLY AND ELECTRICALLY CONDUCTIVE PORTION, AND A METHOD OF FABRICATING SUCH A PART

SAFRAN, Paris (FR)

1. A composite material part comprising:reinforcement made of carbon fibers or yarns consolidated by an organic matrix, the reinforcement comprising warp yarns or fibers and weft yarns or fibers woven together,
wherein said composite material part includes one or more thermally conductive portions in which the carbon fibers or yarns are free of matrix,
wherein the matrix-free carbon fiber or yarn portions are in contact with a material that is thermally conductive, and
wherein the material that is thermally conductive is situated in porosities between the carbon fibers or yarns free of matrix.

US Pat. No. 10,392,538

ADHESIVE COMPOSITIONS COMPRISING A SILSESQUIOXANE POLYMER CROSSLINKER, ARTICLES AND METHODS

3M Innovative Properties ...

1. A pressure sensitive adhesive composition comprising:at least one low glass transition temperature (Tg) (meth)acrylic polymer having a Tg no greater than 10° C.,
a free-radical initiator; and
at least one silsesquioxane (SSQ) polymer crosslinker comprising a plurality of ethylenically unsaturated groups independently selected from vinyl ether and alkenyl.

US Pat. No. 10,392,536

PRESSURE-SENSITIVE ADHESIVE COMPOSITION, PRESSURE-SENSITIVE ADHESIVE FILM, AND METHOD OF MANUFACTURING ORGANIC ELECTRONIC DEVICE USING THE SAME

LG Chem, Ltd., Seoul (KR...

1. A pressure-sensitive adhesive composition, comprising:an encapsulating resin which is a copolymer of a diene and an olefin-based compound having one carbon-carbon double bond, wherein the encapsulating resin has a weight average molecular weight (Mw) of 100,000 to 2,000,000;
a tackifier;
a multifunctional active energy ray-polymerizable compound which is included at 5 to 18 parts by weight relative to 100 parts by weight of the encapsulating resin; and
a silane compound satisfying Formula 1,
wherein the pressure-sensitive adhesive composition has a gel content represented by Equation 1 of 50% or more, and
wherein the multifunctional active energy ray-polymerizable compound forms a crosslinking structure with the silane compound satisfying Formula 1, and the crosslinking structure forms a semi-interpenetrating polymer network with the encapsulating resin:

wherein R1 is hydrogen or an alkyl group, R2 and R3 are each independently hydrogen, or a linear, branched, or cyclic alkyl group, or R2 is linked with R3, thereby forming a cyclic alkyl group, R4, R5, and R6 are each independently hydrogen, an alkyl group, or an alkoxy group, at least one of R4, R5, and R6 is an alkoxy group, and n is an integer of 1 or more,
Gel content (%)=B/A×100  [Equation 1]
wherein A is a mass of the pressure-sensitive adhesive composition, and B is a dry mass of an insoluble content of the pressure-sensitive adhesive composition remaining after being dipped in toluene at 60° C. for 24 hours and filtered through a 200-mesh filter (pore size of 200 ?m).

US Pat. No. 10,392,535

BINDER RESIN FOR INORGANIC PARTICLE-DISPERSED PASTES AND INORGANIC PARTICLE-DISPERSED PASTE

SHOEI CHEMICAL INC., Shi...

1. A binder resin for an inorganic particle-dispersed paste, the binder resin comprising a mixture in which a polyvinyl acetal and a cellulose derivative are mixed so as to satisfy 0.2?X/(X+Y)?0.8, where X and Y stand for parts by mass of the polyvinyl acetal and the cellulose derivative, respectively, and then further mixed with poly(ethylene glycol) bis(carboxymethyl) ether, whereinwhen a paste is obtained by mixing 6 parts by mass, calculated as a solid, of the resin with 100 parts by mass of spherical nickel particles with an average particle diameter of 0.3 ?m, 10 parts by mass of barium titanate particles with an average particle diameter of 0.05 ?m, 0.5 parts by mass of a nonionic surfactant, 68 parts by mass of dihydroterpineol, and 17 parts by mass of mineral spirit to obtain a resultant mixture, and kneading the resultant mixture by using a three-roll mill, the paste is as follows:
when strains of 0.02 and 0.2 are applied to the paste at an angular frequency of 6.284 rad/s, a value of a phase difference ? between each of the strains and a stress caused by each strain is greater than 45°; and
a ratio of a viscosity of the paste at a shear rate of 4 (1/s) to a viscosity thereof at a shear rate of 40 (1/s) is 4.5 or less.

US Pat. No. 10,392,534

ADHESIVE FILM, FOLDABLE DISPLAY DEVICE USING THE SAME, AND METHOD OF MANUFACTURING A FOLDABLE DISPLAY DEVICE

LG Display Co., Ltd., Se...

1. An adhesive film, comprising:a frame comprising a micro-truss structure, the micro-truss structure comprising a plurality of unit cells comprising a plurality of wires intersecting each other in a three-dimensional space; and
an adhesive filling the frame,
wherein the frame further comprises one of:
an arrangement of the unit cells in a horizontal direction, and
an arrangement of the unit cells in the horizontal direction with the unit cells stacked in a vertical direction, and
wherein the frame further comprises:
a high-density part; and
a low-density part.

US Pat. No. 10,392,529

FILM HAVING METALLIC LUSTER, ARTICLE HAVING SAID FILM FORMED THEREON, AND MANUFACTURING METHOD FOR FILM HAVING METALLIC LUSTER

NATIONAL UNIVERSITY CORPO...

1. A film having a metallic luster, said film comprising a thiophene polymer having a distribution peak of weight-average molecular weight of from 200-30000, is doped with at least one of a perchlorate ion,chloride ion and para toluene sulfonic acid ion and is polymerized by chemical polymerization from at least one of alkoxy thiophene and alkyl thiophene, whose number of carbon is 1 or 2,
wherein said thiophene polymer has a layer-like orientational regular structure which is formed by said chemical polymerization and
three peaks are derived from said layer-like orientational regular structure of said thiophene polymer in the range from 5 to 30 degrees by X-ray diffraction measurement.

US Pat. No. 10,392,526

MATTING AGENT AND METHOD FOR OBTAINING THE SAME

Kronos International, Inc...

1. A matting agent useful for preparing pigmented mat surfaces comprising pigment particles wherein such pigment particles are present in agglomerates having an average agglomerate size d50 of from about 2 to about 200 ?m and a specific surface (BET) area of from about 5 to about 50 m2/g and where the pigment particles have an average particle size d50 of from about 200 to about 500 nm.

US Pat. No. 10,392,525

INK JET RECORDING METHOD

FUJIFILM CORPORATION, To...

1. An ink jet recording method comprising:an ejection step of ejecting, onto a substrate, an ink composition A that includes water, a coloring agent, a photopolymerization initiator, and a microcapsule enclosing at least a polymerizable compound therein, and an ink composition B that includes water, a coloring agent, a photopolymerization initiator, and a microcapsule enclosing at least a polymerizable compound therein; and
an irradiation step of irradiating, with light, the ink composition A and the ink composition B ejected on the substrate,
wherein an absorbance ABSA of the ink composition A and an absorbance ABSB of the ink composition B satisfy a formula (1) below, and
a concentration MA of the microcapsule included in the ink composition A and a concentration MB of the microcapsule included in the ink composition B satisfy a formula (2) below:
ABSA MA where ABSA and ABSB respectively represent an average of absorbances of the ink composition A in wavelengths of 360 to 390 nm and an average of absorbances of the ink composition B in wavelengths of 360 to 390 nm, and
MA and MB respectively represent, on a mass basis, a concentration of the microcapsule included in the ink composition A and a concentration of the microcapsule included the ink composition B, and wherein
ABSA, ABSB, MA, and MB satisfy a formula (3) below
(1+0.1×(ABSB/ABSA))×MA

US Pat. No. 10,392,524

CERAMIC INKJET INK FOR RED DECORATION

ELECTRONICS FOR IMAGING, ...

1. A composition comprising:a pigment compound that includes particles of a copper component, wherein the pigment compound is configured to be jetted during an inkjet process, either directly onto a workpiece, or onto a jetted layer on the workpiece, wherein the workpiece is any of a ceramic workpiece or a porcelain workpiece; and
a reduction agent which, when exposed to a firing temperature having a range of 1050 degrees C. to 1300 degrees C., reacts with the pigment compound to form a glaze and cause a reduction reaction that imparts a characteristic red color component to the glaze.

US Pat. No. 10,392,522

ULTRAVIOLET CURABLE COMPOSITION AND RECORDED OBJECT

Seiko Epson Corporation, ...

1. An ultraviolet curable composition comprising:a polymerizable compound;
metal powder; and
fluorine-containing powder,
a content of the fluorine-containing powder being in a range of 0.010 mass % to 5.0 mass %,
a constituting particle of the fluorine-containing powder containing at least one of a particle formed of a fluorine polymer or an inorganic fine particle that is formed of silica and has a surface which is treated by using a fluorine-based surface treating agent.

US Pat. No. 10,392,520

CARBON NANOTUBE COMPOSITE FILM AND METHOD FOR PRODUCING SAID COMPOSITE FILM

NATIONAL INSTITUTE OF ADV...

1. A carbon nanotube composite film comprising:a particle of an inorganic semiconductor; and
a carbon nanotubes network,
wherein the particle of the inorganic semiconductor serves as a node between a plurality of the carbon nanotubes,
wherein the inorganic semiconductor is a metal halide having a melting point of lower than 1000° C.,
wherein the metal halide is at least one selected from a group consisting of copper chloride (CuCl), copper bromide (CuBr), copper iodide (Cue and iron chloride (FeCl2),
wherein an optical transmittance of the carbon composite film is in a range of 50% to 98%,
wherein a thickness of the carbon nanotube composite film is in a range of 1 to 1000 nm, and
wherein a sheet resistance of the carbon nanotube composite film is in a range of 1 to 1000 ?/square.

US Pat. No. 10,392,518

PASTE MATERIAL, WIRING MEMBER FORMED FROM THE PASTE MATERIAL, AND ELECTRONIC DEVICE INCLUDING THE WIRING MEMBER

SAMSUNG ELECTRONICS CO., ...

1. A paste material comprising:a plurality of liquid metal particles that are liquid at 25° C.;
a polymer binder mixed with the plurality of liquid metal particles; and
a plurality of nanofillers mixed with the plurality of liquid metal particles and the polymer binder and each having an aspect ratio equal to or greater than 3,
wherein a weight percent of the plurality of liquid metal particles is greater than a weight percent of the polymer binder and is greater than a weight percent of the plurality of nanofillers.

US Pat. No. 10,392,517

OPTICAL ARTICLE COMPRISING AN ELECTRICALLY CONDUCTIVE LAYER, AND PRODUCTION METHOD

ESSILOR INTERNATIONAL, C...

1. A curable antistatic primer composition comprising:at least one polyalkylene oxide polymer;
at least a lithium salt; and
at least an amorphizer comprising at least a dendritic polymer wherein the composition is further defined as having a weight ratio of (dry extract of said dendritic polymer)/(dry extract of said polyalkylene oxide polymer) ranging from 0.05 to 1.5.

US Pat. No. 10,392,514

STORAGE-STABLE DYE SOLUTIONS

Archroma IP GmbH, Reinac...

1. A dye composition, comprising(a) 14.5% by weight of a compound of formula

(b) 5% by weight of triisopropanolamine, and further 0.15% by weight of 1,2-benzisothiazolin-3-one and 80.35% by weight of water.

US Pat. No. 10,392,512

DETAILING AGENT FOR THREE-DIMENSIONAL (3D) PRINTING

Hewlett-Packard Developme...

1. A detailing agent for three-dimensional (3D) printing, comprising:a colorant present in an amount ranging from about 1.00 wt % to about 3.00 wt % based on a total weight of the detailing agent, wherein the colorant is a dye having substantially no absorbance in a range of 650 nm to 2500 nm;
a co-solvent selected from the group consisting of tetraethylene glycol, tripropylene glycol methyl ether, dipropylene glycol methyl ether, tripropylene glycol butyl ether, dipropylene glycol butyl ether, triethylene glycol butyl ether, 1,2-hexanediol, 2-hydroxyethyl-2-pyrrolidinone, 2-pyrrolidinone, 1,6-hexanediol, and combinations thereof, and the co-solvent is present in an amount ranging from about 1.00 wt % to about 20.00 wt % based on the total weight of the detailing agent;
a surfactant having a hydrophilic-lipophilic balance (HLB) of less than 10, and the surfactant is present in an amount ranging from about 0.01 wt % to about 5.00 wt % based on the total weight of the detailing agent; and
a balance of water based on the total weight of the detailing agent.

US Pat. No. 10,392,511

WATER SOLUBLE FLUORESCENT OR COLORED DYES AND METHODS FOR THEIR USE

Sony Corporation, Tokyo ...

1. A water soluble, oligomeric dye compound having the following structure:
wherein:
M1 is, at each occurrence, independently a moiety comprising three or more aryl or heteroaryl rings, or combinations thereof;
L1, L2, and L3 are, at each occurrence, independently optional linkers comprising atoms selected from C, O, S, N and P;
R1 is, at each occurrence, independently H, alkyl, or alkoxy;
R2 and R3 are independently H, OH, SH, NH2, alkyl, alkylether, hydroxlalkyl, aminoalkyl, hydroxylalkylether, sulfhydrylalkyl, sulfyhdrylalkylether, phosphate, thiophosphate, alkylphospho, alkylthiophospho, —Oalkylphospho, —Oalkylthiophospho, alkyletherphospho, alkyletherthiophospho, —Oalkyletherphospho, —Oalkyletherthiophospho phosphoalkyl, phosphoalkylether, thiophosphoalkyl, thiophosphoalkylether, —Ophosphoalkyl, O-phosphoalkylether, —Othiophosphoalkyl or —Othiophosphoalkylether or a linker comprising a covalent bond to a biomolecule or microparticle; and
n is an integer from 2 to 20.

US Pat. No. 10,392,506

POLYCARBONATE COMPOSITIONS FOR GALVANIC APPLICATIONS HAVING A HIGH REQUIREMENT FOR HEAT DISTORTION POINT

Covestro Deutschland AG, ...

1. An article consisting of a plastics carrier and a multi-ply metal layer applied via a galvanizing process, wherein the plastics carrier is produced from a composition consisting ofA) 70 to 90 parts by weight of at least one polycarbonate,
B) 10 to 30 parts by weight of at least one graft polymer comprising a diene-containing elastomeric particulate graft base and a vinyl (co)polymer sheath,
C) 0 to 15 parts by weight of at least one additive,
wherein the sum of the parts by weight of components A) and B) in the composition is normalized to 100,
(i) characterized in that the rubber content from component B in the composition is at least 6 wt %,
(ii) characterized in that the ratio K/S of the weight fractions of diene-containing elastomeric particulate graft base from component B) in the composition (?K) to the sum of free vinyl (co)polymer from component B) and any free vinyl (co)polymer from component C) in the composition (?S) is at least 1.5,
(iii) characterized in that component A) comprises at least one monomer unit selected from the group consisting of monomer units described by general formula (2)

 in which
R4 represents H, linear or branched C1-C10 alkyl, and
R5 represents linear or branched C1-C10 alkyl, and at least one monomer unit derived from 1,1-bis(4-hydroxyphenyl)-3,3?,5-trimethylcyclohexane,
(iv) characterized in that the proportion (Acyc) of monomer units derived from bis(4-hydroxyphenyl) compounds and bridged via the 1,1?-position of a cyclic hydrocarbon optionally substituted with heteroatoms based on the sum of all monomer units derived from bisphenols in component A) is in the range from 5 to 40 wt % and
(v) characterized in that component A) has a relative solution viscosity of 1.20 to 1.28 determined according to DIN 51562 in methylene chloride.

US Pat. No. 10,392,504

REACTIVE EPOXY COMPOUNDS AND METHOD FOR PRODUCING THE SAME, CORE-SHELL TYPE EPOXY RESIN PARTICLES, WATERBORNE EPOXY RESIN COMPOSITION, AND COATING COMPOSITION CONTAINING THE REACTIVE EPOXY COMPOUNDS

Chang Chun Plastics Co., ...

1. A reactive epoxy compound represented by one formula selected from the group of formulas (S1), (S2), (S3), (S4) and (S5):

US Pat. No. 10,392,503

POLYMER BLEND IN GRANULAR FORM AND PROCESS FOR MAKING SAME

Rohm and Haas Company, P...

1. A polymer blend comprising:(i) one or more first polymers each independently having a weight-average molecular weight of 35,000 to 100,000 g/mol and each independently comprising polymerized units of
(a) 22 to 80 wt % of one or more monoethylenically unsaturated C3-C6 carboxylic acid monomers, and
(b) 20 to 78 wt % of one or more C1-C12 alkyl (meth)acrylate monomers,
wherein at least one of the one or more first polymer comprises polymerized units of:
55 to 80 wt % of methacrylic acid units,
10 to 35 wt % of ethyl acrylate units, and
10 to 35 wt % of butyl acrylate units; and
(ii) one or more second polymers each independently having a weight-average molecular weight of between 2,000 to 35,000 g/mol and each independently comprising polymerized units of 50 to 100 wt % of one or more monoethylenically unsaturated C3-C6 carboxylic acid monomers,
wherein component (i) comprises from 1 wt % to 50 wt % based on the total weight of (i) and (ii), wherein the polymer blend is in granular form, and wherein one or more polymers of the polymer blend is at least partially neutralized.

US Pat. No. 10,392,502

INFORMATION CARRYING CARD COMPRISING A CROSS-LINKED POLYMER COMPOSITION, AND METHOD OF MAKING THE SAME

X-CARD HOLDINGS, LLC, We...

1. A core layer for a plurality of information carrying cards, comprisinga thermoplastic layer defining a plurality of cavities therein, each cavity having a continuous surface profile solely defined by and inside the thermoplastic layer, the continuous surface profile having a bottom wall surface and a side wall surface;
a plurality of inlay layers, each inlay layer comprising a supporting film, and at least one electronic component embedded or mounted on the supporting film, the at least one electronic component partially or fully disposed inside each respective cavity; and
a crosslinked polymer composition disposed in each cavity and contacting the at least one electronic component, the crosslinked polymer composition comprising:
a base polymer resin selected from the group consisting of urethane acrylate, ester acrylate, silicone acrylate, epoxy acrylate, methacrylate, silicone, urethane and epoxy, wherein the crosslinked polymer composition at least partially defines an outer surface of the core layer and has at least one portion disposed above a respective inlayer layer and below the outer surface.

US Pat. No. 10,392,499

INORGANIC FILLER, EPOXY RESIN COMPOSITION INCLUDING THE SAME AND LIGHT EMITTING ELEMENT INCLUDING INSULATING LAYER USING THE COMPOSITION

LG INNOTEK CO., LTD., Se...

1. An inorganic filler, comprising:a boron nitride agglomerate and a coating layer formed on a surface of the agglomerate,
wherein the coating layer comprises a material comprising Si, C and N, and a hydroxyl group (—OH) is formed on a surface of the coating layer,
wherein the boron nitride agglomerate is an agglomerate of planar boron nitride particles,
wherein pores are formed among the planar boron nitride particles in the boron nitride agglomerate,
wherein at least some of the pores are filled with the material comprising Si, C and N,
wherein the hydroxyl group (—OH) is further formed on the material filling the at least some of the pores, and
wherein at least one of the coating layer and the material filling the at least some of the pores comprise silicon oxycarbonitride (SiCNO) or silicon carbonitride (SiCN).

US Pat. No. 10,392,491

HALOGENATED POLYMER COMPOSITE COMPOSITION, ITS MANUFACTURING PROCESS AND ITS USE

Arkema France, Colombes ...

1. A method for manufacturing a polymer composite composition which is a dry powder comprising less than 3 wt % humidity, having a bulk density of at least 0.7 g/cm3 and having a weight medium particle size D50 of between 30 microns and 600 microns, said method comprising the steps of:a) mixing of at least one halogen containing polymer wherein the halogen is chlorine and wherein the halogen containing polymer is a homo- or copolymer of vinylchloride, comprising at least 50 wt % of vinylchloride units, with at least one mineral filler which is calcium carbonate wherein the mineral filler presents from 0.1 wt % to about 90 wt % of the polymer composite comprising halogen containing polymer and mineral filler,
b) recovering of the mixture obtained in a) by spray drying, freeze drying, or coagulation,
c) drying the recovered mixture of step b)
wherein the halogen containing polymer and the mineral filler during mixing step a) are in form of a dispersion in aqueous phase.

US Pat. No. 10,392,490

POLYPROPYLENE/INORGANIC PARTICLE BLEND COMPOSITION FOR PVC-FREE WEAR LAYER IN RESILIENT FLOORING

Dow Global Technologies L...

1. A composition comprising at least the following:A) at least 50 wt %, based on the total weight of the composition, of a propylene-based polymer that has a % crystallinity as determined by differential scanning calorimetry (DSC) of greater than, or equal to, 25%, a MFR from 0.5 to 30.0 g/10 min (230° C./2.16 kg), a molecular weight distribution (Mw/Mn) of 1.5 to 5, and a density of 0.888g/cc to 0.910 g/cc; and
B) from 0.5 to 10.0 wt % of a filler, based on the total weight of the composition.

US Pat. No. 10,392,489

METHOD OF MAKING A LOW DENSITY CELLULAR PVC BOARDS WITH SEALED EDGES

Inteplast Group Corporati...

1. A method for making ornamental trim for use in construction comprising:cutting a foam board through its thickness to provide a foam board component having a top surface, a bottom surface, two cut longitudinal side edges, and two cut end edges, where the cut side edges and cut end edges define the outermost perimeter of the foam board component;
applying a sealing composition to cut edges defining the outermost perimeter of the foam board component comprising a cellular network exposed by said cut edges, wherein the sealing composition comprises PVC particles suspended in flowable medium;
heating the sealing composition to a temperature at which the flowable medium solvates the PVC particles; and
cooling the sealing composition to form a continuous sealing cap on the cut edges to which the sealing composition was applied.

US Pat. No. 10,392,487

PROCESS FOR EXTENDING THE SHELF LIFE OF GASEOUS OLEFINIC PROPELLANTS IN POLYURETHANE FOAMS

ICP Adhesives and Sealant...

1. A two-component polyurethane foam comprising a reaction product of:an “A-side” diisocyanate with an HFO-1234ze propellant; and
a “B-side” blend with an HFO-1234ze propellant;
the polyurethane foam reaction product comprising:
at least two aromatic polyester polyols and no more than approximately 10 wt. % aliphatic polyether polyol,
and wherein the at least two aromatic polyester polyols comprise:

having a viscosity at 77° F. (25° C.), of between approximately 2,000-4,500 cP; and
n being a value sufficient to achieve the viscosity; and

having a viscosity at 77° F. (25° C.) of between approximately 2,500-3,500 cP; and
n being a value sufficient to achieve the viscosity;
at least two catalysts comprising:
at least one tertiary amine catalyst comprising at least two cyclohexyl rings;
at least one aliphatic metal salt catalyst; and
up to about 1.5 wt. % water.

US Pat. No. 10,392,485

HEAT-SHRINKABLE POLYESTER-BASED FILM AND PACKAGE

TOYOBO CO., LTD., Osaka ...

1. A heat-shrinkable polyester-based film comprising ethylene terephthalate units, constituent units derived at least one monomer which forms an amorphous component and constituent units derived from butanediol,wherein an amount of the constituent units derived at least one monomer which forms an amorphous component are 18 mol % or more and an amount of the constituent units derived from butanediol are 1 to 25 mol % based on 100 mol % of all polyester resin components,
wherein the heat-shrinkable polyester-based film satisfies the following requirements (1) to (3):
(1) the secondary shrinkage ratio of the film is 2% or more and 5% or less when the film is cooled to 25° C. from 100° C. after being primarily shrunk in a chamber kept at 100° C. beforehand;
(2) the hot-water heat shrinkage ratio of the film in the traverse direction is 10% or more and 30% or less when the film is dipped in hot water at 70° C. for 10 seconds after being aged under an atmosphere at 30° C. and 85% RH for 672 hours; and
(3) the reversing heat capacity difference before and after the glass transition temperature of the film is 0.12 J/g·° C. or more and 0.25 J/g·° C. or less when the reversing heat capacity difference is measured by temperature-modulated DSC.

US Pat. No. 10,392,484

CELLULOSE ACYLATE FILM, PRODUCTION METHOD OF CELLULOSE ACYLATE FILM, STACK, POLARIZING PLATE, AND LIQUID CRYSTAL DISPLAY DEVICE

FUJIFILM Corporation, To...

1. A cellulose acylate film comprising cellulose acylate and a compound A which is represented by the following formula (J) which has a group represented by the following formula (G) and in which a value obtained by dividing a molecular weight of the compound by a number of the groups represented by formula (G) contained in the compound is 200 or less, wherein a content of the compound A is 15% by weight or more based on a content of the cellulose acylate, an iodine diffusion index X is less than 0.005 and an iodine diffusion index Y is 0.015 or more:Z-(-L12-L11-O-G)n1  Formula (J)
wherein
L11 represents an alkylene group,
L12 represents a single bond, any of —O—, —NR1—, —S— and —C(?O)— or a group formed by a combination of these groups, R1 represents a hydrogen atom or a substituent,
Z represents an n1-valent group,
n1 represents an integer of 2 to 6 and when plural L11 and L12 are present, plural L11 and L12 may be the same or different from each other, and
G represents the group represented by formula (G):

where in formula (G), * represents a connecting site;
the iodine diffusion index X is a value determined in the following manner:
the cellulose acylate film is immersed in an aqueous solution (a) containing 5.4 mg/L of potassium iodide and 0.36 mg/L of iodine at 60° C. for 30 minutes, absorbance D0 of the cellulose acylate film at a wavelength of 360 nm before the immersion in the aqueous solution (a) and absorbance DX of the cellulose acylate film at a wavelength of 360 nm after the immersion in the aqueous solution (a) are measured, and from the absorbance D0 and the absorbance DX, the iodine diffusion index X is calculated according to the following formula (1):
Iodine diffusion index X=(absorbance DX?absorbance D0)/ thickness (?m) of cellulose acylate film;  Formula (1)
the iodine diffusion index Y is a value determined in the following manner:
a sample in which an iodine blocking member is stacked on one side of the cellulose acylate film and a sample in which an iodine blocking member is stacked on an other side of the cellulose acylate film are prepared, each of the samples is immersed in the aqueous solution (a) at 60° C. for 1 minute, the iodine blocking member is peeled off from the cellulose acylate film, absorbance of each of the cellulose acylate films at a wavelength of 360 nm is measured, and of the absorbances, the larger value is taken as absorbance DY and the iodine diffusion index Y is calculated according to the following formula (2):
Iodine diffusion index Y=absorbance DY?absorbance D0  Formula (2).

US Pat. No. 10,392,483

SEMIFINISHED PRODUCT FOR MAKING MOLDED COMPOSITE PART AND METHOD OF MAKING SAME

1. A method of making a semifinished product for the manufacture of a composite fiber molded part, the method comprising the steps of:spinning from a row of orifices of a spinning nozzle low-melting fibers of polypropylene having a predetermined heat-distortion temperature, a predetermined melting temperature, and a melt-flow index of 75 to 2500 g/10 min;
projecting respective air streams from the orifices around the fibers;
forming the low-melting fibers into a nonwoven;
combining high-melting reinforcement fibers having a melting temperature at least 5° C. higher than the melting temperature of the low-melting fibers with the nonwoven formed from the low-melting fibers into a laminated semifinished product while maintaining the low-melting fibers at a fiber temperature that lies in a temperature range between 25° C. below the predetermined heat-distortion temperature and 55° C. above the predetermined heat-distortion temperature of the thermoplastic material of the low-melting fibers; and
applying heat or pressure to the semifinished product such that the low-melting fibers melt and form a thermoplastic material that impregnates the reinforcement fibers and forms a matrix in which the reinforcement fibers are embedded.

US Pat. No. 10,392,481

HIGH STRENGTH POLYETHYLENE PRODUCTS AND A PROCESS FOR PREPARATION THEREOF

Reliance Industries Limit...

1. A process for the preparation of high strength polyethylene laminates comprising the following steps:i. providing an uncompacted pre-dried, at least 50% disentangled ultra-high molecular weight polyethylene (UHMWPE) powder;
ii. feeding said uncompacted UHMWPE powder having temperature ranging from ?5° C. to 28° C. at the nip of at least one pair of heated counter rotating calendaring rollers, rotating at different roller speeds to obtain at least one pre-laminate; and
iii. hot stretching said pre-laminate(s) at a pre-determined temperature below the melting point of the UHMWPE and pre-determined stretching speed in the range of 10 to 60 mm/min to obtain high strength polyethylene laminates,
wherein said high strength polyethylene laminates are selected from the group consisting of sheets and films, and wherein said high strength polyethylene laminates are characterized by tensile strength ranging between 0.5 to 3.0 GPa and tensile modulus ranging between 40 to 200 GPa.

US Pat. No. 10,392,477

METHOD FOR MANUFACTURING COAGULATED PARTICLES FROM LATEX PREPARED BY EMULSION POLYMERIZATION, AGGREGATES FROM LATEX PREPARED BY EMULSION POLYMERIZATION, AND COAGULATED PARTICLES FROM LATEX PREPARED BY EMULSION POLYMERIZATION

KANEKA CORPORATION, Osak...

1. A method for manufacturing coagulated particles from a latex prepared by emulsion polymerization, the method comprising:discharging the latex prepared by emulsion polymerization containing a thickener into a solution containing a coagulating agent, thereby coagulating the latex prepared by emulsion polymerization to form coagulated aggregates having an average size of from 0.1 to 5 cm3 in the solution containing a coagulating agent, and
crushing the coagulated aggregates to obtain the coagulated particles,
wherein the latex includes an amount of the thickener from 0.01 to 3.0 parts by weight, per 100 parts by weight of a polymer solid content of the latex prepared by emulsion polymerization, and
wherein the thickener is a nonionic water-soluble polymer.

US Pat. No. 10,392,474

ANIONIC LINEAR POLYGLYCEROL DERIVATIVES, A METHOD FOR MANUFACTURING AND APPLICATIONS

FREIE UNIVERSITAET BERLIN...

1. A linear polyglycerol compound, comprising an optionally terminally substituted backbone of linearly linked glycerol units, wherein it carries a plurality of sulfate substituents, wherein the degree of substitution of the backbone is between 10 and 100% %, wherein the linear polyglycerol compound has a structure according to one of the following formulae:
with
n=5 to 1000,
X, Y=independently from each other any organic residue with a functional group chosen from the group consisting of alcohol, amine, thiol, azide, alkyne, alkene, carboxylic acid, aldehyde, ketone, halogen, isocyanate, isothiocyanate, Michael acceptor/donor group,
Z=independently from other residues Z in the same polyglycerol molecule a negatively charged sulfate residue,
or an unreacted neutral precursor residue bearing a reactive of an alcohol, amine, thiol, halogen, azide, alkyne, alkene, carboxylic acid, or Michael acceptor/donor group,
wherein at least 10% of all residues Z in the polyglycerol are sulfate residues.

US Pat. No. 10,392,473

MONOMER COMPOSITION AND CURABLE COMPOSITION CONTAINING SAME

DAICEL CORPORATION, Osak...

1. A monomer composition comprising:at least one vinyl ether compound (A); and
at least one oxetane compound (B);
the at least one vinyl ether compound (A) comprising
a multifunctional vinyl ether compound in an amount of 10 to 80 weight percent of the total weight of the monomer composition,
the at least one oxetane compound (B) comprising:
a bifunctional oxetane compound represented by Formula (b) in an amount of 0.5 to 15 weight percent of the total weight of the monomer composition; and
a monofunctional oxetane compound represented by Formula (b?) in an amount of 5 to 45 weight percent of the total weight of the monomer composition, Formulae (b) and (b?) expressed as follows:
wherein Ring Z is selected from an aromatic hydrocarbon ring and a structure including two or more aromatic hydrocarbon rings bonded to each other through a single bond or a linkage group,
wherein R represents a monovalent aliphatic hydrocarbon group; R? is selected from hydrogen and ethyl; and m represents an integer of 0 or more.

US Pat. No. 10,392,470

POLYESTER NANOGEL CORE STAR POLYMERS FOR DELIVERY OF THERAPEUTIC AGENTS

International Business Ma...

1. A nanogel star polymer, comprising:a crosslinked hydrophobic polyester core C?; and
6 to 50 independent linear block copolymer arms, each of the arms comprising i) a hydrophilic PEG block P? comprising a poly(ethylene oxide) chain and ii) a hydrophobic polyester block P?, a first end unit of the polyester block linked to the PEG block, a second end unit of the polyester block linked to the core C?, wherein the polyester block P? comprises an ester repeat unit of structure

US Pat. No. 10,392,468

HIGHLY FUNCTIONAL NATURAL MATERIAL-DERIVED EPOXY RESIN, PREPARATION METHOD THEREFOR, AND EPOXY RESIN CURING COMPOSITION USING SAME

1. A method of preparing natural material-derived epoxy resin represented by the following Formula 1, the method comprising:a first step including mixing 550 to 650 parts by weight of epichlorohydrin (ECH) obtained from glycerin as a starting material with 100 parts by weight of a compound represented by the following Formula 2, dissolving the mixture at an elevated temperature of 60 to 75° C., adding 5 to 11 parts by weight of sodium hydroxide (NaOH) to 100 parts by weight of a compound represented by the following Formula 2 and conducting preliminary reaction for 2 to 4 hours;
a second step including conducting main reaction of the reactants of the first step at a temperature of 60 to 75° C. and at a reduced pressure of 180 to 250 torr, the main reaction being carried out for 3 to 6 hours by adding 44 to 60 parts by weight of sodium hydroxide (NaOH) to 100 parts by weight of the compound represented by the following Formula 2;
a third step including standing the reaction solution after reaction of the second step, separating the supernatant by reverse aliquoting and filtering the same; and
a fourth step including collecting epichlorohydrin from the filtrate

wherein n is a natural number of 0 to 300,

US Pat. No. 10,392,462

PHOTOSENSITIVE COMPOSITION CONTAINING OXIME-ESTER PHOTOINITIATOR AND APPLICATION THEREOF

Changzhou Tronly Advanced...

1. A photosensitive composition containing an oxime ester photoinitiator, comprising the following components:(A) 20-60 parts by mass of an ultraviolet photosensitive prepolymer resin;
(B) 10-30 parts by mass of an active diluent monomer; and
(C) 1-5 parts by mass of an oxime ester photoinitiator;
the oxime ester photoinitiator as component (C) being at least one selected from the group consisting of bisoxime ester compounds represented by the following general formula (I):

wherein,
R1 is
wherein * represents a binding position, A is a single bond; B is a R5N-group, wherein R5 is hydrogen, a C1-C20 linear or branched alkyl group, a C3-C20 cycloalkyl group, a C4-C20 cycloalkylalkyl group, or a C4-C20 alkylcycloalkyl group; R6 and R7 each independently represent hydrogen, halogen, a nitro group, a hydroxy group, a carboxyl group, a sulfonic acid group, an amino group, a cyano group, or an alkoxy group, or a C1-C20 linear or branched alkyl group, a C3-C20 cycloalkyl group, a C4-C20 cycloalkylalkyl group, or a C4-C20 alkylcycloalkyl group which are optionally substituted with one or more groups selected from the group consisting of halogen, a nitro group, a hydroxy group, a carboxyl group, a sulfonic acid group, an amino group, a cyano group, and an alkoxy group;X and Y each represent a carbonyl (—CO—);
R2 and R3 each independently represent hydrogen, a C1-C20 linear or branched alkyl group, a C3-C20 cycloalkyl group, a C4-C20 cycloalkylalkyl group, a C4-C20 alkylcycloalkyl group, or a C7-C20 aralkyl group, and optionally, one or more hydrogens in the above groups may be each independently substituted with a group selected from the group consisting of halogen, a nitro group, a hydroxy group, a carboxyl group, a sulfonic acid group, an amino group, a cyano group, and an alkoxy group;
R4 independently represents a C1-C20 linear or branched alkyl group, a C3-C20 cycloalkyl group, a C4-C20 cycloalkylalkyl group, a C4-C20 alkylcycloalkyl group, a C3-C20 heteroaryl group, or a C6-C20 aryl group, and optionally, one or more hydrogens in the above groups may be each independently substituted with a group selected from the group consisting of halogen, a phenyl group, a nitro group, a hydroxy group, a carboxyl group, a sulfonic acid group, an amino group, a cyano group, and an alkoxy group.

US Pat. No. 10,392,460

PROCESS FOR PRODUCING GRAFT COPOLYMERS ON POLYOLEFIN BACKBONE

BOREALIS AG, Vienna (AT)...

1. A process of producing a modified olefin polymer (X) comprising a free-radical polymerisable monomer grafted to a polyolefin backbone in an extruder, which process comprises: contacting, in an extruder, an olefin polymer (A) and the free-radical polymeriseable monomer (D) and optionally a free-radical generator (C) to produce a mixture; extruding the mixture in the extruder in the presence of a stable nitroxide radical (B) that is formed by decomposition of an alkoxyamine (F) added to the extruder together with the olefin polymer (A) and, when included, the free-radical generator (C), thereby graft copolymerising the free-radical polymerisable monomer (D) to the olefin polymer (A) to produce the modified polymer composition (X); recovering the modified olefin polymer (X) from the extruder; and cooling the modified olefin polymer (X);wherein the free-radical polymerisable monomer (D) is an unsaturated hydrolysable silane compound or a mixture of unsaturated hydrolysable silane compounds;
and wherein the alkoxyamine (F) has the formula

wherein each R is independently a linear or branched alkyl group haying from 1 to 3 carbon atoms and R1 is one of a hydrogen atom, an alkali metal, NH4+, Bu4N+ or Bu3NH+, where Bu denotes a butyl group.

US Pat. No. 10,392,459

PHOTOCURABLE COMPOSITION AND DEVICE INCLUDING BARRIER LAYER FORMED FROM COMPOSITION

CHEIL INDUSTRIES, INC., ...

1. A photocurable composition comprising:(A) a photocurable monomer; and
(B) a monomer represented by Formula 1,
wherein the photocurable monomer (A) includes one or more of a C1 to C20 alkyl group-containing (meth)acrylate, a C2 to C20 diol di(meth)acrylate, a C3 to C20 triol tri(meth)acrylate, or a C4 to C20 tetraol tetra(meth)acrylate,
wherein the photocurable composition includes, in terms of solid content, 60 parts by weight to 95 parts by weight of the photocurable monomer (A) and 5 parts by weight to 40 parts by weight of the monomer (B) based on 100 parts by weight of (A)+(B),

wherein, in Formula 1,
X1 and X2 are each independently O, S, NH, or NR?, in which R? is a hydrogen or a substituted or unsubstituted C1 to C20 alkyl group;
R1 and R2 are each independently a substituted or unsubstituted C6 to C30 aryl group or a substituted or unsubstituted C7 to C30 arylalkyl group,
R3 is a substituted or unsubstituted C1 to C30 alkylene group, a substituted or unsubstituted C5 to C30 cycloalkylene group, a substituted or unsubstituted C1 to C30 alkyl ether group, a substituted or unsubstituted C1 to C30 alkylamine group, a substituted or unsubstituted C6 to C30 arylene group, a substituted or unsubstituted C7 to C30 arylalkylene group, or a substituted or unsubstituted C1 to C30 alkyleneoxy group;
Z1 is hydrogen,
Z2 is a group represented by Formula 2:

wherein, in Formula 2, * represents a binding site to N in Formula 1; R4 is a substituted or unsubstituted C1 to C30 alkylene group, a substituted or unsubstituted C6 to C30 arylene group, a substituted or unsubstituted C7 to C30 arylalkylene group, or a substituted or unsubstituted C1 to C30 alkyleneoxy group; R5 is hydrogen or a substituted or unsubstituted C1 to C5 alkyl group; and n is an integer from 0 to 20.

US Pat. No. 10,392,458

RESIN BLEND

LG Chem, Ltd., Seoul (KR...

1. A resin blend comprising:a first resin; and
a second resin that is an acrylic polymer having a difference in surface energy, melt viscosity or solubility parameter from the first resin,
wherein the first resin is a polymer of a monomer blend comprising: an alkyl (meth)acrylate containing an alkyl group having 1 to 14 carbon atoms; a monomer represented by Formula 1; and a monomer represented by Formula 3,
wherein the second resin is a polymer of a monomer blend comprising: 47 to 73 parts by weight of an alkyl (meth)acrylate containing an alkyl group having 1 to 14 carbon atoms; 20 to 30 parts by weight of a monomer represented by Formula 1; and 3 to 27 parts by weight of a monomer at least one selected from the group consisting of ?-butyrolactone (meth)acrylate, N-vinyl pyrrolidone, N-vinyl phthalimide, N-succinimidyl acrylate, norbonene lactone (meth)acrylate, hydroxyethyl (meth)acrylate, N-methylol acrylamide and N-phenyl acrylamide, wherein the second resin has a difference in surface energy of 0.1 to 35 mN/m at 25° C. from the first resin, and wherein the second resin has a difference in melt viscosity of 0.1 to 3,000 Pa*s from the first resin at a shear rate of 100 to 1,000 s?1 and a processing temperature of the resin blend:

wherein R1 represents hydrogen, or an alkyl group having 1 to 4 carbon atoms,
Ar represents a phenyl group,
R2 represents hydrogen, or —X—R6, where —X— represents —O—, or —OC(O)—, and R6 represents an alkyl group having 1 to 4 carbon atoms,
Y represents oxygen, or NR10, where R10 represents hydrogen, an alkyl group having 1 to 12 carbon atoms, or a cycloalkyl group having 3 to 8 carbon atoms.

US Pat. No. 10,392,451

LIGAND COMPOUND, ORGANIC CHROMIUM COMPOUND, CATALYST SYSTEM FOR OLEFIN OLIGOMERIZATION, AND METHOD FOR OLIGOMERIZING OLEFINS USING THE SAME THEREOF

LG Chem, Ltd., Seoul (KR...

1. A ligand compound containing at least one group represented by Chemical Formula 1 in a molecule:
wherein, in Chemical Formula 1,
* means that the group represented by Chemical Formula 1 is a radical,
A is boron (B), nitrogen (N), phosphorus (P) or antimony (Sb),
each X is independently phosphorus (P), arsenic (As), or antimony (Sb),
R1 to R4 are each independently an aryl group having 6 to 20 carbon atoms in which at least one substituent is substituted or bonded at the meta or para position of the aryl group, wherein the at least one substituent is selected from the group consisting of an alkyl group, an alkoxy group, an alkylsulfanyl group and an alkylsilyl group.

US Pat. No. 10,392,450

PROCESS FOR ADDING A CHAIN SHUTTLING AGENT

Dow Global Technologies L...

1. A process for the polymerization of one or more polymerizable C2 to C10 alpha-olefin monomers to form a block copolymer comprising two or more regions or segments of differentiated polymer composition or properties, the process comprising:(A) feeding a first mixture that includes a chain shuttling agent, a solvent, the one or more C2 to C10 alpha-olefin polymerizable monomers, and optionally hydrogen into a first reactor or reactor zone;
(B) feeding a second mixture that includes at least one olefin polymerization catalyst and at least one cocatalyst into the first reactor or reactor zone, the second mixture being separate from the first mixture prior to entering the first reactor or reactor zone;
(C) contacting the first mixture and the second mixture under polymerization conditions in the first reactor or reactor zone to form a reaction mixture that is characterized by the formation of polymer chains from the one or more polymerizable C2 to C10 alpha-olefin monomers;
(D) optionally providing the reaction mixture to a second reactor or reactor zone and optionally adding one or more additional solvents, polymerizable C2 to C10 alpha-olefin monomers, and/or catalysts; and
(E) allowing polymerization to occur in at least one of the first reactor or reactor zone and the second reactor or reactor zone to form polymer chains that are differentiated from the polymer chains formed in (C), such that the resultant polymer molecules comprise two or more chemically or physically distinguishable blocks,
wherein the first mixture has a flow rate in pounds per hour into the first reactor or reactor zone that is from 95 times to 1,000,000 times greater than the flow rate in pounds per hour of the second mixture into the first reactor or reactor zone.

US Pat. No. 10,392,449

POLYMERIZATION INITIATOR, MODIFIED CONJUGATED DIENE-BASED POLYMER, AND METHODS FOR PREPARING THEM

LG Chem, Ltd., (KR)

1. A polymerization initiator comprising a compound represented by the following Formula 1:
in Formula 1,
Cy is a cyclic saturated hydrocarbon group having from 5 to 8 carbon atoms, which is unsubstituted or substituted with an alkyl group having from 1 to 4 carbon atoms, and A1 and A2 are each independently a functional group represented by the following Formula 2:

in Formula 2,
R is a linear hydrocarbon group having from 1 to 20 carbon atoms, or a monocyclic or multicyclic saturated hydrocarbon group having from 3 to 20 carbon atoms, X is a divalent hydrocarbon group having from 1 to 5 carbon atoms, M is an alkali metal, and a is 0 or 1.

US Pat. No. 10,392,428

GLP-1 DERIVATIVES AND USES THEREOF

whereinXaa7 is L-histidine, (S)-2-Hydroxy-3-(1H-imidazol-4-yl)-propionic acid, D-histidine, deamino-histidine, homohistidine, N?-acetyl-histidine, N?-formyl-histidine, N?-methyl-histidine, 3-pyridylalanine, 2-pyridylalanine, or 4-pyridylalanine;
Xaa8 is Ala, Gly, Ser, Aib, (1-aminocyclopropyl) carboxylic acid, or (1-aminocyclobutyl) carboxylic acid;
Xaa12 is Phe or Leu;
Xaa16 is Val or Leu;
Xaa18 is Ser, Val, Arg, or Leu;
Xaa19 is Tyr or Gln;
Xaa20 is Leu or Met;
Xaa22 is Gly or Glu;
Xaa23 is Gln, Glu, or Arg;
Xaa25 is Ala or Val;
Xaa26 is Arg;
Xaa27 is Glu or Leu;
Xaa30 is Ala, Glu, or Arg;
Xaa31 is Trp or His;
Xaa33 is Val;
Xaa34 is Lys, Arg, His, Asn, or Gln;
Xaa35 is Lys, Gly, or Ala;
Xaa36 is Lys, Arg, or Gly;
Xaa37 is Gly, Pro, or Lys;
Xaa38 is Lys, Gly, or absent;
Xaa39 is Lys or absent;
wherein at least one of Xaa34, Xaa35, Xaa36, Xaa37, Xaa38, and Xaa39 is Lys;
which derivative comprises a side chain that is attached to the Lys residue of Xaa34, Xaa35, Xaa36, Xaa37, Xaa38, or Xaa39,
which side chain comprises:
(i) a Branched linker of Chem. 11:

wherein q is an integer in the range of 0-5, w is an integer in the range of 0-5, with the provisos that when w is 0 q is an integer in the range of 1-5, and when q is 0 w is an integer in the range of 1-5; and
(ii) a 1st and a 2nd Protractor of Chem. 12:

wherein the Branched linker is connected
a) at its —CO end to the epsilon amino group of the Lys residue of Xaa34, Xaa35, Xaa36, Xaa37, Xaa38, or Xaa39, via a Pre-linker, and
b) at each of its two —NH ends to the —CO end of each of the 1st and 2nd Protractor, respectively, via a 1st and a 2nd Post-linker, respectively;
wherein each of the Pre-linker, the 1st Post-linker, and the 2nd Post-linker comprises a —CO group and an —NH group;
or a pharmaceutically acceptable salt, amide, or ester thereof.

US Pat. No. 10,392,422

MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS

RQX PHARMACEUTICALS, INC....

1. A compound of Formula (I):
wherein:
E1 is phenyl
E2 is phenyl;
L1 is a bond;
L2 is a bond;
X is —CH2OH, —CH(OH)CH3, —N(R4)CH(R24)CN, —NHCH(R24)C(O)CH3, —NHN(R24)C(O)CH3, —NHCH(R24)CH?CHS(O)2CH3, —NHCH(R24)CH?CHS(O)2NH2,

n4, n5, and n6 are each independently 1 or 2;
n7 is 0, 1 or 2;
R21b and R22b are independently at each occurrence hydrogen or (C1-C6)alkyl;
R24 is H or (C1-C6)alkyl;
R25 is —CH3, —CH2Cl, —CH2OR25b, —CH2R30, —C(R26)2C(O)NH2, —CH2SO2N(R25b)2, —CH2N(R25b)SO2(C1-C6alkyl), —CH2PO3H, —CH2P(O)(OH)OCH3, —CH2OC(O)CH3, —CH2OC(O)R30, —CH2CO2R25b, —CF2CO2R25b, —CH2CH2CO2R25b, —CH2CH2C(O)N(R25b)2, —CH2CH2C(O)N(H)CH(R26)CO2R25b, —CH2N(H)CH(R26)C(O)N(H)R25b, —CH2CH2R30, —N(H)CH2(R30), —CH?CHR30, —CH?CHSO2R25b,

R25a is H, —OH, —OCH3, NH2, SO2(C1-C6)alkyl, or (C1-C6)alkyl;
each R25b is independently H or (C1-C6)alkyl;
R25c is H or (C1-C6)alkyl;
R25d is —OH, —OCH3, or NH2;
each R26 is independently H, halo or (C1-C6)alkyl;
each R27 is independently —OH, halo, (C1-C6)alkyl, or R26 and R27 are joined to form a cycloalkyl ring;
R28 is H, —CH2OH, —CH2NH2, —C(O)CH3, or (C1-C6)alkyl;
each R29 is independently —OH, halo, or (C1-C6)alkyl;
R30 is heterocyclyl, heteroaryl, or aryl;
n9 is 1, 2 or 3;
n10 is 0, 1, 2, 3 or 4;
R5 is aryl, heteroaryl, or a linear or branched alkyl chain of about 1-22 carbon atoms, wherein R5 is bonded to the carbonyl carbon to which it is attached directly or by an O or NR4, to provide an amide, carbamate, or urea linkage, respectively; optionally comprising within the chain or at a chain terminus optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted
wherein Z is a bond, O, S, NH, CH2 or C?C; or R5 is a linear or branched alkyl chain of about 1-22 carbon atoms, comprising within the chain at least one —O— or —N(R4)—;each R2 and R3 are each independently hydroxy or OR40;
each R40 is independently —(C1-C6)alkyl; or —(C1-C6)alkyl-NR41R42;
each R41 and R42 is hydrogen or —(C1-C6)alkyl;
n1 and n2 are independently 0 or 1;
n3 and n8 are 1;
each m is independently 0 or 1;
R1 is hydrogen or (C1-C6)alkyl;
R4, R4?, and R4? are each independently at each occurrence hydrogen or (C1-C6)alkyl;
R6 is hydrogen or (C1-C6)alkyl;
RA1, RA1?, RA2, RA3, RA3? are each independently hydrogen or (C1-C6)alkyl;
RA4, RA4?, RA7, RA7?, RA8, RA8?, RA9, RA9?, RA10, and RA10? are independently at each occurrence hydrogen or (C1-C6)alkyl optionally substituted with 1 to 3 J;
RA6 is H, amino, or (C1-C6)alkyl optionally substituted with 1 to 3 J;
each J is independently OR?, (CH2)0-pN(R?)2, (CH2)0-pSR?, (CH2)0-pS(O)2N(R?)2, (CH2)0-pC(O)OR?, or (CH2)0-pC(O)N(R?)2,
wherein p is 4;
each R? is independently at each occurrence hydrogen or (C1-C6)-alkyl;
or a pharmaceutically acceptable salt or solvate thereof.

US Pat. No. 10,392,421

CYTOTOXIC PEPTIDES AND CONJUGATES THEREOF

Novartis AG, Basel (CH)

1. An immunoconjugate of Formula (III):wherein:Ab represents an antigen binding moiety;
L is selected from -L1 L2L3L4L5L6-, -L6L5L4L3L2L1-, -L1 L2L3L4L5-, -L5L4L3L2L1-, -L1L2L3L4-, -L4L3L2L1- -L1L2L3-, -L3 L2 L1-, -L1L2-, -L2L1- and -L1,
wherein
L1 is selected from —(CH2)m—, —C(?O)(CH2)m—, —C(?O)X1X2C(?O)(CH2)m—, —C(?O)X1X2C(?O)(CH2)mNR12C(?O)(CH2)m—, —C(?O)X1X2C(?O)(CH2)mX3(CH2)m—, —C(?O)X1X2C(?O)((CH2)mO)n(CH2)m—, —C(?O)X1X2C(?O)((CH2)mO)n(CH2)mNR12C(?O)(CH2)m—, —C(?O)X1X2C(?O)((CH2)mO)n(CH2)mNR12C(?O)(CH2)mX3(CH2)m—, —C(?O)X1X2C(?O)((CH2)mO)n(CH2)mX3(CH2)m—, —C(?O)X1X2C(?O)(CH2)mNR12C(?O)((CH2)mO)n(CH2)m—, —C(?O)X1X2C(?O)(CH2)mNR12C(?O)((CH2)mO)n(CH2)mX3(CH2)m—, —C(?O)X1X2(CH2)mX3(CH2)m—, —C(?O)X1X2((CH2)mO)n(CH2)m—, —C(?O)X1X2((CH2)mO)n(CH2)mNR12C(?O)(CH2)m—, —C(?O)X1X2((CH2)mO)n(CH2)mNR12C(?O)(CH2)mX3(CH2)m—, —C(?O)X1X2((CH2)mO)n(CH2)mX3(CH2)m—, —C(?O)X1X2(CH2)mNR12((CH2)mO)n(CH2)m—, —C(?O)X1X2C(?O)(CH2)mNR12((CH2)mO)n(CH2)mX3(CH2)m—, —(CH2)mNR12C(?O)(CH2)m—, —C(?O)((CH2)mO)n(CH2)m—, —(CH2)mS(?O)2((CH2)mOn(CH2)m—, —C(?O)(CH2)mNR12(CH2)m—, —C(?O)NR12(CH2)m—, —C(?O)NR12(CH2)mX3(CH2)m—, —C(?O)NH(CH2)mNR12C(?O)X2X2C(?O)(CH2)m—, —C(?O)X1C(?O)NR12(CH2)mNR12C(?O)(CH2)m—, —C(?O)X1C(?O)NR12(CH2)mX3(CH2)m—, —C(?O)NR12(CH2)mNR12C(?O)(CH2)m—, —C(?O)NR12(CH2)mNR12C(?O)(CH2)mX3(CH2)m—,

 —(CH2)mC(?O)NR12(CH2)mNR12C(?O)(CH2)m—, —(CH2)mC(?O)—, —(CH2)mC(?O)X2X1C(?O)—, —(CH2)mX3(CH2)mC(?O)X2X1C(?O)—, —(CH2)mC(?O)NR12(CH2)m—, —(CH2)mX3(CH2)mC(?O)NR12(CH2)m—, —(CH2)mNR12C(?O)(CH2)mX3(CH2)m—, —(CH2)m(O(CH2)m)nC(?O)—, —(CH2)m(O(CH2)m)nS(?O)2(CH2)m—, —(CH2)mNR12(CH2)mC(?O)—, —(CH2)mNR12C(?O)—, —(CH2)mC(?O)X2X1C(?O)NR12(CH2)mNHC(?O)—, —(CH2)mC(?O)NR12(CH2)mNR12C(?O)X1—, —(CH2)mC(?O)NR12(CH2)mNR12C(?O)—,

 -((CH2)mO)n(CH2)m—, —(CH2)m(O(CH2)m)n-, —(CH2)m(O(CH2)m)nX3(CH2)m—, —(CH2)mX3((CH2)mO)n(CH2)m—, —(CH2)mX3(CH2)mC(?O)—, —C(?O)(CH2)mX3(CH2)m—, —(CH2)mX3(CH2)m(O(CH2)m)nC(?O)—, —C(?O)((CH2)mO)n(CH2)mX3(CH2)m—, —(CH2)mC(?O)NR12(CH2)mC(?O)—, —C(?O)(CH2)mNR12C(?O)(CH2)m—, —C(?O)(CH2)mNR12C(?O)O(CH2)m—, —(CH2)mOC(?O)NR12(CH2)mC(?O)—, —S(?O)2(CH2)mNR12C(?O)O(CH2)m—, —(CH2)mOC(?O)NR12(CH2)mS(?O)2—, —(CH2)mC(?O)NR12(CH2)m(O(CH2)m)nC(?O)—, —C(?O)((CH2)mO)n(CH2)mNR12C(?O)(CH2)m—, —(CH2)mC(?O)NR12(CH2)mC(?O)NR12(CH2)m—, —(CH2)mNR12C(?O)(CH2)mNR12C(?O)(CH2)m—, —C(?O)NR12(CH2)mNR12C(?O)—, —(CH2)mS(CH2)m—, —NR12C(?O)(CH2)m—, —NR12C(?O)(CH2)mX3(CH2)m—, —(CH2)mX3(CH2)mC(?O)NR12—, —(CH2)mC(?O)NR12—, —(CH2)mNR12(CH2)m—, —(CH2)mX3(CH2)m—, —((CH2)mO)n(CH2)mX3(CH2)m—, —(CH2)mX3(CH2)m(O(CH2)m)n-, —NR12(CH2)m—, —NR12C(R12)2(CH2)m—, —(CH2)mC(R12)2NR12—, —(CH2)mC(?O)NR12(CH2)mNR12—, —NR12(CH2)mNR12C(?O)(CH2)m—, —NR12C(R12)2(CH2)mNR12C(?O)(CH2)m—, —(CH2)mC(?O)NR12(CH2)mC(R12)2NR12—, —NR12(CH2)mX3(CH2)m—, —NR12C(R12)2(CH2)mX3(CH2)m—, —(CH2)mX3(CH2)mC(R12)2NR12—, —NR12C(R12)2(CH2)mOC(?O)NR12(CH2)m—, —(CH2)mNR12C(?O)O(CH2)mC(R12)2NR12—, —NR12C(R12)2(CH2)mOC(?O)NR12(CH2)mX3(CH2)m—, —NR12(CH2)mO)n(CH2)mX3(CH2)m—, —(CH2)mX3(CH2)m(O(CH2)m)nNR12—, —NR12(CH2)mO)n(CH2)m—, —(CH2)m(O(CH2)m)nNR12—, —NR12(CH2)mO)n(CH2)m—, —(CH2)mX3(CH2)mNR12C(?O)O(CH2)mC(R12)2NR12—, —NR12C(R12)2(CH2)mOC(?O)NR12((CH2)mO)n(CH2)m—, —(CH2)m(O(CH2)m)nNR12C(?O)O(CH2)mC(R12)2NR12—, —NR12C(R12)2(CH2)mOC(?O)NR12((CH2)mO)n(CH2)mX3(CH2)m—, —(CH2)mX3(CH2)m(O(CH2)m)nNR12C(?O)O(CH2)mC(R12)2NR12—, —(CH2)mX3(CH2)mNR12—, —NR12((CH2)mO)n(CH2)mX3(CH2)m—, —(CH2)mX3(CH2)m(O(CH2)m)nNR12—, —(CH2)mNR12—, —NR12((CH2)mO)n(CH2)m—, —NR12((CH2)mO)n(CH2)mNR12C(?O)(CH2)m—, —(CH2)mC(?O)NR12(CH2)m(O(CH2)m)nNR12—, —(CH2)m(O(CH2)m)nNR12—, —(C(R12)2)m—, —(CH2CH2O)n—, —(OCH2CH2)n—, —(CH2)mO(CH2)m—, —S(?O)2(CH2)m—, —(CH2)mS(?O)2—, —S(?O)2(CH2)mNR12C(?O)(CH2)m—, —(CH2)mC(?O)NR12(CH2)mS(?O)2—, —S(?O)2(CH2)mX3(CH2)m—, —(CH2)mX3(CH2)mS(?O)2—, —(CH2)mX2X1C(?O)—, —C(?O)X2X1(CH2)m—, —(CH2)m(O(CH2)m)nC(?O)X2X1C(?O)—, —C(?O)X1X2C(?O)( (CH2)mO)n(CH2)m—, —(CH2)m(O(CH2)m)nX2X1C(?O)—, —(CH2)mX3(CH2)mX2X1C(?O)—, —C(?O)X2X1(CH2)mX3(CH2)m—, —(CH2)mX3(CH2)m(O(CH2)m)nX2X1C(?O)—, —(CH2)mX3(CH2)mC(?O)NR12(CH2)mNR12C(?O)—, —(CH2)mX3(CH2)mC(?O)NR12(CH2)mC(?O)—, —C(?O)(CH2)mNR12C(?O(CH2)mX3(CH2)m—, —(CH2)mX3(CH2)mC(?O)NR12(CH2)m(O(CH2)m)nC(?O)—, —C(?O)((CH2)mO)n(CH2)mNR12C(?O)(CH2)mX3(CH2)m—, —(CH2)mNR12C(?O)X1X2C(?O)(CH2)m—, —(CH2)mC(?O)X2X1C(?O)NR12(CH2)m—, —X4X1X2C(?O)(CH2)m—, —(CH2)mC(?O)X2X1X4—, —X1C(?O)(CH2)mNHC(?O)(CH2)m—, —(CH2)mC(?O)NH(CH2)mC(?O)X1—, —C(?O)CHRaaNR12—, —CHRaaC(?O)—, —C(?O)NR12—, —C(?O)O—, —S—, —SCH2(C?O)NR12—, —NR12C(?O)CH2S—, —S(?O)2CH2CH2S—, —SCH2CH2S(?O)2—, —(CH2)2S(?O)2CH2CH2S—, —SCH2CH2S(?O)2CH2CH2—, —NR12C(?S)—, —(CH2)mX3(O(CH2)m)nC(?O)—, —C(?O)((CH2)mO)nX3(CH2)m—, —(CH2)mNR12C(?O)((CH2)mO)n(CH2)m—, —(CH2)m(O(CH2)m)nC(?O)NR12(CH2)m—, —(CH2)mNR12C(?O)NR12(CH2)m—, —(CH2)mX3(CH2)mNR12C(?O)—, —C(?O)NR12(CH2)mX3(CH2)m—, —NR12S(?O)2(CH2)mX3(CH2)m—, —(CH2)mX3(CH2)mS(?O)2NR12—,

R20 is H or Me, and R30 is H, —CH3 or phenyl;
R21 is

each R25 is independently selected from H or C1-4 alkyl;
Raa is a side chain of an amino acid selected from glycine, alanine, tryptophan, tyrosine, phenylalanine, leucine, isoleucine, valine, asparagine, glutamic acid, glutamine, aspatic acid, histidine, arginine, lysine, cysteine, methionine, serine, threonine, phenylglycine and t-butylglycine;
R32 is independently selected from H, C1-4 alkyl, phenyl, pyrimidine and pyridine;
R33 is independently selected from

R34 is independently selected from H, C1-4 alkyl, and C1-6 haloalkyl;
X1 is self immolative spacer selected from

X2 is dipeptide selected from

X3 is

 and
X4 is

and L2, L3, L4, L5, and L6 are each independently selected from a bond and L1;
y is an integer from 1 to 16;
R1 is a 6 membered heterocycloalkyl containing 1-2 N heteroatoms and a C1-C2alkylene bridge, wherein the 6 membered heterocycloalkyl is unsubstituted or substituted with 1 to 3 substituents independently selected from R5 and R6;
or R1 is a 5-8 membered fused bicyclic heterocycloalkyl containing 1-2 N heteroatoms, wherein the 5-8 membered fused bicyclic heterocycloalkyl is unsubstituted or substituted with 1 to 3 substituents independently selected from R5 and R6;
R2 is —C1-C6alkyl;
R3 is

R5 is C 1-C6alkyl, —C(?O)R11, —(CH2)mOH, —C(?O)(CH2)mOH,—C(?O)((CH2)mO)nR12, —((CH2)mO)nR12, or C1-C6alkyl which is optionally substituted with —CN, —C(?O)NH2 or 1 to 5 hydroxyl;
R6 is halo, oxo, OH, C1-C6alkyl, —N(R14)2, —R16 and —NR12C(?O)R11;
R11 is C1-C6alkyly or C1-C6alkyl which is optionally substituted with 1 to 5 hydroxyl;
each R12 is independently selected from H and C1-C6alkyly;
each R14 is independently selected from H and C1-C6alkyly;
R16 is an N-linked 4-8 membered heterocycloalkyl containing 1-2 heteroatoms independently selected from N and O;
R17 is a bond, —NH—, —NHS(?O)2—,

R18 is a bond,

R19 is H or C1-C6alkyly ;
each m is independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10,
and
each n is independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16,17 and 18.

US Pat. No. 10,392,419

MODIFIED CYCLIC DINUCLEOTIDE COMPOUNDS

Boehringer Ingelheim Inte...

1. A compound of formula (I)
wherein
Base1 and Base2 are independently selected from the group consisting of purine, adenine, guanine, xanthine, and hypoxanthine, connected through their N9 nitrogen atoms,
or a salt thereof.

US Pat. No. 10,392,418

OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF MAKING THE SAME

Geron Corporation, Menlo...

1. A method of synthesizing a polynucleotide of the formula:wherein:each B is independently a purine, a protected purine, a pyrimidine or a protected pyrimidine, or an analog thereof;
each X is independently oxygen or sulfur;
each R3 is hydrogen, fluoro, or hydroxyl, an alkoxy, a substituted alkoxy or a protected hydroxyl;
L is an optional linker;
Z is H, a lipid, a support, a carrier, an oligonucleotide, a PEG, a polypeptide, a detectable label, or a tag;
R6 is amino, hydroxyl, a protected amino, a protected hydroxy, —O-L-Z or NH-L-Z;
R is hydrogen, an alkyl, a substituted alkyl, an aryl, a substituted aryl, or a phosphate protecting group; and
n is an integer of 1 to 1000; or a salt thereof;the method comprising the steps of:(a) deprotecting a protected 3? amino group of a terminal nucleoside attached to a solid phase support, said deprotecting forming a free 3? amino group;
(b) reacting the free 3? amino group with either:
(i) a 3?-protected amino-dinucleotide phosphoramidate-5?-phosphoramidite dimer; or
(ii) a 3?-protected aminonucleoside-5?-phosphoramidite monomer;
in the presence of a nucleophilic catalyst to form an internucleoside N3??P5? phosphoramidite linkage;
(c) oxidizing the linkage; and
(d) repeating steps (a) through (c) until the polynucleotide is synthesized, wherein the repeating steps (a) through (c) comprises performing step (b)(i) at least once.

US Pat. No. 10,392,416

CRYSTAL FORMS OF BETA-NICOTINAMIDE MONONUCLEOTIDE

Metro International Biote...

1. A compound having the structure of formula (I),
or a salt thereof, wherein the compound or salt thereof is in a crystalline form, wherein the crystalline form is a hydrate.

US Pat. No. 10,392,415

CRYSTAL FORMS OF ?-NICOTINAMIDE MONONUCLEOTIDE

Metro International Biote...

1. A crystalline form of a compound having the structure of formula (I),
wherein the crystalline form is a dimethylsulfoxide solvate.

US Pat. No. 10,392,414

SYNTHESES, ACTIVITIES, AND METHODS OF USE OF DIHYDRONICOTINAMIDE RIBOSIDE DERIVATIVES

CORNELL UNIVERSITY, Itha...

1. A compound of formula (I):
wherein R1, R2, and R3 are independently selected from hydrogen, formyl, optionally substituted C1-C12 alkylcarbonyl, and optionally substituted C6-C10 arylcarbonyl,
X is NHR4 or NR4R5,
R4 and R5 are independently optionally substituted C1-C12 alkyl or optionally substituted C6-C10 aryl, and
wherein the alkyl or aryl portion of R4 and R5 is optionally substituted with one or more substituents selected from halo, amino, alkyl, alkoxy, aryloxy, hydroxyalkyl, and any combination thereof,
or a salt thereof.

US Pat. No. 10,392,413

SUBSTITUTED 4-PHENYL PYRIDINE COMPOUNDS AS NON-SYSTEMIC TGR5 AGONISTS

ARDELYX, INC., Fremont, ...

1. A compound of Formula (I?):
or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof,
wherein:
Q is C?(O), —CH2—, —NR5— or —O—;
when Q is C?(O) then Q1 is —NR5—, when Q is —NR5— or —O— then Q1 is —CH2—, or when Q is —CH2— then Q1 is —O(CH2)0-1— or —NR5—;
X1 is CR6 or N;
X2 is CR7 or N;
X3 is CR8 or N;
X4 is CR9 or N;
Y is CRb or N;
Ra and Rb are each independently H, (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, or halogen;
R1 is H, (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, halogen, —S(O)p(C1-C6) alkyl, (C3-C8) cycloalkyl, heterocycloalkyl, —O—(C3-C8) cycloalkyl, or —O-heterocycloalkyl, wherein the alkyl, alkoxy, cycloalkyl, and heterocycloalkyl are optionally substituted with one or more substituents selected from the group consisting of halogen, (C1-C4) alkoxy, —OH, —NH2, —NH(C1-C4) alkyl, and —N((C1-C4) alkyl)2; or
R1 and Ra together with the carbon atoms to which they are attached form a heterocycloalkyl; or
R1 and R3, when on adjacent atoms, together with the carbon atoms to which they are attached form a heterocycloalkyl optionally substituted with one or more substituents selected from the group consisting of (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, and halogen;
R2 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, or (C1-C6) haloalkoxy;
R2? is H, (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, or (C1-C6) haloalkoxy; or
R2 and R2? together with the carbon atom to which they are attached form a (C3-C8) cycloalkyl or heterocycloalkyl;
each R3 is independently, at each occurrence, (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, halogen, —S(O)p(C1-C6) alkyl, (C3-C8) cycloalkyl, heterocycloalkyl, —O—(C3-C8) cycloalkyl, or —O-heterocycloalkyl, wherein the alkyl, alkoxy, cycloalkyl, and heterocycloalkyl are optionally substituted with one or more substituents selected from the group consisting of halogen, (C1-C4) alkoxy, —OH, —NH2, —NH(C1-C4) alkyl, and —N((C1-C4) alkyl)2; or
R1 and R3 together with the carbon atoms to which they are attached form a heterocycloalkyl optionally substituted with one or more substituents selected from the group consisting of (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, and halogen;
R4 is H, (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, (C1-C6) aminoalkyl, halogen, (C3-C8) cycloalkyl, heterocycloalkyl, —OH, —NH2, CN, —S(O)m(C1-C6) alkyl, —NH(C1-C4) alkyl, or —N((C1-C4) alkyl)2;
each R5 is independently H, (C1-C6) alkyl, —C(O)NR10R11, —C(O)(C1-C6) alkyl, or —C(O)O(C1-C6) alkyl;
each R6 and R9 is independently H, (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, (C1-C6) aminoalkyl, halogen, (C3-C8) cycloalkyl, heterocycloalkyl, —OH, —NH2, CN, —S(O)o(C1-C6) alkyl, —NH(C1-C4) alkyl, or —N((C1-C4) alkyl)2;
each R7 and R8 is independently H, (C1-C8) alkenyl, (C1-C8) alkynyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, (C1-C6) aminoalkyl, halogen, (C3-C8) cycloalkyl, (C3-C8) cycloalkenyl, heterocycloalkyl, —OH, —NH2, —S(O)qNH2, —S(O)qOH, CN, or (C1-C18) alkyl, wherein 0 to 7 methylene of the (C1-C18) alkyl is optionally replaced by a moiety selected from the group consisting of —O—, —NR13—, —S(O)q—, —C(O)—, —C(CH2)—, or —C(NH)—, provided that when any two methylene in the alkyl is replaced, then two —O—, two —S(O)q—, or two —NR13— and —O— and —NR13— are not contiguous, wherein the alkyl is optionally substituted with one or more R12, and wherein the cycloalkyl and cycloalkenyl are optionally substituted with one or more R13;
R10 and R11 are each independently H or (C1-C6) alkyl optionally substituted with one or more substituent independently selected from the group consisting of —NH2 and OH;
R12 is D, —OH, halogen, —NH2, —NH(C1-C6) alkyl, —N((C1-C6) alkyl)2, —C(O)OH, —OC(O)(C1-C6) alkyl, (C3-C8) cycloalkyl, heterocycloalkyl, (C6-C10) aryl, heteroaryl, or R17, wherein the cycloalkyl, heterocycloalkyl, aryl, and heteroaryl are optionally substituted with one or more substituents selected from the group consisting of —OH, —NH2, —NH(C1-C6) alkyl, —N((C1-C6) alkyl)2, halogen, and R14;
R13 is H, —OH, (C3-C8) cycloalkyl, heterocycloalkyl, (C6-C10) aryl, heteroaryl, or (C1-C12) alkyl, wherein 0 to 7 methylene of the (C1-C12) alkyl is optionally replaced by a moiety selected from the group consisting of —O—, —NR13—, —S(O)r—, —C(O)—, or —C(NH)—, provided that a when any two methylene in the alkyl is replaced, then O and N are not contiguous and wherein the alkyl is optionally substituted with one or more R15, and wherein the cycloalkyl, heterocycloalkyl, aryl, and heteroaryl are optionally substituted with one or more substituents selected from the group consisting of —OH, —C(O)OH, —NH2, —NH(C1-C6) alkyl, and —N((C1-C6) alkyl)2;
R14 is (C3-C8) cycloalkyl, heterocycloalkyl, —O—(C3-C8) cycloalkyl, —O-heterocycloalkyl, (C1-C12) alkyl or (C2-C12) alkenyl, wherein 0 to 7 methylene of the (C1-C12) alkyl and the (C2-C12) alkenyl are optionally replaced by a moiety selected from the group consisting of —O—, —NR13—, —S(O)r—, —C(O)—, or —C(NH)—, provided that a when any two methylene in the alkyl or alkenyl is replaced, then O and N are not contiguous and wherein the alkyl and alkenyl are optionally substituted with one or more R15, and the cycloalkyl and heterocycloalkyl are optionally substituted with one or more R16; or
when R12 is cycloalkyl or heterocycloalkyl, two R14 together with the atom to which they are attached form C?(O); or when R12 is cycloalkyl or heterocycloalkyl, two R14 together with the atoms to which they are attached form a (C3-C8) cycloalkyl or heterocycloalkyl optionally substituted with one or more R13; or when R12 is cycloalkyl or heterocycloalkyl, two R14 together with the atom to which they are attached form a (C3-C8) spirocycloalkyl or a spiroheterocycloalkyl optionally substituted with one or more R13; or when R12 is cycloalkyl or heterocycloalkyl, two R14 together with the atom to which they are attached form a (C6-C10) aryl or heteroaryl optionally substituted with one or more R13;
R15 is —OH, —NH2, —NH(C1-C6) alkyl, —N((C1-C6) alkyl)2, (C3-C8) cycloalkyl, heterocycloalkyl, (C6-C10) aryl or heteroaryl, wherein the (C3-C8) cycloalkyl and heterocycloalkyl are optionally substituted with one or more substituents selected from the group consisting of (C1-C6) hydroxyalkyl, (C1-C6) aminoalkyl, —C(O)OH, —OH, —NH2, —NH(C1-C6) alkyl, —N((C1-C6) alkyl)2, and oxo;
R16 is —OH, —C(O)OH, —NH2, —NH(C1-C6) alkyl, —N((C1-C6) alkyl)2, (C1-C6) alkoxy, (C1-C6) hydroxyalkyl, (C3-C8) cycloalkyl, heterocycloalkyl, —O—(C3-C8) cycloalkyl, —O-heterocycloalkyl, (C6-C10) aryl or heteroaryl, wherein the (C3-C8) cycloalkyl and heterocycloalkyl are optionally substituted with one or more substituents selected from the group consisting of (C1-C6) hydroxyalkyl, (C1-C6) aminoalkyl, —C(O)OH, —OH, —NH2, —NH(C1-C6) alkyl, —N((C1-C6) alkyl)2, and oxo;
R17 is (C1-C18) alkyl or (C2-C18) alkenyl, wherein 0 to 8 methylene of the (C1-C18) alkyl and the (C2-C18) alkenyl are optionally replaced by a moiety selected from the group consisting of —O—, —NR13—, —S(O)r—, —C(O)—, or —C(NH)—, provided that a when any two methylene in the alkyl or alkenyl is replaced, then O and N are not contiguous and wherein the alkyl and alkenyl are optionally substituted with one or more R18;
R18 is R19, (C6-C10) aryl, or heteroaryl optionally substituted with one or more R21;
R19 is (C1-C18) alkyl wherein 0 to 8 methylene of the (C1-C18) alkyl is optionally replaced by a moiety selected from the group consisting of —O—, —NR13—, —S(O)r—, —C(O)—, or —C(NH)—, provided that a when any two methylene in the alkyl or alkenyl is replaced, then O and N are not contiguous and wherein the alkyl is optionally substituted with one or more R20;
R20 is (C6-C10) aryl or heteroaryl optionally substituted with one or more R21;
R21 is H, (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, or halogen; or
two R21 together when on adjacent atoms form a cycloalkyl or heterocycloalkyl optionally substituted with one or more R22,
R22 is —C(O)NH2, —C(O)NH(C1-C6) alkyl, —C(O)N((C1-C6) alkyl)2, —C(O) (C3-C7) cycloalkyl, or —C(O)heterocycloalkyl, wherein the cycloalkyl and heterocycloalkyl are optionally substituted with one or more substituents independently selected from the group consisting of —OH and CN;
each m, o, p, q, and r is independently, at each occurrence, 0, 1, or 2; and
n is 0, 1, or 2.

US Pat. No. 10,392,412

PLATINUM ANTICANCER AGENTS

THE REGENTS OF THE UNIVER...

1. A compound, or a pharmaceutically acceptable salt thereof, having the formula:
wherein R1 is independently hydrogen, halogen, —CY13, —CN, —SR9, —OSO2R8, —OSO3H, —NH2NH2, —ONR6R7, —NH2C(O)NHNH2, —C(O)R8, —C(O)NR6R7, —NH2C(O)NR6R7, —NR6R7, —OC(O)R8, —OC(O)NR6R7, —OR9, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
R2 is independently halogen, —CY23, —CN, —SOqR10, —SOuNR11R12, —NHNH2, —ONR11R12, —NHC?(O)NHNH2, —NHC?(O)NR11R12, —N(O)m, —NR11R12, —C(O)R13, —C(O)—OR13, —C(O)NR11R12, —OR10, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
two adjacent R2 substituents may optionally be joined to form a substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
R3 is an unsubstituted C1-C4 alkyl or H;
R4, R5 and R32 are independently halogen,
—N3, —SCN, or —CN;R6, R7, R8, R9, R10, R11, R12, and R13 are independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
z is an integer from 0 to 4;
u is independently an integer from 1 to 2;
m is independently an integer from 1 to 2;
q is independently an integer from 0 to 4;
Y1 and Y2 are independently —Cl, —Br, —I, or —F.

US Pat. No. 10,392,408

SILOXANE OLIGOMERS FOR THE TREATMENT OF SOLID SURFACES

AVMOR LTD, Laval (CA)

1. A siloxane oligomer of formula:
wherein:
R1 is alkylene optionally interrupted with one or more —NR20-group;
R2 is alkylene;
R3 is —H, —F or optionally substituted alkyl;
R4 is alkyl or fluoroalkyl;
R10 is fluoroaryl or alkyl optionally substituted, preferably end-substituted, by:
fluoroalkyl,
glycidyloxy,
optionally substituted aryl,
optionally substituted aryloxy, or
—N+(R21)(R22)(R23);
R20 is H or alkyl;
R21, R22 and R23 are independently alkyl, optionally substituted aryl, or alkyl-O-alkyl; and
m and n represent the number of repeat units, m being 1 or greater and n being 0 or greater.

US Pat. No. 10,392,407

METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES

IMMUNOGEN, INC., Waltham...

1. A method of preparing a compound of formula (3a),
or a salt thereof, said method comprising the steps of:
(i) introducing an alcohol protecting group onto one of the primary alcohols of a compound of formula (1a) by reacting the compound of formula (1a) with an alcohol protecting reagent,

to form a compound of formula (2a),

or a salt thereof, and
(ii) reacting a halogenating reagent, a sulfonating reagent or an esterification reagent with the compound of formula (2a),
wherein P1 is an alcohol protecting group; X1 is a leaving group selected from the group consisting of: —Br, —I, —Cl, a sulfonate ester, and an activated ester; and R101 is (C1-C3)alkyl, pyridyl, or nitropyridyl.

US Pat. No. 10,392,406

SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES AND PRODRUGS THEREOF

1. A compound represented by the following formula:
or its pharmaceutically acceptable salt.

US Pat. No. 10,392,405

MACROCYCLIC IMMUNOMODULATORS

ChemoCentryx, Inc., Moun...

1. A compound of Formula (I) or Formula (II):
or a pharmaceutically acceptable salt thereof; wherein:
R is selected from the group consisting of H, halogen, CN, C1-3 haloalkyl, C1-3 alkyl and C1-3 alkoxy;
R1 is selected from the group consisting of halogen, C5-8 cycloalkyl, C6-10 aryl and thienyl, wherein the C6-10 aryl and thienyl are optionally substituted with 1 to 5 R1a substituents;
each R1a independently selected from the group consisting of halogen, —CN, —Rc, —CO2Ra, —CONRaRb, —C(O)Ra, —OC(O)NRaRb, —NRbC(O)Ra, —NRbC(O)2Rc, —NRa—C(O)NRaRb, —NRaRb, —ORa, —O—X1—ORa,—O—X1—CO2Ra, —O—X1—CONRaRb, —X1—OR3, —X1—NRaRb, —X1—CO2Ra, —X1—CONRaRb, —SF5, and —S(O)2NRaRb, wherein each X1 is a C1-4 alkylene; each Ra and Rb is independently selected from hydrogen, C1-8 alkyl, and C1-8 haloalkyl, or when attached to the same nitrogen atom can be combined with the nitrogen atom to form a five or six-membered ring having from 0 to 2 additional heteroatoms as ring members selected from N, O or S, wherein the five or six-membered ring is optionally substituted with oxo; each Rc is independently selected from the group consisting of C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl and C1-8 haloalkyl; and optionally when two R1a substituents are on adjacent atoms, they are combined to form a fused five, six or seven-membered carbocyclic or heterocyclic ring optionally substituted with from 1 to 3 substituents independently selected from halogen, oxo, C1-8 haloalkyl and C1-8 alkyl; or
R1 is
whereineach of R1b, R1c, R1d and R1e is independently selected from the group consisting of H, halogen, CF3, CN, C1-4 alkyl and —O—C1-4 alkyl, wherein the C1-4 alkyl and —O—C1-4 alkyl are optionally further substituted with halogen, hydroxyl, methoxy or ethoxy;
L is a linking group selected from the group consisting of:

wherein each of the subscripts q is independently 1, 2, 3 or 4, and L is optionally further substituted with one or two members selected from the group consisting of halogen, hydroxy, C1-3 alkyl, —O—C1-3 alkyl, C1-3 hydroxyalkyl, C1-3 haloalkyl and —CO2H;
Z is selected from the group consisting of azetidinyl, pyrollidinyl, piperidinyl, morpholinyl, pyridyl, pyrimidinyl, guanidinyl, quinuclidine, and 8-azabicyclo[3.2.1]octane, each of which is optionally substituted with from 1 to 3 groups independently selected from halogen, hydroxy, C1-3 alkyl, —NH2, —NHC1-3alkyl, —N(C1-3alkyl)2, —O—C1-3 alkyl, C1-3 hydroxyalkyl, C1-3 haloalkyl and —CO2H;
or
Z is selected from the group consisting of —CO2Rz1and —NRz1Rz2; wherein Rz1 is selected from the group consisting of H, C1-8 alkyl, C1-8 haloalkyl and C1-8 hydroxyalkyl; and Rz2 is selected from —C1-8 alkyl, C1-8 haloalkyl, C1-8 alkyl-COOH, C1-8 alkyl-OH, C1-8 alkyl-CONH2, C1-8 alkyl-SO2NH2, C1-8 alkyl-PO3H2, C1-8 alkyl-C(O)NHOH, —C(O)—C1-8 alkyl-OH, —C(O)—C1-8alkyl-COOH, C3-10 cycloalkyl, —C3-10 cycloalkyl-COOH, —C3-10 cycloalkyl-OH, C4-8 heterocyclyl, —C4-8 heterocyclyl-COOH, —C4-8 heterocyclyl-OH, —C1-8 alkyl-C4-8 heterocyclyl, —C1-8 alkyl-C3-10 cycloalkyl, C5-10 heteroaryl and —C1-8alkyl-C5-10 heteroaryl;
each R2a, R2b and R2cis independently selected from the group consisting of H, halogen, —CN, —Rd, —CO2Re, —CONReRf, —OC(O)NReRf, —NRfC(O)Re, —NRfC(O)2Rd, —NRe—C(O)NReRf, —NReRf, —ORe, —X2—ORe, —X2—NReRf, —X2—CO2Re, —SF5, and —S(O)2NReRf, wherein each X2 is a C1-4 alkylene; each Re and Rf is independently selected from hydrogen, C1-8 alkyl, and C1-8 haloalkyl, or when attached to the same nitrogen atom can be combined with the nitrogen atom to form a five or six-membered ring having from 0 to 2 additional heteroatoms as ring members selected from N, O and S, and optionally substituted with oxo; each Rd is independently selected from the group consisting of C1-8 alkyl, C2-8 alkenyl, and C1-8 haloalkyl;
R3 is selected from the group consisting of —NRgRh and C4-12 heterocyclyl, wherein the C4-12 heterocyclyl is optionally substituted with 1 to 6 R3a;
each R3ais independently selected from the group consisting of halogen, —CN, Ri, —CO2Rj, —CONRjRk, —CONHC1-6 alkyl-OH, —C(O)Rj, —OC(O)NRjRk, —NRjC(O)Rk, —NRjC(O)2Rk, —CONHOH, —PO3H2, —NRj—X3—C(O)2Rk, —NRjC(O)NRjRk, —NRjRk, —ORj, —S(O)2NRjRk, —O—X3—ORj, —O—X3—NRjRk, —O—X3—CO2Rj, —O—X3—CONRjRk, —X3—ORj, —X3—NRjRk, —X3—CO2Rj, —X3—CONRjRk, —X3—CONHSO2Rj and SF5; wherein X3 is C1-6 alkylene and is optionally further substituted with OH, SO2NH2, CONH2, C(O)NHOH, PO3H2, COO—C1-8alkyl or CO2H, wherein each Rj and Rk is independently selected from hydrogen, C1-8 alkyl optionally substituted with 1 to 2 substituents selected from OH, SO2NH2, CONH2, C(O)NHOH, PO3H2, B(OH)2, COO—C1-8alkyl or CO2H, and C1-8 haloalkyl optionally substituted with 1 to 2 substituents selected from OH, SO2NH2, CONH2, C(O)NHOH, PO3H2, COO—C1-8alkyl or CO2H, or when attached to the same nitrogen atom Rj and Rk can be combined with the nitrogen atom to form a five or six-membered ring having from 0 to 2 additional heteroatoms as ring members selected from N, O or S, and optionally substituted with oxo; each Ri is independently selected from the group consisting of C1-8 alkyl, C2-8 alkenyl, and C1-8 haloalkyl each of which may be optionally substituted with OH, SO2NH2, CONH2, C(O)NHOH, PO3H2, COO—C1-8alkyl or CO2H;
Rg is selected from the group consisting of H, C1-8 haloalkyl and C1-8 alkyl;
Rh is selected from C1-8 alkyl, C1-8 haloalkyl, C1-8 hydroxyalkyl, C1-8alkyl-CO2Rj, C1-8alkyl-CONRjRk, C1-8alkyl-CONHSO2Rj, C1-8 alkyl-SO2NRjRk, C1-8 alkyl-PO3H2, C1-8 alkyl-C(O)NHOH, C1-8 alkyl-NRjRk, —C(O)Rj, C3-10 cycloalkyl, —C3-10 cycloalkyl-COORj, —C3-10 cycloalkyl-ORj, C4-8 heterocyclyl, —C4-8 heterocyclyl-COORj, —C4-8 heterocyclyl-ORj, —C1-8 alkyl-C4-8 heterocyclyl, —C(?O)OC1-8 alkyl-C4-8 heterocyclyl, —C1-8 alkyl-C3-10 cycloalkyl, C5-10 heteroaryl, —C1-8 alkyl-5-10 heteroaryl, —C1-8 alkyl-C6-10 aryl, —C1-8 alkyl-(C?O)—C6-10 aryl, —CO2—C1-8 alkyl-O2C—C1-8 alkyl, —C1-8 alkyl-NH(C?O)—C2-8 alkenyl , —C1-8 alkyl-NH(C?O)—C1-8 alkyl, —C1-8 alkyl-NH(C?O)—C2-8 alkynyl, —C1-8 alkyl-(C?O)—NH—C1-8 alkyl-COORj, and —C1-8 alkyl-(C?O)—NH—C1-8 alkyl-ORj optionally substituted with CO2H; or
Rh combined with the N to which it is attached is a mono-, di- or tri-peptide comprising 1-3 natural amino acids and 0-2 non-natural amino acids, wherein
the non-natural aminoacids have an alpha carbon substituent selected from the group consisting of C2-4 hydroxyalkyl, C1-3 alkyl-guanidinyl, and C1-4 alkyl-heteroaryl,
the alpha carbon of each natural or non-natural amino acid is optionally further substituted with a methyl group, and
the terminal moiety of the mono-, di-, or tri-peptide is selected from the group consisting of C(O)OH, C(O)O—C1-6 alkyl, and PO3H2, wherein
the C1-8 alkyl portions of Rh are optionally further substituted with from 1 to 3 substituents independently selected from OH, COOH, SO2NH2, CONH2, C(O)NHOH, COO—C1-4 alkyl, PO3H2 and C5-6 heteroaryl optionally substituted with 1 to 2 C1-3 alkyl substituents,
the C5-10 heteroaryl and the C6-10 aryl portions of Rh are optionally substituted with 1 to 3 substituents independently selected from OH, B(OH)2, COOH, SO2NH2, CONH2, C(O)NHOH, PO3H2, COO—C1-8 alkyl, C1-4alkyl, C1-4alkyl-OH, C1-4alkyl-SO2NH2, C1-4alkyl CONH2, C1-4alkyl-C(O)NHOH, C1-4alkyl-PO3H2, C1-4alkyl-COOH, and phenyl;
the C4-8 heterocyclyl and C3-10 cycloalkyl portions of Rh are optionally substituted with 1 to 4 Rh1 substituents;
each Rh1 substituent is independently selected from C1-4 alkyl, C1-4 alkyl-OH, C1-4 alkyl-COOH, C1-4 alkyl-SO2NH2, C1-4 alkyl CONH2, C1-4 alkyl-C(O)NHOH, C1-4 alkyl-PO3H, OH, COO—C1-8 alkyl, COOH, SO2NH2, CONH2, C(O)NHOH, PO3H2, B(OH)2 and oxo;
R4 is selected from the group consisting of O—C1-8 alkyl, O—C1-8 haloalkyl, C6-10 aryl, C5-10 heteroaryl, —O—C1-4 alkyl-C4-7 heterocycloalkyl, —O—C1-4 alkyl-C6-10aryl and —O—C1-4 alkyl-C5-10 heteroaryl, each of which is optionally substituted with 1 to 5 R4a;
each R4a is independently selected from the group consisting of halogen, —CN, —Rm,—CO2Rn, —CONRnRp, —C(O)Rn, —OC(O)NRnRp, —NRnC(O)Rp, —NRnC(O)2Rm, —NRn—C(O)NRnRp, —NRnRp, —ORn, —O—X4—ORn, —O—X4—NRnRp, —O—X4—CO2Rn, —O—X4—CONRnRp, —X4—ORn, —X4—NRnRp, —X4—CO2Rn, —X4—CONRnRp, —SF5, —S(O)2RnRp, —S(O)2NRnRp, C3-7 cycloalkyl and C4-7 heterocycloalkyl, wherein the cycloalkyl and heterocycloalkyl rings are optionally substituted with 1 to 5 Rt, wherein each Rt is independently selected from the group consisting of C1-8 alkyl, C1-8 haloalkyl, —CO2Rn, —CONRnRp, —C(O)Rn, —OC(O)NRnRp, —NRnC(O)Rp, —NRnC(O)2Rm, —NRn—C(O)NRnRp, —NRnRp, —ORn, —O—X4—ORn, —O—X4—NRnRp, —O—X4—CO2Rn, —O—X4—CONRnRp, —X4—ORn, —X4—NRnRp, —X4—CO2Rn, —X4—CONRnRp, —SF5, and —S(O)2NRnRp;
wherein each X4 is a C1-6 alkylene; each Rn and Rp is independently selected from hydrogen, C1-8 alkyl, and C1-8 haloalkyl, or when attached to the same nitrogen atom can be combined with the nitrogen atom to form a five or six-membered ring having from 0 to 2 additional heteroatoms as ring members selected from N, O or S, and optionally substituted with oxo; each Rm is independently selected from the group consisting of C1-8 alkyl, C2-8 alkenyl, and C1-8 haloalkyl; and optionally when two R4a substituents are on adjacent atoms, they are combined to form a fused five or six-membered carbocyclic or heterocyclic ring optionally substituted with oxo;
and wherein R3 and R4 are joined to form a 12- to 20-membered macrocycle;
n is 0, 1, 2 or 3;
each R5 is independently selected from the group consisting of halogen, —CN, —Rq, —CO2Rr, —CONRrRs, —C(O)Rr, —OC(O)NRrRs, —NRrC(O)Rs, —NRrC(O)2Rq, —NRr—C(O)NRrRs, —NRrRs, —ORr, —O—X5—ORr, —O—X5—NRrRs, —O—X5—CO2Rr, —O—X5—CONRrRs, —X5—ORr, —X5—NRrRs, —X5—CO2Rr, —X5—CONRrRs, —SF5, —S(O)2NRrRs, wherein each X5 is a C1-4 alkylene; each Rr and Rs is independently selected from hydrogen, C1-8 alkyl, and C1-8 haloalkyl, or when attached to the same nitrogen atom can be combined with the nitrogen atom to form a five or six-membered ring having from 0 to 2 additional heteroatoms as ring members selected from N, O or S, and optionally substituted with oxo; each Rq is independently selected from the group consisting of C1-8 alkyl, and C1-8 haloalkyl;
R6a and R6c are each independently selected from the group consisting of H, C1-4 alkyl and C1-4 haloalkyl;
m is 0, 1, 2, 3 or 4;
each R6b is independently selected from the group consisting of F, C1-4 alkyl, O—Ru, C1-4 haloalkyl, NRuRv, wherein each Ru and Rv is independently selected from hydrogen, C1-8 alkyl, and C1-8 haloalkyl, or when attached to the same nitrogen atom can be combined with the nitrogen atom to form a five or six-membered ring having from 0 to 2 additional heteroatoms as ring members selected from N, O or S, and optionally substituted with oxo.

US Pat. No. 10,392,404

COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS

Novartis AG, Basel (CH)

1. A compound of formula I or II:
in which:
L is selected from —NHC(O)— and —C(O)NH—;
Y1 is selected from N and CH;
R1 is selected from H, halo, isopropyl, methyl-sulfonyl, OR6, NR5R6, methoxy-ethoxy, 2-oxa-5-azabicyclo [2.2.1]heptan-5-yl, 3-oxa-8-azabicyclo[3.2.1]octan-8-yl, 8-oxa-3-azabicyclo[3.2.1]octan-3-yl, 2-oxo-1,2-dihydropyridin-4-yl, tetrahydro-2H-pyranyl, 4-oxopyridin-1(4H)-yl, pyrazolyl, pyridazinyl and azetidinyl; wherein said azetidinyl, pyrazolyl or 2-oxo-1,2-dihydropyridin-4-yl is unsubstituted or substituted with 1 to 3 groups independently selected from methyl and hydroxy;
R2 is selected from H and methyl;
R3 is selected from H, methyl and amino;
R4 is selected from:

wherein

 indicates the point of attachment with L;
R5 is selected from H and methyl;
R6 is selected from H and methyl, ethyl, propyl, isopropyl, cyclopropyl, methoxy, hydroxy-ethyl, methoxy-ethyl, tetrahydro-2H-pyranyl, pyridinyl, tetrahydrofuranyl and oxetanyl; or R5 and R6, together with the nitrogen to which R5 and R6 are attached form a group selected from morpholino, 2-oxopyridin-1(2H)-yl, 1,1-dioxidothiomorpholino, piperazinyl, pyrrolidinyl, imidazolyl and pyrazolyl; wherein said morpholino, pyrazolyl or imidazolyl can be unsubstituted or substituted with 1 to 2 methyl groups;
R7 is selected from H, methyl, —CF3, —C(CH3)2CN, —C(CH3)2OH, —C(CH3)2F, —CF2CH3, —CF2H, isopropyl, cyclopropyl and methyl-sulfonyl; wherein said cyclopropyl is unsubstituted or substituted with cyano;
R8 is selected from H, methyl, ethyl, isopropyl, —C(CH3)2OH and —C(CH3)2NH2;
R9 is selected from H and ethyl; or a pharmaceutically acceptable salt thereof.

US Pat. No. 10,392,403

PROCESS FOR PREPARING THIENOPYRIMIDINE COMPOUND AND INTERMEDIATES USED THEREIN

HANMI PHARM. CO., LTD., ...

1. A method for preparing the compound of Formula 1, comprising steps of:1) subjecting the compound of Formula 3 to a reaction with the compound of Formula 4 in an organic solvent under the presence of a base to obtain the compound of Formula 2; and
2) subjecting the compound of Formula 2 to a reaction with the compound of Formula 5 in an organic solvent under the presence of an acid to obtain the compound of Formula 1:

US Pat. No. 10,392,402

HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS

Translational Drug Develo...

1. A compound of Formula (I):
or an enantiomer, a mixture of enantiomers, or a mixture of two or more diastereomers thereof; or a pharmaceutically acceptable salt, solvate, or hydrate thereof;
wherein:

A is pyrazol-4-yl or
wherein
(i) G is CR?;
(ii) X is hydrogen, C1-6 alkyl, C3-7 cycloalkyl, —OR2 or NR3R4; and
(iii) R?, R?, R2, R3, and R4 are independently —H, C1-6 alkyl or C3-7 cycloalkyl;
Z is selected from the group consisting of:

 wherein
(i) R5 is —H, C1-6 alkyl or C3-7 cycloalkyl;
(ii) R7 and R8 are independently —H, halo, C1-6 alkyl, C3-7 cycloalkyl, —O—(C1-6 alkyl), —OH, —CN, —COOR?, —OC(O)R?, —NHR?, —N(R?)2, —NHC(O)R? or —C(O)NHR?; and
(iii) G1, G2, and G3 are independently CH or N;
Z? is a bond or NR6, wherein R6 is —H, C1-6 alkyl or C3-7 cycloalkyl;
R is —H, C1-6 alkyl or C3-7 cycloalkyl;
R1 is —H or C1-6 alkyl;
Q is a bond or C1-6 alkyl;
J is a bond or C1-6 alkyl;
W is —H, —OR9 or —NR10R11, wherein R9, R10 and R11 are independently —H, C1-6 alkyl, C3-7 cycloalkyl, formyl, C1-6 alkylcarbonyl, C3-7 cycloalkylcarbonyl or C1-6 alkylsulfonyl; and
Ar is a phenyl, substituted with —F, —Br, —I, —OH, —CN, —COORa, —ORa, —SRa, —OC(O)Ra, —NHRa, —NRaRb, —NHC(O)Ra, —NHC(O)NRaRb, —C(O)NRaRb, —NS(O)2Ra, —S(O)2NRaRb, —S(O)2Ra, guanidino, nitro, nitroso, C1-6 alkyl, aryl, C3-7 cycloalkyl or 3- to 10-membered heterocycle; Ar is a naphthyl, optionally substituted with halo, —OH, —CN, —COORa, —ORa, —SRa, —OC(O)Ra, —NHRa, —NRaRb, —NHC(O)Ra, —NHC(O)NRaRb, —C(O)NRaRb, —NS(O)2Ra, —S(O)2NRaRb, —S(O)2Ra, guanidino, nitro, nitroso, C1-6 alkyl, aryl, C3-7 cycloalkyl or 3- to 10-membered heterocycle; or Ar is a C5-10 heterocycle, optionally substituted with halo, —OH, —CN, —COORa, —ORa, —SRa, —OC(O)Ra, —NHRa, —NRaRb, —NHC(O)Ra, —NHC(O)NRaRb, —C(O)NRaRb, —NS(O)2Ra, —S(O)2NRaRb, —S(O)2Ra, guanidino, nitro, nitroso, C1-6 alkyl, C3-7 cycloalkyl or 3- to 10-membered heterocycle; wherein the C1-6 alkyl, aryl, C3-7 cycloalkyl, or 3 to 10-membered heterocycle is unsubstituted or substituted with one or more of halo, —OH, —CN, —COORa, —ORa, —SRa, —OC(O)Ra, —NHRa, —NRaRb, —NHC(O)Ra, —NHC(O)NRaRb, —C(O)NRaRb, —NS(O)2Ra, —S(O)2NRaRb, —S(O)2Ra, guanidino, nitro, nitroso, C1-6 alkyl, aryl or C3-7 cycloalkyl; wherein each of Ra and Rb is independently —H or C1-6 alkyl; and optionally Ra and Rb together attaching to N or O form a 4- to 8-membered heterocycle.

US Pat. No. 10,392,401

CRYSTAL FORM A OF COMPOUND AND PREPARATION METHOD THEREOF

SHANGHAI INSTITUTE OF MAT...

1. Crystal form A of (R)-methyl-2-(3-aminopiperidin-1-yl)-3-(2-cyanobenzyl)-4-carbonyl-3,4-dihydrothiophene[3,2-d] pyrimidine-6-carboxylic acid crystal of formula I, wherein XRD pattern of the crystal form A includes following characteristic absorption peaks expressed by crystal plane distance d: 8.87±0.2 ?, 14.18±0.2 ?, 20.67±0.2 ?, 25.18±0.2 ?, 28.61±0.2 ?

US Pat. No. 10,392,400

PALLADIUM-MEDIATED KETOLIZATION

President and Fellows of ...

1. A compound of Formula (H-1):
or a pharmaceutically acceptable salt thereof, wherein:
RP5, RP6, and RP7 are independently hydrogen, optionally substituted alkyl, or an oxygen protecting group;
each instance of R4 is independently hydrogen, halogen, or optionally substituted alkyl, or two R4 groups are taken together to form:

each instance of R6 is independently hydrogen, halogen, or optionally substituted alkyl, or two R6 groups are taken together to form:

R5, R8, R9, and R10 are independently hydrogen, halogen, or optionally substituted alkyl;
RX is hydrogen or —ORXa, wherein RXa is hydrogen, optionally substituted alkyl, or an oxygen protecting group; and
RY is hydrogen or —ORYa, wherein RYa is hydrogen, optionally substituted alkyl, or an oxygen protecting group;
optionally wherein RXa and RYa are joined together with the intervening atoms to form optionally substituted heterocyclyl;
optionally wherein RP5 and RP6 are joined together with the intervening atoms to form optionally substituted heterocyclyl; or
optionally wherein RP6 and RP7 are joined together with the intervening atoms to form optionally substituted heterocyclyl.

US Pat. No. 10,392,399

CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF

kala pharmaceuticals, Inc...

1. A crystalline form of Compound 1:
wherein the crystalline form has an X-ray powder diffraction (XRPD) pattern comprising peaks at 8.5-9.5 degrees 2?, 18-19 degrees 2?, 19-19.5 degrees 2?, and 25.0-25.5 degrees 2?.

US Pat. No. 10,392,398

INHIBITORS OF LATE SV40 FACTOR (LSF) AS CANCER CHEMOTHERAPEUTICS

TRUSTEES OF BOSTON UNIVER...

1. A method for reducing cell proliferation in a cancer that overexpresses LSF in a subject, the method comprising administering an effective amount of a compound of Formula (III?) to a subject in need thereof, wherein the Formula (III?) has the structure:
wherein:
R1? is an aryl substituted with at least one C1-C6 alkoxyl and at least one di(C1-C24alkyl)amino, halogen or C2-C8alkenyl;
R2 and R3 are hydrogen;
R4 is hydrogen;
R5 is hydrogen;
R6 and R7 are hydrogen;
R10 and R11 are hydrogen;
and pharmaceutically acceptable salts thereof, and wherein the compound is capable of inhibiting late SV40 factor (LSF).

US Pat. No. 10,392,397

HETEROCYCLIC THIOSEMICARBAZONE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS

NantBio, Inc., Culver Ci...

1. A compound having a structure according to Formula Id, Ie, Ig, or Ih
wherein:
R1 is hydrogen, F, Cl, Br, I, CN, C1-C4 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, CF3, CHF2, CH2F, C2-C6 alkynyl, or CON(R5)R6;
R2 is hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, alkylthio, aryl, arylalkyl, or oxo;
R is (i), (ii), or (iii), wherein:
(i) is heteroaryl or aryl, each of which is substituted with from 0 to 4 substituents selected from the group of halogen, hydroxy, cyano, CF3, CHF2, CH2F, —COOH, —SO2NH2, oxo, nitro, C1-C4 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, CON(R5)R6, SO2N(R5)R6, and N(R7)R8;
(ii) is C1-C4 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, CON(R5)R6, or N(R7)R8;
(iii) is a group having the formula (A):

wherein:
R3 is selected from the group consisting of hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C10 aryl or heteroaryl, (C3-C7cycloalkyl)C1-C4 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 alkylthio, C2-C6 alkanoyl, C1-C6 alkoxycarbonyl, C2-C6 alkanoyloxy, mono- or di-(C3-C8 cycloalkyl)aminoC0-C4alkyl, (4- to 7-membered heterocycle)C0-C4alkyl, C1-C6 alkylsulfonyl, mono- or di-(C1-C6 alkyl) sulfonamido, and mono- or di-(C1-C6 alkyl)aminocarbonyl, each of which is substituted with from 0 to 4 substituents independently selected from the group consisting of halogen, hydroxy, cyano, amino, —COOH, nitro, CF3, and oxo;
R4 is hydrogen, C1-C4 alkyl, or oxo;
Z is CH when R3 is hydrogen, or Z—R3 is O, or Z is N; and
R5 and R6 are independently selected from the group consisting of hydrogen, C1-C4 alkyl, cycloalkyl, alkenyl, and alkynyl; and
R7 and R8 are independently selected from the group consisting of hydrogen, C1-C4 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C10 aryl or heteroaryl, C2-C6 acyl, C1-C6 alkoxycarbonyl, and C2-C6 alkanoyloxy, each of which is substituted with from 0 to 4 substituents independently selected from the group consisting of halogen, hydroxy, cyano, amino, —COOH, nitro, CF3, and oxo.

US Pat. No. 10,392,395

NITROGEN-CONTAINING AROMATIC COMPOUNDS AND METAL COMPLEXES

SUMITOMO CHEMICAL COMPANY...

1. An aromatic compound comprising 2 or more covalently-bound sections, the aromatic compound containing no metal atoms, satisfying the following conditions (a) and (b):(a) individually, each of the 2 or more sections, which may be the same or different, includes at least 4 coordinatable nitrogen atoms, and the at least 4 coordinatable nitrogen atoms in each individual section are coordinatable with a single metal atom within each individual section,
(b) at least one of the nitrogen atoms in each individual section is a nitrogen atom in a 6-membered nitrogen-containing heterocyclic ring,
wherein the sections are selected from the group consisting of sections represented by the following formulae:

wherein

 represents a bond in an aromatic ring;
wherein each P1A, P1B and P1C is part of a first polycyclic aromatic heterocyclic ring comprising two 6-membered aromatic rings, at least one of which is a heterocyclic ring; each P2A, P2B and P2C is part of a second polycyclic aromatic heterocyclic ring comprising two 6-membered aromatic rings, at least one of which is a heterocyclic ring; each W1A and W1B is part of a first 5-membered heterocyclic ring; and each W2A and W2B is part of a second 5-membered heterocyclic ring; and wherein hydrogens therein may be substituted with halogeno, hydroxy, carboxyl, mercapto, sulfonic acid, nitro, amino, cyano, phosphonic acid, silyl substituted with C1-4 alkyl, C1-50 straight-chain or branched alkyl, C3-50 cyclic alkyl, alkenyl, alkynyl, alkoxy, C6-60 aryl, C7-50 aralkyl, or monovalent heterocyclic groups, and
wherein:
W1A and W1B can form a 5-membered ring with each other;
W2A and W2B can form a 5-membered ring with each other;
P1A and P1B can form a 6-membered ring with each other;
P1B and P1C can form a 6-membered ring with each other;
P2A and P2B can form a 6-membered ring with each other;
P2B and P2C can form a 6-membered ring with each other; and
P1C and P2A can form a 6-membered ring with each other.

US Pat. No. 10,392,394

ANTIMICROBIAL COMPOUNDS AND METHODS

Board of Supervisors of L...

1. A compound having the structure:
wherein R and R? may be the same or different; and R and R? are independently selected from the group consisting of R1, R2, R3, R4, R5, and R6:

wherein m is an integer from 1 to 30;
wherein n is an integer from 0 to 20;
wherein A is A1:

wherein X is selected from the group consisting of F, Cl, Br, I, CF3SO3 (triflate), acetate, and gluconate;
wherein Y is hydrogen or an unsubstituted aliphatic group containing 1 to 6 carbons, and wherein the various Y groups may be the same or different;
wherein Z is selected from the group consisting of one hydrogen atom, two hydrogen atoms, and an unsubstituted aliphatic group containing 1 to 6 carbons;
wherein R1 is selected from the group consisting of hydrogen, an unsubstituted aliphatic group containing 1 to 18 carbons, benzyl, and a cyclic aliphatic or aromatic group containing 5 to 18 carbons; wherein, for clarity, it is noted that R1 and R1 are different; and
wherein L is selected from the group consisting of L3, L4, L5, L6, L7, L8, L9, L10, and L11:

US Pat. No. 10,392,393

PYRROLOBENZODIAZEPINES

Medimmune Limited, Cambr...

1. A compound with the formula I:
wherein:
R2 is of formula II?:

where A is a C5-7 aryl group, X is selected from the group consisting of: OH, SH, CO2H, COH, N?C?O, NHNH2, CONHNH2,

 and NHRN, wherein RN is selected from H and C1-4 alkyl, and either:
(i) Q1 is a single bond, and Q2 is selected from a single bond and —Z—(CH2)n—, where Z is selected from a single bond, O, S and NH and n is from 1 to 3; or
(ii) Q1 is —CH?CH—, and Q2 is a single bond;
R12 is selected from the group consisting of ?CH2, ?CHRD1 and ?CRD1RD2, where RD1 and RD2 are independently selected from R, CO2R, COR, CHO, CO2H, and halo;
R6 and R9 are independently selected from the group consisting of: H, R, OH, OR, SH, SR, NH2, NHR, NRR?, nitro, Me3Sn and halo;
R7 is selected from the group consisting of: H, R, OH, OR, SH, SR, NH2, NHR, NHRR?, nitro, Me3Sn and halo;
where R and R? are independently selected from optionally substituted C1-12 alkyl, C3-20 heterocyclyl and C5-20 aryl groups;
either:
(a) R10 is H, and R11 is OH, ORA, where RA is C1-4 alkyl;
(b) R10 and R11 form a nitrogen-carbon double bond between the nitrogen and carbon atoms to which they are bound; or
(c) R10 is H and R11 is SOzM, where z is 2 or 3 and M is a monovalent pharmaceutically acceptable cation;
R? is a C3-12 alkylene group, which chain is optionally interrupted by one or more heteroatoms, and/or aromatic rings;
Y and Y? are independently selected from the group consisting of O, S, and NH;
R6?, R7?, R9? are selected from the same groups as R6, R7 and R9 respectively and R10? and R11? are the same as R10 and R11, wherein if R11 and R11? are SOZM, M may represent a divalent pharmaceutically acceptable cation.

US Pat. No. 10,392,392

SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS

Tolero Pharmaceuticals, I...

1. A compound having the following structure:

US Pat. No. 10,392,389

HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK

BioEnergenix LLC, San Fr...

9. A pharmaceutical composition comprising a compound as recited in claim 1 together with a pharmaceutically acceptable carrier.

US Pat. No. 10,392,388

MEROPENEM DERIVATIVES AND USES THEREOF

kala pharmaceuticals, Inc...

1. A compound of Formula (I):
or a pharmaceutically acceptable salt thereof;
wherein:
- - - - - - is a single bond or null;
is a single bond or a double bond;
RB is —C(?O)—N(Me)2, —CH2—NH—S(?O)2—NH2, ?NH,

RA is substituted aliphatic, unsubstituted aliphatic, substituted aryl, or unsubstituted aryl;
RC is substituted 3- to 7-membered monocyclic carbocyclyl, or unsubstituted 3- to 7-membered monocyclic carbocyclyl; and
RF is hydrogen or methyl.

US Pat. No. 10,392,387

SUBSTITUTED BENZO[4,5]IMIDAZO[1,2-A]PHENANTHRO[9,10-C][1,8]NAPHTHYRIDINES, BENZO[4,5]IMIDAZO[1,2-A]PHENANTHRO[9,10-C][1,5]NAPHTHYRIDINES AND DIBENZO[F,H]BENZO[4,5]IMIDAZO[2,1-A]PYRAZINO[2,3-C]ISOQUINOLINES AS THERMALLY ASSISTED DELAYED FLUORESCENT MATERIA

ARIZONA BOARD OF REGENTS ...

1. A compound represented by the formula:
each R1 independently represents hydrogen, deuterium, halogen, hydroxy, thiol, nitro, cyano, isonitrile, alkylsulfinyl, sulfonic acid, carboxy, hydrazino, aryl, cycloalkyl, cycloalkenyl, heterocyclyl, heteroaryl, alkyl, alkenyl, alkynyl, amino, monoalkylamino, dialkylamino, monoarylamino, diarylamino, alkoxy, aryloxy, haloalkyl, aralkyl, alkoxycarbonyl, acylamino, alkoxycarbonylamino, aryloxycarbonylamino, sulfonylamino, sulfamoyl, carbamoyl, alkylthio, ureido, phosphoramide, trialkylsilyl, triarylsilyl, or trialkoxysilyl; and
each R2 independently represents hydrogen, deuterium, halogen, hydroxy, thiol, nitro, cyano, isonitrile, alkylsulfinyl, sulfonic acid, carboxy, hydrazino, aryl, cycloalkyl, cycloalkenyl, heterocyclyl, heteroaryl, alkyl, alkenyl, alkynyl, amino, monoalkylamino, dialkylamino, monoarylamino, diarylamino, alkoxy, aryloxy, haloalkyl, aralkyl, alkoxycarbonyl, acylamino, alkoxycarbonylamino, aryloxycarbonylamino, sulfonylamino, sulfamoyl, carbamoyl, alkylthio, ureido, phosphoramide, trialkylsilyl, triarylsilyl, or trialkoxysilyl;
wherein the aryl, cycloalkyl, cycloalkenyl, heterocyclyl, heteroaryl, alkyl, alkenyl, alkynyl, amino, monoalkylamino, dialkylamino, monoarylamino, diarylamino, alkoxy, aryloxy, haloalkyl, aralkyl, alkoxycarbonyl, acylamino, alkoxycarbonylamino, aryloxycarbonylamino, sulfonylamino, sulfamoyl, carbamoyl, alkylthio, ureido, phosphoramide, trialkylsilyl, trialkoxysilyl, and triarylsilyl are each optionally and independently substituted with one or more substituents independently selected from the group consisting of deuterium, halogen, hydroxy, thiol, nitro, cyano, isonitrile, alkylsulfinyl, sulfonic acid, carboxy, hydrazino, aryl, cycloalkyl, cycloalkenyl, heterocyclyl, heteroaryl, alkyl, alkenyl, alkynyl, amino, monoalkylamino, dialkylamino, monoarylamino, diarylamino, alkoxy, aryloxy, haloalkyl, aralkyl, alkoxycarbonyl, acylamino, alkoxycarbonylamino, aryloxycarbonylamino, sulfonylamino, sulfamoyl, carbamoyl, alkylthio, ureido, phosphoramide, trialkylsilyl, trialkoxysilyl, and triarylsilyl.

US Pat. No. 10,392,386

JAK INHIBITORS CONTAINING A 4-MEMBERED HETEROCYCLIC AMIDE

1. A method of treating an inflammatory or fibrotic respiratory disease in a mammal, the method comprising administering to the mammal a pharmaceutical composition comprising a compound of formula (I):wherein:R1 is selected from hydrogen, C1-3alkyl, and C3-6cycloalkyl, and X is —C(O)R2
wherein
R2 is —NR13R14, wherein
R13 and R14 are taken together with the nitrogen atom to which they are attached form a 4-membered heterocyclyl, wherein the heterocyclyl is optionally substituted with —NR5R6 and R7,
R5 and R6 are independently C1-3alkyl or R5 and R6 taken together with the nitrogen atom to which they are attached form a 5- or 6-membered heterocyclyl optionally including an oxygen atom,
R7 is C1-3alkyl, optionally substituted with a 5- or 6-membered heterocyclyl containing one nitrogen atom,
or a pharmaceutically-acceptable salt thereof,and a pharmaceutically-acceptable carrier.

US Pat. No. 10,392,385

N-((1-PHENYL-9H-PYRIDO[3,4-B]INDOL-3-YL)METHYL)CINNAMAMIDES AS POTENTIAL ANTICANCER AGENTS AND PREPARATION THEREOF

1. N-((1-phenyl-9H-pyrido[3,4-b]indol-3-yl)methyl) cinnamamides of formula A:
wherein
R1=3-F, 3,4,5-OMe, 4-OMe, H, 4-CF3, 4-Cl, 4-OH-3-OMe, 3,4-CH2—O—CH2, 3,5-F, 4-OH, 1-napthyl, 9-phenanthryl, or 4-Me, and
R2=3,4,5-OMe, 3,4-Cl, 4-F, 3,5-F, 2,5-OMe, 4-Cl, 4-OH-3-OMe, 3-OH, 3,4,5-OH, 4-CF3, 4-OMe, or 4-NH2.

US Pat. No. 10,392,384

METHOD FOR THE PREPARATION OF (4S)-4-(4-CYANO-2-METHOXYPHENYL)-5-ETHOXY-2,8-DIMETHYL-1,4-DIHYDRO-1-6-NAPHTHYRIDINE-3-CARBOXAMIDE AND RECOVERY OF (4S)-4-(4-CYANO-2-METHOXYPHENYL)-5-ETHOXY-2,8-DIMETHYL-1,4-DIHYDRO-1-6-NAPHTHYRIDINE-3-CARBOXAMIDE BY ELECTROC

BAYER PHARMA AKTIENGESELL...

1. A process for preparing compounds of the formulae M1a(S) and M1b(R)
comprising oxidizing the compound of the formula ent-(I)

US Pat. No. 10,392,383

3-(1H-BENZO[D]IMIDAZOL-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES AND THERAPEUTIC USES THEREOF

Samumed, LLC, San Diego,...

1. A compound, or a pharmaceutically acceptable salt thereof, of Formula I:
wherein
R1 and R2 are independently selected from the group consisting of H and halide;
R3 is selected from the group consisting of -heteroaryl optionally substituted with 1-4 R6 and -heterocyclyl optionally substituted with 1-10 R7;
R5 is selected from the group consisting of H, -heteroaryl optionally substituted with 1-4 R8, -heterocyclyl optionally substituted with 1-10 R9, and -aryl optionally substituted with 1-5 R10;
each R6 is independently selected from the group consisting of halide, —(C1-6 alkyl), —(C2-6 alkenyl), —(C2-6 alkynyl), —(C1-4 alkylene)pheterocyclyl optionally substituted with 1-10 R11, —(C2-4 alkenylene)pheterocyclyl optionally substituted with 1-10 R11, —(C2-4 alkynylene)pheterocyclyl optionally substituted with 1-10 R11, —(C1-4 alkylene)pcarbocyclyl optionally substituted with 1-12 R12, —(C2-4 alkenylene)pcarbocyclyl optionally substituted with 1-12 R12, —(C2-4 alkynylene)pcarbocyclyl optionally substituted with 1-12 R12, —(C1-4 alkylene)paryl optionally substituted with 1-5 R13, —(C2-4 alkenylene)paryl optionally substituted with 1-5 R13, —(C2-4 alkynylene)paryl optionally substituted with 1-5 R13, —NHC(?O)R14, —NR15R16, —(C1-6 alkylene)NR17R18, —(C2-6 alkenylene)NR17R18, —(C2-6 alkynylene)NR17R18, and —(C1-4 alkylene)pOR24;
each R7 is independently selected from the group consisting of —(C1-4 alkyl), —(C2-4 alkenyl), —(C2-4 alkynyl), halide, —CF3, and —CN;
each R8 is independently selected from the group consisting of —(C1-6 alkyl), —(C2-6 alkenyl), —(C2-6 alkynyl), halide, —CF3, —OCH3, —CN, and —C(?O)R19;
each R9 is independently selected from the group consisting of —(C1-6 alkyl), —(C2-6 alkenyl), —(C2-6 alkynyl), halide, —CF3, —CN, and —OCH3;
each R10 is independently selected from the group consisting of —(C1-6 alkyl), —(C2-6 alkenyl), —(C2-6 alkynyl), halide, —CF3, —CN, —(C1-6 alkylene)pNHSO2R19, —(C2-6 alkenylene)pNHSO2R19, —(C2-6 alkynylene)pNHSO2R19, —NR15(C1-6 alkylene)NR15R16, —NR15(C2-6 alkenylene)NR15R16, —NR15(C2-6 alkynylene)NR15R16, —(C1-6 alkylene)pNR15R16, —(C2-6 alkenylene)pNR15R16, —(C2-6 alkynylene)pNR15R16, and —OR27;
each R11 is independently selected from the group consisting of amino, —(C1-4 alkyl), —(C2-4 alkenyl), —(C2-4 alkynyl), halide, —CF3, and —CN;
each R12 is independently selected from the group consisting of —(C1-4 alkyl), —(C2-4 alkenyl), —(C2-4 alkynyl), halide, —CF3, and —CN;
each R13 is independently selected from the group consisting of —(C1-4 alkyl), —(C2-4 alkenyl), —(C2-4 alkynyl), halide, —CF3, and —CN;
each R14 is independently selected from the group consisting of —(C1-9 alkyl), —(C1-4 haloalkyl), —(C2-9 alkenyl), —(C2-9 alkynyl), -heteroaryl optionally substituted with 1-4 R20, -aryl optionally substituted with 1-5 R21, —CH2aryl optionally substituted with 1-5 R21, -carbocyclyl optionally substituted with 1-12 R22, —CH2carbocyclyl optionally substituted with 1-12 R22, —(C1-4 alkylene)pNR25R26, —(C2-4 alkenylene)pNR25R26, —(C2-4 alkynylene)pNR25R26, -heterocyclyl optionally substituted with 1-10 R23, and —CH2heterocyclyl optionally substituted with 1-10 R23;
each R15 is independently selected from the group consisting of H, —(C1-6 alkyl), —(C2-6 alkenyl), and —(C2-6 alkynyl);
each R16 is independently selected from the group consisting of H, —(C1-6 alkyl), —(C2-6 alkenyl), —(C2-6 alkynyl), —CH2aryl optionally substituted with 1-5 R21, and —CH2carbocyclyl optionally substituted with 1-12 R22;
each R17 is independently selected from the group consisting of H, —(C1-6 alkyl), —(C2-6 alkenyl), and —(C2-6 alkynyl);
each R18 is independently selected from the group consisting of H, —(C1-6 alkyl), —(C2-6 alkenyl), —(C2-6 alkynyl), —CH2aryl optionally substituted with 1-5 R21, and —CH2carbocyclyl optionally substituted with 1-12 R22;
each R19 is independently selected from the group consisting of —(C1-6 alkyl), —(C2-6 alkenyl), and —(C2-6 alkynyl);
each R20 is independently selected from the group consisting of —(C1-4 alkyl), —(C2-4 alkenyl), —(C2-4 alkynyl), halide, —CF3, and —CN;
each R21 is independently selected from the group consisting of —(C1-4 alkyl), —(C2-4 alkenyl), —(C2-4 alkynyl), halide, —CF3, and —CN;
each R22 is independently selected from the group consisting of —(C1-4 alkyl), —(C2-4 alkenyl), —(C2-4 alkynyl), halide, —CF3, and —CN;
each R23 is independently selected from the group consisting of —(C1-4 alkyl), —(C2-4 alkenyl), —(C2-4 alkynyl), halide, —CF3, and —CN;
R24 is selected from the group consisting of H, —(C1-6 alkyl), —(C2-6 alkenyl), —(C2-6 alkynyl), —(C1-4 alkylene)pheterocyclyl optionally substituted with 1-10 R23, —(C2-4 alkenylene)pheterocyclyl optionally substituted with 1-10 R23, —(C2-4 alkynylene)pheterocyclyl optionally substituted with 1-10 R23, —(C1-4 alkylene)pcarbocyclyl optionally substituted with 1-12 R22, —(C2-4 alkenylene)pcarbocyclyl optionally substituted with 1-12 R22, —(C2-4 alkynylene)pcarbocyclyl optionally substituted with 1-12 R22, —(C1-4 alkylene)paryl optionally substituted with 1-5 R21, —(C2-4 alkenylene)paryl optionally substituted with 1-5 R21, —(C2-4 alkynylene)paryl optionally substituted with 1-5 R21, —(C1-6 alkylene)pNR25R26, —(C2-4 alkenylene)pNR25R26, and —(C2-4 alkynylene)pNR25R26;
each R25 is independently selected from the group consisting of H, —(C1-6 alkyl), —(C2-6 alkenyl), and —(C2-6 alkynyl);
each R26 is independently selected from the group consisting of H, —(C1-6 alkyl), —(C2-6 alkenyl), and —(C2-6 alkynyl);
R27 is selected from the group consisting of H, —(C1-6 alkyl), —(C2-6 alkenyl), —(C2-6 alkynyl), —(C1-4 alkylene)pheterocyclyl optionally substituted with 1-10 R23, —(C2-4 alkenylene)pheterocyclyl optionally substituted with 1-10 R23, —(C2-4 alkynylene)heterocyclyl optionally substituted with 1-10 R23, —(C1-6 alkylene)pNR25R26, —(C2-6 alkenylene)NR25R26, and —(C2-6 alkynylene)NR25R26; and
each p is independently an integer of 0 or 1.

US Pat. No. 10,392,382

COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE

ALLERGAN, INC., Irvine, ...

1. A compound, wherein the compound is:or a pharmaceutically acceptable salt thereof.

US Pat. No. 10,392,381

PREVENTION AND TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE

Ohio University, Athens,...

1. A method for treating or reducing the risk of developing non-alcoholic fatty liver disease (NAFLD) in a subject in need thereof, the method comprising:administering to the subject a therapeutically effective amount of at least one compound of General Formula (I) or (II):

or a pharmaceutically-acceptable salt or solvate thereof, in which:
R1 is chosen from methyl, ethyl, propyl, 2-propenyl, hexyl, Q1,

R2 is chosen from Q2, phenyl,

R3 is chosen from H, -methyl, ethyl, n-propyl, isopropyl, butyl, 3-butenyl, phenyl, or 2-phenylethyl;
Q1 is
in which groups R4, R5, and R6 are independently chosen from H, halo, —NO2, —CN, or —OCH3; andQ2 is
in which exactly two or exactly three of groups R7, R8, R9, and R10 are hydrogen and remaining groups R7, R8, R9, and R10 that are not hydrogen are independently chosen from methoxy, ethoxy, hydroxy, trifluoromethoxy, methyl, trifluoromethyl, N-methylamino, (N,N)-dimethylamino, cyano, halo, or nitro;with the proviso that when R2 is phenyl and R3 is —H, R1 is selected from the group consisting of hexyl, Q1,

US Pat. No. 10,392,379

HEPATITIS B CORE PROTEIN MODULATORS

Assembly Biosciences, Inc...

1. A compound represented by:
wherein
Y is S(O)y, wherein y is 2;
RZ is H;
Rm? and Rm are each H;
L is a bond or C1-2alkylene (optionally substituted by halogen or C1-2alkyl);
A is a 5-7 membered monocyclic heterocyclic or 5-6 membered monocyclic heteroaryl ring optionally substituted by one or two substituents selected from the group consisting of halogen, hydroxyl, cyano, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxy, and NR?R?;
B is selected from the group consisting of phenyl (optionally substituted by one, two or three substituents represented by R33), 5-6 membered monocyclic heteroaryl optionally substituted by one, two or three substituents represented by R33), and 9-10 membered bicyclic heteroaryl (optionally substituted by one, two or three substituents represented by R33);
R? is selected, independently for each occurrence, from H, methyl, ethyl, and propyl;
R? is selected, independently for each occurrence, from H, methyl, ethyl, propyl, (optionally substituted by hydroxyl), butyl (optionally substituted by hydroxyl), —C(O)-methyl and —C(O)-ethyl, or R? and R? taken together with the nitrogen to which they are attached may form a 4-7 membered heterocycle optionally substituted by one, two or more substituents selected from the group consisting of halogen, hydroxyl, NH2, —C(O)—O—C1-3alkyl, —C(O)—C1-3alkyl, carboxy, oxo, and C1-3alkyl;
each of moieties R4, R5, R6, R7, R8, R9, and R10 is independently selected for each occurrence from the group consisting of hydrogen, C1-6alkyl, C2-6alkynyl, C2-6alkenyl, halogen, hydroxyl, nitro, cyano, and NR?R?;
R33 is independently selected for each occurrence from the group consisting of H, halogen, hydroxyl, nitro, cyano, C1-6alkyl, —C(O)—O—C1-6alkyl, —C(O)—NR?R?, —C(?NH)—NR?R?, C2-6alkenyl, C2-6alkynyl, C1-6alkoxy, carboxy, —CHO, NR?R?, —C(O)—C1-6alkyl, —C(O)—C1-6 alkoxy, C3-6cycloalkyl, —S(O)w—C1-6alkyl (where w is 0, 1 or 2), —S(O)w—NR?R? (where w is 0, 1 or 2), and —NR?—S(O)w— C1-6alkyl (where w is 0, 1 or 2);
q is 0, 1, 2 or 3;
wherein for each occurrence, C1-6alkyl may be optionally substituted with one, two, three or more substituents selected from the group consisting of halogen, hydroxyl, nitro, cyano, carboxy, C2-6alkenyl, C2-6alkynyl, C1-6alkoxy, NR?R?, —NR?—S(O)w— C1-6alkyl (where w is 0, 1 or 2), and S(O)w—NR?R? (where w is 0, 1 or 2); C1-6alkoxy may be optionally substituted with one, two, three or more substituents selected from the group consisting of halogen, hydroxyl, nitro, cyano, carboxy, C1-6alkyl, NR?R?, —NR?—S(O)w— C1-6alkyl (where w is 0, 1 or 2), and S(O)w—NR?R? (where w is 0, 1 or 2); and
pharmaceutically acceptable salts thereof.

US Pat. No. 10,392,378

DERIVATIVES OF 5-PHENYL- OR 5-HETEROARYLATHIAZOL-2-CARBOXYLIC AMIDE USEFUL FOR THE TREATMENT OF INTER ALIA CYSTIC FIBROSIS

Proteostasis Therapeutics...

1. A compound represented by formula III or IV:or a pharmaceutically acceptable salt or stereoisomer thereof, wherein;X3 is selected from the group consisting of O, S, and NRhh;
pp is 1, 2, or 3;
R11 is independently selected for each occurrence from the group consisting of hydrogen, halogen, and C1-4alkyl (optionally substituted by one, two or three halogens);
L1 is C3-6cycloalkylene, wherein L1 may be optionally substituted by one, two or three substituents selected from the group consisting of halogen, hydroxyl, and C1-3alkyl (optionally substituted by one, two or three substituents each selected independently from Rff);
R44 is a 5-6 membered monocyclic heteroaryl having one, two or three heteroatoms each selected from O, N, and S; wherein heteroaryl may be optionally substituted by one or two substituents each selected independently from Rgg;
Rff is selected for each occurrence from the group consisting of halogen, hydroxyl, C1-4alkyl, C1-4alkoxy, C2-4alkenyl, C3-6cycloalkyl, —NR?R?, —NR?—S(O)w—C1-3alkyl, S(O)w—NR?R?, and —S(O)w—C1-3alkyl, where w is 0, 1, or 2, wherein C1-4alkyl, C1-4alkoxy, C2-4alkenyl and C3-6cycloalkyl may be optionally substituted by one, two or three substituents each independently selected from the group consisting of halogen, hydroxyl, —NR?R?, —NR?—S(O)w—C1-3alkyl, S(O)W—NR?R?, and —S(O)W—C1-3alkyl;
Rgg is selected for each occurrence from the group consisting of halogen, hydroxyl, C1-6alkyl, C1-6 alkoxy, C2-6alkenyl, C3-6cycloalkyl, —NR?R?, —NR?—S(O)w—C1-3alkyl, S(O)w—NR?R?, and —S(O)w—C1-3alkyl, where w is 0, 1, or 2, wherein C1-6alkyl, C1-6 alkoxy C2-6alkenyl and C3-6cycloalkyl may each be optionally substituted by one, two or three substituents each independently selected from the group consisting of halogen, C1-6alkyl, C1-6alkoxy, hydroxyl, C(O)OH, —C(O)OC1-6alkyl, —O—C3-6cycloalkyl, —O-heterocycle, —O-heteroaryl, —O-phenyl, —NR?R?, —NR?—S(O)w—C1-3alkyl, S(O)W—NR?R?, and —S(O)w-C1-3alkyl;
w is 0, 1 or 2; and
Rhh is selected for each occurrence from the group consisting of H, C1-6alkyl and C3-6cycloalkyl.

US Pat. No. 10,392,377

SUBSTITUTED 2-IMINO-1,3-THIAZOLIDIN-4-ONES AS N-ARACHIDONOYLETHANOLAMINE CELLULAR UPTAKE INHIBITORS

UNIVERSITAT BERN, Bern (...

1. A compound of formula (1):
wherein:
R1 is selected from formula (2b), formula (2c), formula (2g) or formula (2h):

wherein:
T? is selected from —CH2—, —NH—, —NRc—, —S—, —O—, —CH(CH3)— or —C(CH3)2—;
T? is selected from ?CH— or ?N—;
Rc is selected from —CH3, —CH2F, —CHF2, —CF3, —CH2OH, —CH2CH3, —CH2CF3, —CHFCF3, —CF2CF3, —CH2CH2CH3 or —CH(CH3)2;
R6 is selected from —H, —CH3, —OH, —OCH3 or —OCH2CH3;
each Z1 is independently selected from —F, —Cl, —Br, —I, —CN, —Ra, —ORa, —(CH2)rORa, —SRa, —(CH2)rSRa or —N(Ra)2;
each Ra is independently selected from H, an unsubstituted C1-C8-alkyl, an unsubstituted C2-C8-alkenyl or an unsubstituted C2-C8-alkynyl;
r is 1, 2, 3 or 4; and
n is 0, 1, 2 or 3; or
R1 is selected from formula (2b?), formula (2c?), formula (2g?) or formula (2h?):

wherein:
D is C1-C4-alkyl;
T? is selected from —CH2—, —NH—, —NRc—, —S—, —O—, —CH(CH3)— or —C(CH3)2—;
T? is selected from ?CH— or ?N—;
Rc is selected from —CH3, —CH2F, —CHF2, —CF3, —CH2OH, —CH2CH3, —CH2CF3, —CHFCF3, —CF2CF3, —CH2CH2CH3 or —CH(CH3)2;
R6 is selected from —H, —CH3, —OH, —OCH3 or —OCH2CH3;
each Z1 is independently selected from —F, —Cl, —Br, —I, —CN, —Ra, —ORa, —(CH2)rORa, —SRa, —(CH2)rSRa or —N(Ra)2;
each Ra is independently selected from H, an unsubstituted C1-C8-alkyl, an unsubstituted C2-C8-alkenyl or an unsubstituted C2-C8-alkynyl;
r is 1, 2, 3 or 4; and
n is 0, 1, 2 or 3;
R2 is selected from an unsubstituted cycloalkyl, a substituted or unsubstituted aryl, an unsubstituted saturated heterocyclyl, or a substituted or unsubstituted heteroaryl;
wherein:
the substituted aryl or the substituted heteroaryl is substituted by at least one Z2;
each Z2 is independently selected from —F, —Cl, —Br, —I, —CN, —Rb, —ORb, —(CH2)rORb, —SRb, —(CH2)rSRb or —N(Rb)2;
each Rb is independently selected from H, an unsubstituted C1-C12-alkyl, an unsubstituted C2-C12-alkenyl or an unsubstituted C2-C12-alkynyl; and
r is 1, 2, 3 or 4; or
R2 is formula -L-Ar;
wherein:
L is an alkyl, an alkenyl or an alkynyl; and
Ar is a substituted or unsubstituted C6-aryl or a substituted or unsubstituted C5-C6-heteroaryl;
wherein:
the substituted C6-aryl or substituted C5-C6-heteroaryl is substituted by at least one Z2;
each Z2 is independently selected from —F, —Cl, —Br, —I, —CN, —Rb, —ORb, —(CH2)rORb, —SRb, —(CH2)rSRb or —N(Rb)2;
each Rb is independently selected from H, an unsubstituted C1-C12-alkyl, an unsubstituted C2-C12-alkenyl or an unsubstituted C2-C12-alkynyl; and
r is 1, 2, 3 or 4; and
R3 is selected from an unsubstituted alkyl, an unsubstituted alkoxy, an unsubstituted alkenyl, an unsubstituted alkynyl, an unsubstituted cycloalkyl, an unsubstituted saturated heterocyclyl, a substituted or unsubstituted aryl or a substituted or unsubstituted heteroaryl;
wherein:
the substituted aryl or substituted heteroaryl is substituted by at least one Z3;
each Z3 is independently selected from —F, —Cl, —Br, —I, —CN, —Rd, —ORd, —(CH2)rORd, —SRd, —(CH2)rSRd or —N(Rd)2;
each Rd is independently selected from H, an unsubstituted C1-C12-alkyl, an unsubstituted C2-C12-alkenyl or an unsubstituted C2-C12-alkynyl; and
r is 1, 2, 3 or 4; or
R3 is formula -D-Ar;
wherein:
D is an alkyl, an alkenyl or an alkynyl; and
Ar is a substituted or unsubstituted C6-aryl or a substituted or unsubstituted C5-C6-heteroaryl;
wherein:
the substituted C6-aryl or substituted C5-C6-heteroaryl is substituted by at least one Z3;
each Z3 is independently selected from —F, —Cl, —Br, —I, —CN, —Rd, —ORd, —(CH2)rORd, —SRd, —(CH2)rSRd or —N(Rd)2;
each Rd is independently selected from H, an unsubstituted C1-C12-alkyl, an unsubstituted C2-C12-alkenyl or an unsubstituted C2-C12-alkynyl; and
r is 1, 2, 3 or 4.

US Pat. No. 10,392,376

HETEROCYCLIC INHIBITORS OF ATR KINASE

Board of Regents, The Uni...

1. A compound of structural Formula (II):
or a salt thereof, wherein:
R1 and R2 are independently chosen from C1-4alkyl, C1-4haloalkyl, C3-6cycloalkyl, C3-6heterocycloalkyl, C5-10aryl, and 5-10 membered heteroaryl, any of which is optionally substituted with one or more R5 groups, or R1 and R2, together with the sulfur to which they are both attached, form a 4, 5, 6, or 7-membered heterocycloalkyl ring which is optionally substituted with one or more R5 groups;
R3 is chosen from hydrogen, C1-6alkyl, and C1-6haloalkyl;
R4 is chosen from C5-10aryl or 5-10 membered heteroaryl, either of which is optionally substituted with one or more R6 groups;
each R5 is independently chosen from NR8R9, halogen, cyano, hydroxy, oxo, alkyl, haloalkyl, C3-6cycloalkyl, 3-6 membered heterocycloalkyl, hydroxyalkyl, OR8, NR7C(O)R8, NR7C(O)OR8, NR7C(O)NR8R9, C(O)R8, C(O)OR8, and C(O)NR8R9;
each R6 is independently chosen from NR11R12, halogen, cyano, hydroxy, oxo, alkyl, haloalkyl, C3-6cycloalkyl, 3-6 membered heterocycloalkyl, hydroxyalkyl, OR11, NR10C(O)R11, NR10C(O)OR11, NR10C(O)NR11R12, C(O)R11,C(O)OR11, and C(O)NR11R12;
each R7, R8 and R9 is independently chosen from hydrogen, C1-4alkyl, C3-6cycloalkyl, and 3-6 membered heterocycloalkyl, any of which is optionally substituted with halo, hydroxy, C1-3alkyl, C1-3haloalkyl and C1-3alkoxy; or any two of R7, R8 and R9, together with the atom to which they are both attached can form a 3-7 membered cycloalkyl or heterocycloalkyl ring; and
each R10, R11 and R12 is independently chosen from hydrogen, C1-4alkyl, C3-6cycloalkyl, 3-6 membered heterocycloalkyl, any of which is optionally substituted with one or more groups chosen from halo, hydroxy and alkoxy; or any two of R10, R11 and R12, together with the atom to which they are both attached, can form a 3-7 membered cycloalkyl or heterocycloalkyl ring.

US Pat. No. 10,392,375

HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF

Merck Patent GmbH, Darms...

1. A method for treating an IRAK-mediated disorder in a patient in need thereof, comprising:administering to said patient a compound of
formula I,

or a pharmaceutically acceptable salt thereof, wherein:
is selected from
each Ra is independently —R, halogen, -haloalkyl, —OR, —SR, —CN, —NO2, —SO2R, —SOR, —C(O)R, —CO2R, —C(O)N(R)2, —NRC(O)R, —NRC(O)N(R)2, —NRSO2R, or —N(R)2;
Ring X is a C3-10 aryl; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; a fused C3-10 aryl, a fused 5-10 membered saturated or partially unsaturated carbocyclic ring, a fused 5-10 membered heterocylic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a fused 5-10 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; each of which is optionally substituted;
R1 is —R, halogen, -haloalkyl, —OR, —SR, —CN, —NO2, —SO2R, —SOR, —C(O)R, —CO2R, —C(O)N(R)2, —NRC(O)R, —NRC(O)N(R)2, —NRSO2R, or —N(R)2;
R2 is —R, halogen, -haloalkyl, —OR, —SR, —CN, —NO2, —SO2R, —SOR, —C(O)R, —CO2R, —C(O)N(R)2, —NRC(O)R, —NRC(O)N(R)2, —NRSO2R, or —N(R)2;
R3 is C1-6 aliphatic, a 3-8 membered saturated or partially unsaturated carbocyclic ring, or a 3-7 membered heterocylic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; each of which is optionally substituted; or R3 is -haloalkyl;
R4 is —R, halogen, -haloalkyl, —OR, —SR, —CN, —NO2, —SO2R, —SOR, —C(O)R, —CO2R, —C(O)N(R)2, —NRC(O)R, —NRC(O)N(R)2, —NRSO2R, or —N(R)2;
Z is N or CR;
each R is independently hydrogen, C1-6 aliphatic, C3-10 aryl, a 3-8 membered saturated or partially unsaturated carbocyclic ring, a 3-7 membered heterocylic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; each of which is optionally substituted; or
two R groups on the same atom are taken together with the atom to which they are attached to form a C3-10 aryl, a 3-8 membered saturated or partially unsaturated carbocyclic ring, a 3-7 membered heterocylic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; each of which is optionally substituted;
and
p is 0, 1, 2, 3, 4, or 5, and
wherein said IRAK-mediated disorder is an autoimmune or chronic inflammatory disease selected from the group consisting of multiple sclerosis, systemic sclerosis, amyotrophic lateral sclerosis (ALS), lupus erythematosus, systemic lupus erythematosus and lupus nephritis.

US Pat. No. 10,392,373

OXAZOLE DERIVATIVES THAT INHIBIT SYK

AB Science, Paris (FR)

1. A compound of formula (I):
or a pharmaceutically acceptable salt thereof, wherein:
R1, R2, R3, and R4 are each independently selected from:
hydrogen,
cyano,
haloalkyl,
halogen,
an alkyl group optionally substituted with a group selected from a heterocycle or —NRR?,
an alkoxy group optionally substituted with a group selected from a heterocycle or —NRR?,
a water-solubilising group,
heterocycle,
—CO—NRR?,
—SO2—NRR?,
—NRR?,
—NR—CO—R?, or
a —NR—SO2R? group;
wherein R and R? are each independently selected from hydrogen or an alkyl group;
R5 is an alkyl group optionally substituted with a group selected from heterocycle, hydroxyl, cyano, amino, or alkoxy;
R6 is selected from hydrogen, an alkyl group, or a cycloalkyl group;
W is selected from aryl or heteroaryl groups, the aryl or heteroaryl groups being optionally substituted by one or more substituents selected from:
cyano,
haloalkyl,
halogen,
an alkyl group optionally substituted with a heterocycle,
a cycloalkyl group,
an alkoxy group optionally substituted with a heterocycle,
an aryl group,
a heteroaryl group,
a heterocycloalkyl group optionally substituted with an alkyl group,
a water-solubilising group,
—CO—NRR?,
—SO2—NRR?,
—NRR?,
—NR—CO—R?, or
a —NR—SO2R? group;
wherein R and R? are each independently selected from hydrogen or alkyl group,
wherein the water-solubilising group is selected from:
N—(CH2)zR?,
N—(CH2)z—C(O)R?,
N—(CH2)z—C(O)OR?,
N—(CH2)z—S(O)2R?,
N—(CH2)z—S(O)2OR?,
N—(CH2)z—C(O)NR?R??,
or one of the following structures (a)-(k):

wherein:
L is selected from CH or N;
M is selected from —CH(R?)—, —CH2—, —O—, —S—, —NH—, —N(—(CH2)z—R?)—, —N(—(CH2)z—C(O)R?)—, —N(—(CH2)z—C(O)OR?)—, —N(—(CH2)z—S(O)2R?)—, —N(—(CH2)z—S(O)2OR?)— or
—N(—(CH2)z—C(O)NR?R??)—,
with the proviso that L and M are not both simultaneously CH and CH2, respectively;
z is an integer ranging from 0 to 6;
R? and R?? are each independently selected from: hydrogen; a C1-C10 alkyl group which is optionally substituted with one or more heteroatoms selected from F, Cl, Br, I, O, and N; a C1-C10 alkoxy group; an unsubstituted aryl; or an unsubstituted heteroaryl.

US Pat. No. 10,392,372

COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY

Proteostasis Therapeutics...

1. A compound represented by formula III:or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:X1 is N;
pp is 1, 2, or 3;
R11 is independently selected for each occurrence from the group consisting of hydrogen, halogen, and C1-4 alkyl (optionally substituted by one, two or three halogens);
R31 is selected from the group consisting of hydrogen, fluorine, and C1-4 alkyl;
L1 is C3-5 cycloalkylene, wherein L1 may be optionally substituted by one, two or three substituents selected from the group consisting of halogen, hydroxyl, and C1-3 alkyl (optionally substituted by one, two or three substituents each selected independently from Rff);
R44 is a 5-6 membered monocyclic heteroaryl having one, two or three heteroatoms each selected from O, N, and S; wherein heteroaryl may be optionally substituted by one or two substituents each selected independently from Rgg;
Rff is selected for each occurrence from the group consisting of halogen, hydroxyl, C1-4 alkyl, C1-4 alkoxy, C2-4 alkenyl, C3-6 cycloalkyl, —NR?R?, —NR?—S(O)w—C1-3 alkyl, S(O)w—NR?R?, and —S(O)w—C1-3 alkyl, where w is 0, 1, or 2, wherein C1-4 alkyl, C1-4 alkoxy, C2-4 alkenyl and C3-6 cycloalkyl may be optionally substituted by one, two or three substituents each independently selected from the group consisting of halogen, hydroxyl, —NR?R?, —NR?—S(O)w—C1-3 alkyl, S(O)w—NR?R?, and —S(O)w—C1-3 alkyl;
Rgg is selected for each occurrence from the group consisting of halogen, hydroxyl, cyano, —NR?R?, —NR?—S(O)w—C1-3 alkyl, —S(O)w—NR?R?, —S(O)w—C1-3 alkyl, where w is 0, 1, or 2; heterocycle, C1-6 alkyl, C3-6 cycloalkyl, and C2-6 alkenyl, wherein C1-6 alkyl, C3-6 cycloalkyl, and C2-6 alkenyl are optionally substituted by one, two, or three substituents each independently selected from Rjj; and heterocycle is optionally substituted by one, two, or three substituents each independently selected from Rll;
Rjj is selected for each occurrence from the group consisting of halogen, hydroxyl, C1-6 alkoxy (optionally substituted by one, two, or three substituents each independently selected from Rkk); C3-6 cycloalkyl, C3-6 cycloalkoxy, heterocycle, C(O)OH, —C(O)OC1-6 alkyl, —NR?R?, —NR?—S(O)w—C1-3 alkyl, —S(O)w—NR?R?, and —S(O)w—C1-3 alkyl, where w is 0, 1, or 2;
Rkk is selected for each occurrence from the group consisting of halogen, hydroxyl, C1-6 alkyl (optionally substituted by one, two, or three substituents each independently selected from halogen, hydroxyl, C3-6 cycloalkyl, and heterocycle (optionally substituted by C1-6 alkyl)), C3-6 cycloalkyl (optionally substituted by one, two, or three substituents each independently selected from halogen, hydroxyl, and C1-6 alkyl), phenyl, heterocycle (optionally substituted by one, two or three substituents independently selected from halogen, hydroxyl, and C1-6 alkyl), and heteroaryl;
Rll is selected for each occurrence from the group consisting of halogen, hydroxyl, C1-6 alkyl (optionally substituted by one, two, or three substituents each independently selected from halogen, hydroxyl, and C3-6 cycloalkyl) and heterocycle (optionally substituted by one, two or three substituents independently selected from halogen, hydroxyl, and C1-6 alkyl);
R? and R? are each independently selected for each occurrence from H, C1-4 alkyl, phenyl and heterocycle;
w is 0, 1 or 2; and
Rhh is selected for each occurrence from the group consisting of H, C1-6 alkyl and C3-6 cycloalkyl.

US Pat. No. 10,392,371

COMPOUNDS USEFUL AS MODULATORS OF TRPM8

Senomyx, Inc., San Diego...

1. A composition comprising:(a) at least one cooling agent compound selected from the group consisting of
or a salt thereof, and(b) at least one additional cooling agent.

US Pat. No. 10,392,370

PROCESS FOR THE PREPARATION OF DACLATASVIR DIHYDROCHLORIDE AND ITS INTERMEDIATES

OPTIMUS DRUGS PVT LTD, H...

1. An improved process for the preparation of Daclatasvir dihydrochloride of formula (I) which comprises the steps of:a. 1,1?-biphenyl-4,4?-diylbis(2-chloroethanone) of formula (Ma) is reacted with compound of formula (IVa) in absence of base to obtain compound of formula (V);

b. The product of step a) is cyclized in presence of a cyclisation agent to obtain compound of formula (VI);

c. The product of step b) is deprotected in presence of p-toluene sulphonic acid at 20-40° C. to obtain compound of formula (VIIc);

d. The product of step c) is reacted with compound of formula (VIII) in presence of coupling agent/base to get Daclatasvir and it reacts with hydrochloric acid to obtain Daclatasvir dihydrochloride of formula (I)

US Pat. No. 10,392,369

N-[(PYRIMIDINYLOXY)PROPANYL]BENZAMIDES

Boehringer Ingelheim Inte...

1. A compound of formula I
in which
Ar represents

R1 represents hydrogen, fluoro, or methyl;
R2 and R3 independently represent hydrogen, fluoro, methyl, or —OCH3;
R4 represents hydrogen;
R5 represents bromo or —CF3;
wherein at least two of the substituents R1, R2, R3 and R4 represent hydrogen;
or a pharmaceutically acceptable salt thereof.

US Pat. No. 10,392,368

PYRAZOLO AND TRIAZOLO BICYCLIC COMPOUNDS AS JAK KINASE INHIBITORS

1. A compound of formula (I):
or a pharmaceutically acceptable salt thereof, wherein
X1 and X2 are each independently selected from N and CH;
X3 is selected from the group consisting of N, CH, C—CH3, C—CF3, C—CHF2, C—CH2—O—CH3, C—SMe, C—NMe2, C—NH—CH3, C—Cl, C—CN, and C—OMe;

 is selected from the group consisting of

Ra, Rb, Rc, and Rf are each independently selected from the group consisting of H and C1-3 alkyl;
Rd, Re, Rg, Rh, Ri, Rj, Rl, Rm, Rn and Ro are each independently selected from the group consisting of H and C1-3 alkyl wherein the C1-3 alkyl group may be optionally substituted with 1 to 3 halogens;
optionally Rd and Re may be joined to form a cyclopropyl ring;
A is selected from the group consisting of
(a) a 4 to 10 membered monocyclic heterocyclic group containing one nitrogen atom and optionally containing one additional heteroatom selected from N, S, S(O)2 and O, and
(b) a 6 to 10 membered multicyclic heterocyclic group containing one nitrogen atom and optionally containing one additional heteroatom selected from N, S, and O,
wherein L is linked to a carbon atom in A and A is optionally substituted with 1 to 3 Rk groups;
each Rk is independently selected from the group consisting of F, CN, C1-3 alkoxy, cyclopropyl, and C1-3 alkyl, wherein the C1-3 alkyl group may be optionally substituted with OH, OMe or 1 to 3 halogens;
R1 is selected from the group consisting of

wherein Rp and Rq are each independently selected from the group consisting of H, C3-5 cycloalkyl and C1-6 alkyl, wherein the C1-6 alkyl group may be optionally substituted with 1 to 3 substituents independently selected from the group consisting of C1-3 alkoxy and —S—C1-3 alkyl,
or Rp and Rq form a 4 to 6 membered monocyclic heterocyclic group containing one nitrogen atom and optionally containing one additional heteroatom selected from N, S, and O, wherein the 4 to 6 membered monocyclic heterocyclic group is optionally substituted with 1 to 3 substituents independently selected from the group consisting of C1-6 alkyl, C1-3 alkoxy, —S—C1-3 alkyl and —C1-3 alkyl-C1-3 alkoxy;
R2 is selected from the group consisting of H, Cl, OMe, Me and F;
R3 is selected from the group consisting of H and F;
R4 is selected from the group consisting of H and F; and
R5 is selected from the group consisting of H, Me and F.

US Pat. No. 10,392,366

AZETIDINE COMPOUNDS AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS

SANOFI, Paris (FR)

1. A compound of formula Iwherein:X is N or C—R1;
Y is N or C—R2;
A is O or CH2;
R1 is H, F or CN;
R2 is H or F;
R3a and R3b are independently H or (C1-C6)-alkyl;
B is a bond, O or C?O;
R4 is a bond or (CH2)p;
p is 1 or 2;
R5 is CF3, (C3-C8)-cycloalkyl, phenyl or 5- or 6-membered heteroaryl ring;
wherein the groups (C3-C8)-cycloalkyl, phenyl and 5- or 6-membered heteroaryl ring are optionally substituted with 1 to 3 groups selected from the group consisting of F and (C1-C4)-alkyl;
R6 is H or (C1-C6)-alkyl;
R7 is OH, NH2, (CH2)n—COOR13, (CH2)n—CONR14R15, S(O)mR16, NHCO—R19, O(CO)NR20R21, COR22,

or R6 and R7, together with the carbon atom to which they are attached, form a ring of formula L, which is spiro connected to the azetidine moiety of formula I in the position marked by the asterix;
L is

Ra is H or (C1-C6)-alkyl;
n is 0 or 1;
m is 0, 1 or 2;
R13 is H or (C1-C2)-alkyl, optionally substituted with NH2, NH(C1-C2)-alkyl or N((C1-C2)-alkyl)2;
R14 and R15 are independently H, (C3-C6)-cycloalkyl, (C1-C6)-alkyl or (C1-C6)-alkyl substituted with 1 to 3 groups selected from the group consisting of CONH2 and OH;
R16 is (C1-C6)-alkyl;
R19 is (C1-C2)-alkylene-O—(C1-C2)-alkyl or (C1-C2)-alkyl;
R20 is H or (C1-C2)-alkyl;
R21 is H or (C1-C2)-alkyl; and
R22 is azetidinyl, pyrrolidinyl, piperidinyl or piperazinyl;
wherein the azetidinyl, pyrrolidinyl, piperidinyl or piperazinyl is optionally substituted with 1 to 3 groups selected from the group consisting of OH and COCH3,
or a stereoisomer or a physiologically acceptable salt thereof.

US Pat. No. 10,392,365

ANTIFUNGAL COMPOUND PROCESS

Mycovia Pharmaceuticals, ...

1. A process to prepare enantio-enriched amino-alcohol 1-6* or 1-7*,or a mixture thereof, the method comprising:(i) reacting ester 2,
with morpholine to yield morpholine amide 2b,
(ii) displacing the morpholino portion of morpholine amide 2b,
to yield ketone 3,
(iii) reacting ketone 3,
with trimethylsulfoxonium iodide (TMSI) to yield epoxide 4,
(iv) ring-opening epoxide 4,
with ammonia to yield amino-alcohol ±4b,
(v) enriching the enantiomeric purity of amino-alcohol ±4b,
to yield enantio-enriched amino-alcohol 4b or 4c:or a mixture thereof; and(vi) arylating enantio-enriched amino-alcohol 4b or 4c,
or a mixture thereof, to yield enantio-enriched aryl-pyridine 1-6* or 1-7*,or a mixture thereof;wherein each R1 is independently halo or

US Pat. No. 10,392,364

PROCESS FOR SYNTHESIS OF LENALIDOMIDE

AVRA LABORATORIES PVT. LT...

1. A process for preparation of Lenalidomide, comprising;i. Brominating methyl 2-methyl-3-nitrobenzoate with NBS or 1,3-Dibromo-5,5-dimethyl-hydantoin in presence of AIBN in acetonitrile at a temperature in the range of 55-75° C. to isolate methyl 2-(bromomethyl)-3-nitrobenzoate (II);

ii. Condensing methyl 2-(bromomethyl)-3-nitrobenzoate (II) with 3-amino-piperidine-2,6-dione hydrochloride (III) in DMSO and a base at a temperature in the range of 50-55° C. to obtain 3-(4-nitro-1-oxoisoindolin-2-yl)piperidine-2,6-dione (IV);

iii. hydrogenating 3-(4-nitro-1-oxoisoindolin-2-yl)piperidine-2,6-dione (IV) catalytically using 10% Pd/C under hydrogen atmosphere at 60-100 psi for about 6-12 hours in ammonia bubbled NMP or in a solvent mixture of aqueous ammonia and NMP to obtain crude 3-(4-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione (Lenalidomide);

iv. Dissolving the crude mass of step (iii) in acetone and refluxing to obtain pure Lenalidomide followed by recrystallizing from the mixture of water and IPA in 1:2 ratio at a temperature of about 100° C. to obtain pure wet 3-(4-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione (Lenalidomide).

US Pat. No. 10,392,362

METHOD FOR SYNTHESIZING LACTIDE BY MEANS OF CATALYSIS OF LACTID ACID

The Hong Kong Research In...

1. A method for the catalytic synthesis of lactide from lactic acid, characterized in that the synthesis of lactide from lactic acid is catalyzed solely by a zinc oxide aqueous nanoparticle dispersion.

US Pat. No. 10,392,361

PROCESS FOR THE SYNTHESIS OF INTERMEDIATES OF NEBIVOLOL

Menarini International Op...

1. A process for the synthesis of chromanyl haloketones of formula IIIa and/or IIIb as separate isomers or as a racemic mixturecomprising reacting an ester of formula IIa and/or IIb,
wherein R is a linear C1-C6 alkyl group, in a form of a separate isomer or as a racemic mixture with a metal-organic compound and a salt of a haloacetic acid of general formula A

wherein X is F, Cl, Br, or I and Y?H, Li, Na, K, or Mg;
wherein the reacting of the ester with the metal-organic compound is carried out at a temperature between ?10° C. and +10° C.,
wherein the metal-organic compound is an organic magnesium compound of formula RMgX, where X is a halogen and R is an amine or a linear or branched, C1-C6 alkyl residue; and
in situ decarboxylating in the presence of an aqueous inorganic acid until the reaction reaches a pH equal to or less than 5, to result in the corresponding chromanyl haloketone of formula IIIa and/or IIIb in the form of a separate isomer or in racemic form.

US Pat. No. 10,392,360

SYNTHETIC ROUTE TO ANHYDRORYANODOL, RYANODOL AND STRUCTURAL ANALOGUES

California Institute of T...

13. A compound of formula (I) that is:
wherein:
R1 is benzyloxymethyl, trimethylsilylethoxy methyl, or methoxymethyl;
R2 is C1-6alkyl;
R3 is C1-6alkyl; and
R4 is C1-6alkyl.

US Pat. No. 10,392,359

COMPOUND FOR ORGANIC ELECTRIC ELEMENT, ORGANIC ELECTRIC ELEMENT COMPRISING THE SAME AND ELECTRONIC DEVICE THEREOF

DUK SAN NEOLUX CO., LTD.,...

1. A compound of Formula 1 below:
wherein,
X is O or S,
R1 to R3 are each independently selected from the group consisting of hydrogen, deuterium, tritium, halogen, a cyano group, a nitro group, a C6-C60 aryl group, a fluorenyl group, a C2-C60 heterocyclic group containing at least one heteroatom selected from the group consisting of O, N, S, Si, and P, a fused ring group of a C3-C60 aliphatic ring and a C6-C60 aromatic ring, a C1-C50 alkyl group, a C2-C20 alkenyl group, a C2-C20 alkynyl group, a C1-C30 alkoxyl group, a C6-C30 aryloxyl group, and the above formula 2, and with the proviso that at least one of R1 to R3 is the above formula 2,
R4 to R7 are each independently selected from the group consisting of hydrogen, deuterium, tritium, halogen, a cyano group, a nitro group, a C6-C60 aryl group, a C2-C60 heterocyclic group containing at least one heteroatom selected from the group consisting of O, N, S, Si, and P, a fused ring group of a C3-C60 aliphatic ring and a C6-C60 aromatic ring, a C1-C50 alkyl group, a C2-C20 alkenyl group, a C2-C20 alkynyl group, a C1-C30 alkoxyl group, and a C6-C30 aryloxyl group, and with the proviso that dibenzofuryl group and dibenzothienyl group are excluded from R4 to R7; neighboring R4 to R7 may be optionally linked each other to form a ring;
in the Formula 2,
Ar1 to Ar4 are each independently selected from the group consisting of a C6-C60 aryl group, a C2-C60 heterocyclic group containing at least one heteroatom selected from the group consisting of O, N, S, Si, and P, a fluorenyl group, a fused ring group of a C3-C60 aliphatic ring and a C6-C60 aromatic ring, a C1-C50 alkyl group, a C2-C20 alkenyl group, a C2-C20 alkynyl group, a C1-C30 alkoxyl group, and a C6-C30 aryloxyl group,
L1 is selected from the group consisting of a single bond, a C6-C60 arylene group and a C2-C60 heterocyclic group containing at least one heteroatom selected from O, N, S, Si, and P,
L2 to L5 are each independently selected from the group consisting of a single bond, a C6-C60 arylene group, a C2-C60 heterocyclic group containing at least one heteroatom selected from O, N, S, Si, and P, a fluorenylene group, a fused ring group of a C3-C60 aliphatic ring and a C6-C60 aromatic ring, and an C1-C60 aliphatic hydrocarbon group, each of L1 to L5, except for a single bond, may be optionally further substituted with one or more substituents selected from the group consisting of deuterium, halogen, a silane group, a siloxane group, a boron group, a germanium group, a cyano group, a nitro group, a C1-C20 alkylthio group, a C1-C20 alkoxyl group, a C1-C20 alkyl group, a C2-C20 alkenyl group, a C2-C20 alkynyl group, a C6-C20 aryl group, a C6-C20 aryl group substituted with deuterium, a fluorenyl group, a C2-C20 heterocyclic group containing at least one heteroatom selected from the group consisting of O, N, S, Si, and P, a C3-C20 cycloalkyl group, a C7-C20 arylalkyl group, and a C8-C20 arylalkenyl group,
when R1 to R3, and Ar1 to Ar4 are each the aryl group, fluorenyl group, heterocyclic group, fused ring group, alkyl group, alkenyl group, alkynyl group, alkoxyl group, or aryloxy group, each of these may be optionally further substituted with one or more substituents selected from the group consisting of deuterium, halogen, a silane group substituted or unsubstituted with a C1-C20 alkyl group or a C6-C20 aryl group, a siloxane group, a boron group, a germanium group, a cyano group, a nitro group, a C1-C20 alkylthio group, a C1-C20 alkoxyl group, a C1-C20 alkyl group, a C2-C20 alkenyl group, a C2-C20 alkynyl group, a C6-C20 aryl group, a C6-C20 aryl group substituted with deuterium, a fluorenyl group, a C2-C20 heterocyclic group containing at least one heteroatom selected from the group consisting of O, N, S, Si, and P, a C3-C20 cycloalkyl group, a C7-C20 arylalkyl group, and a C8-C20 arylalkenyl group, and when those substituents are adjacent, they are linked each other to form a ring, and
when R4 to R7 are each the aryl group, heterocyclic group, fused ring group, alkyl group, alkenyl group, alkynyl group, alkoxyl group, or aryloxy group, each of these may be optionally further substituted with one or more substituents selected from the group consisting of deuterium, halogen, a silane group substituted or unsubstituted with a C1-C20 alkyl group or a C6-C20 aryl group, a siloxane group, a boron group, a germanium group, a cyano group, a nitro group, a C1-C20 alkylthio group, a C1-C20 alkoxyl group, a C1-C20 alkyl group, a C2-C20 alkenyl group, a C2-C20 alkynyl group, a C6-C20 aryl group, a C6-C20 aryl group substituted with deuterium, a fluorenyl group, a C2-C20 heterocyclic group except dibenzofuryl group and dibenzothienyl group containing at least one heteroatom selected from the group consisting of O, N, S, Si, and P, a C3-C20 cycloalkyl group, a C7-C20 arylalkyl group, and a C8-C20 arylalkenyl group.

US Pat. No. 10,392,358

OXIDATION CHEMISTRY ON FURAN ALDEHYDES

Micromidas, Inc., West S...

1. A method of producing a halomethylfuroic acid, or a salt thereof, comprising combining a halomethylfurfural, an organosulfur compound, and an oxidant to produce a halomethylfuroic acid, or a salt thereof,wherein the oxidant is:
(i) a compound of formula Wb-O2Xb, wherein Wb is a Group I cation and Xb is halo;
(ii) a compound of formula Wd-O3Xd, wherein Wd is a Group I cation and Xd is halo;
(iii) a compound of formula HXbO2, wherein Xb is halo;
(iv) a compound of formula HXdO3, wherein Xd is halo; or
(v) a compound of formula XcO2, wherein Xc is halo.

US Pat. No. 10,392,357

GLUCAGON-LIKE PEPTIDE 1 MODULATOR AND USES THEREOF

Acaemia Sinica, Taipei (...

1. A compound of formula (I),wherein,X is O or S;
R1 is

R2 is H or a nitrogen protecting group;
R3 and R4 are independently H, halogen, optionally substituted alkyl, or alkenyl; or R3 and R4 are taken together to form an optionally substituted 6-membered carbocycle or heterocycle;
R? is H or optionally substituted alkyl; and
n and m are independently an integral between 1 to 10, provided that when X is O, then R3 and R4 are not H; when X is S, then m is not for 4.

US Pat. No. 10,392,356

DERIVATIVES OF SOBETIROME

1. A pharmaceutical composition comprising one or more pharmaceutically acceptable carriers and an effective amount of a compound with the structure:
or any pharmaceutically acceptable salt thereof, where R1 is heteroalkyl, substituted heteroalkyl, substituted cycloalkyl, heterocycloalkyl, substituted heterocycloalkyl, substituted aryl, heteroaryl, or substituted heteroaryl.

US Pat. No. 10,392,355

PROCESSES FOR PREPARING OXATHIAZIN-LIKE COMPOUNDS

GEISTLICH PHARMA AG, Wol...

1. A process for preparing compound 2245, compound 2250, and/or compound 2255, comprising reacting compound 2244 as follows:
reacting compound 2245 as follows:
and/or reacting compound 2245 as follows:

US Pat. No. 10,392,354

HIGHLY SELECTIVE ANTI-CANCER AGENTS TARGETING NON-SMALL CELL LUNG CANCER AND OTHER FORMS OF CANCER

The University of Toledo,...

1. A method of treating a mammalian disease comprising administering a therapeutically effective amount of a pharmaceutical composition to a subject in need thereof, wherein the pharmaceutical composition comprises a compound of the following structural formula:wherein:n=1 or 2;
X is N or CH;
Y is S, O, or NH;
R is selected from the group consisting of:
?O;
2H;
—OR3, wherein R3 is hydrogen, alkyl, aryl, glycosyl, or polyether groups;
(CO)OR4, wherein R4 is hydrogen, alkyl, aryl, or aralkyl groups;
—NR5R6, wherein R5 and R6 are H, alkyl, aryl, or aralkyl groups; and,
?N—OR7, wherein R7 is hydrogen, alkyl, aryl, aralkyl, glycosyl, or polyether groups;
R1 is hydrogen, alkyl-, aryl-, or aralkyl;
Z is absent or selected from the group consisting of:
halide, wherein R2 is absent;
oxygen;
nitrogen, wherein there are two R2 groups;
(CO)O—; O(CO)—; O(CO)O—;
(CO)N<, wherein there are two R2 groups; and,
NH(CO)—; and NH(CO)N<, wherein there are two R2 groups;
wherein where Z is absent, R2 connects directly to a ring; and
R2 is hydrogen, alkyl-, aryl-, aralkyl-, glycosyl-, or polyether-, wherein multiple occurrences of R2 are the same or different;
or a prodrug, salt, stereoisomer, racemate, solvate, or hydrate thereof;
wherein the mammalian disease is a cancer.

US Pat. No. 10,392,353

PROCESSES FOR MAKING SUBSTITUTED QUINAZOLINE COMPOUNDS USING HYDROGEN BONDING CATALYSTS

1. A process for preparing a compound of Formula (I):
or a salt thereof, comprising contacting a compound of formula (viii):

or a salt thereof, with a catalyst of formula (V):

wherein each occurrence of R5 is independently selected from the group consisting of phenyl; naphthyl and pyridine; wherein each of the phenyl and naphthyl is optionally substituted with one to three substituents independently selected from halogen, —O—C1-C4alkyl, —CN, —NO2, —O-Tf, and C1-C4alkyl, wherein C1-C4 alkyl can be optionally substituted with one to four halogens; and
each occurrence of R6 is independently selected from the group consisting of Tf and Nf;
in a suitable solvent for a time sufficient to form a compound of formula (I);
wherein:
R1 represents up to 3 phenyl group substituents, each independently selected from C1-C6 alkyl, C1-C6 haloalkyl, halo, —CN, —OH and C1-C6 alkoxy;
R2 represents up to 3 phenyl group substituents, each independently selected from C1-C6 alkyl, C1-C6 haloalkyl, halo, —CN, —OH and C1-C6 alkoxy;
R3 represents up to 3 phenyl group substituents, each independently selected from C1-C6 alkyl, C1-C6 haloalkyl, halo, —CN, —OH and C1-C6 alkoxy; and
R4 is C1-C6 alkyl or C3-C7 cycloalkyl.

US Pat. No. 10,392,352

ETOMIDATE DERIVATIVE AND INTERMEDIATE, PREPARATION METHOD AND USE THEREOF

JIANGSU NHWALUOKANG PHARM...

1. An etomidate derivative of Formula 1:
wherein,
X and Y are independently halogen or hydrogen, with the proviso that X and Y are not hydrogen at the same time; and
R1 is C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl or C6-10 aryl, optionally substituted with one or more substituents selected from the group consisting of halogen, hydroxyl, amino, cyano, C1-6 alkoxyl, C2-7 alkoxycarbonyl, C3-6 cycloalkyl and C6-10 aryl,
or a pharmaceutically acceptable salt, a polymorph, or a solvate thereof.

US Pat. No. 10,392,351

METHOD FOR PREPARING NILOTINIB INTERMEDIATE

SUZHOU LIXIN PHARMACEUTIC...

1. A method for preparing a nilotinib intermediate 3-(4-methyi-IH-imidazol-1-yl)-5-trifluoromethyl phenylamine (I),
comprising the following steps:
a) converting trifluorotoluene to a nitrobenzotrifluoride through a nitration reaction;
b) converting the nitrobenzotrifluoride to 3-bromo-5-nitro-trifluorotoluene by a bromination reaction;
c) reacting 3-bromo-5-nitro-trifluorotoluene and 4-methyl-1H-imidazole by a condensation reaction to produce 3-(4-methyl-1H-imidazol-1-yl)-5-nitrotrifluorotoluene in the presence of a catalyst, a promoter and a combination of two mixed acid-binding agents at a temperature of 130-160° C., with a yield of the condensation reaction higher than 70%; and
d) reducing 3-(4-methyl-1H-imidazol-1-yl)-5-nitrotrifluorotoluene through a reduction reaction to produce the nilotinib intermediate (I);
wherein:
the catalyst for the condensation reaction is cuprous iodide, zinc iodide, stannous chloride, palladium chloride or silver iodide;
the promoter for the condensation reaction is 8-hydroxyquinoline, 2,6-dimethylpyridine, 4-dimethylaminopyridine, N-methylmorpholine, N-ethyl morpholine, 1,5-diazabicyclo[4.3.0]-non-5-ene, 1,8-diazabicyclo [5.4.0]-undec-7-ene or 1,4-diazabicyclo[2.2.2] octane; and
the mixed acid-binding agents for the condensation reaction consists of a first mixed acid-binding agent selected from the group consisting of sodium hydride, potassium hydride, sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, sodium tert-butoxide, potassium tert-butoxide, sodium methylate and sodium ethoxide, and a second mixed acid-binding agent selected from the group consisting of triethylamine, ethanediamine and diisopropylethylamine;wherein:there is a mole ratio of 1.1:0.15 between the first mixed acid-binding agent and the second mixed acid-binding agent;there is a mole ratio of 1:1.2:0.15 between the 3-bromo-5-nitro-trifluorotoluene, 4-methyl-1H-imidazole, and catalyst; andthere is a mole ratio of 1:0.15 between the 3-bromo-5-nitro-trifluorotoluene and the promoter.

US Pat. No. 10,392,350

N-SUBSTITUTED PYRAZOLYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF

Lycera Corporation, Ann ...

1. A compound represented by Formula I:
including all stereoisomers, geometric isomers, and tautomers; or a pharmaceutically acceptable salt or solvate of any of the foregoing; wherein:
A1 is phenyl substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, C1-C4 haloalkyl, and C1-C6 alkyl;
R1 and R2 are independently hydrogen, halogen, C1-C4 haloalkyl, C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkoxy, or cyano;
R3 and R4 are independently hydrogen, halogen, C1-C4 haloalkyl, C1-C6 alkyl, C3-C6 cycloalkyl, or cyano;
R5 is one of the following:
(a) C1-C6 alkyl substituted by 1 or 2 substituents independents from the group consisting of hydroxyl, C1-C6 alkoxy, cyano, —CO2H, —CO2R6, —C(O)R6, —C(O)N(R7)(R8), —N(R7)C(O)(R6), —N(R7)(R8), —S(O)R6, —SO2R6, —SO2N(R7)(R8), and —N(R7)SO2(R6); or
(b) C2-C6 alkenyl;
R6 represents independently for each occurrence C1-C6 alkyl, C3-C6 cycloalkyl, aryl, or heteroaryl, each of which is optionally substituted with 1 or 2 substituents independently selected from the group consisting of hydroxyl, cyano, halogen, —CO2H, and aryl; and
R7 and R8 each represent independently for each occurrence hydrogen, C1-C6 alkyl, or C3-C6 cycloalkyl; or R7 and R8 are taken together with the nitrogen atom to which they are attached to form a 3 to 7 membered heterocyclic ring.

US Pat. No. 10,392,349

AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS

NOVIRA THERAPEUTICS, INC....

1. A compound of Formula I:
or a pharmaceutically acceptable salt thereof;
wherein
R4 is H or —C1-C3 alkyl;
each R1 is, independently at each occurrence, —OH, halo, —CN, —NO2, —C1-C6 alkyl, —O—C1-C6 alkyl, —C1-C6 heteroalkyl, —O—C1-C6 heteroalkyl, —C3-C10 cycloalkyl, —C3-C10 heterocycloalkyl, aryl, heteroaryl, —C1-C4 alkyl-(C3-C10 cycloalkyl), —C1-C4 alkyl-(C3-C10 heterocycloalkyl), —C1-C4 alkyl-(aryl), or —C1-C4 alkyl-(heteroaryl), wherein the alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl groups are optionally substituted 1-5 times with halo, —OH, —CN, or —NO2;
each R2 is, independently at each occurrence, —OH, halo, —CN, —NO2, R6, or —OR6, wherein R6 is, independently at each occurrence, —C1-C6 alkyl, —C1-C6 heteroalkyl, —C3-C10 cycloalkyl, —C3-C10 heterocycloalkyl, aryl, heteroaryl, —C1-C4 alkyl-(C3-C10 cycloalkyl), —C1-C4 alkyl-(C3-C10 heterocycloalkyl), —C1-C4 alkyl-(aryl), or —C1-C4 alkyl-(heteroaryl), wherein the alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl groups are optionally substituted 1-5 times with halo, —OH, —CN, or —NO2;
or two R2 groups, and the phenyl ring to which they are attached, join to form benzimidazole;
Cy is

R7 and R8 are, independently at each occurrence, —C1-C6 alkyl, aryl, heteroaryl, —C1-C4 alkyl-(aryl), or —C1-C4 alkyl-(heteroaryl), wherein the aryl or heteroaryl groups are optionally substituted with —C1-C3 alkyl;
or R7 and R8 join to form a 3- to 10-membered ring;
R11 is, independently at each occurrence, —OH, halo, —CN, —NO2, ?O, —OC(O)CH3, —O—C1-C6 alkyl, —C1-C6 heteroalkyl, —O—C1-C6 heteroalkyl, —C3-C10 cycloalkyl, —O—C3-C10 cycloalkyl, —C3-C10 heterocycloalkyl, aryl, heteroaryl, —C1-C4 alkyl-(C3-C10 cycloalkyl), —C1-C4 alkyl-(C3-C10 heterocycloalkyl), —C1-C4 alkyl-(aryl), or —C1-C4 alkyl-(heteroaryl), wherein the alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl groups are optionally substituted 1-5 times with halo, —OH, —CN, or —NO2;
R12 is, independently at each occurrence, H or —C1-C6 alkyl;
R13 and R14, together with the carbons to which they are attached, join to form a cyclopropyl ring;
m is 0, 1, 2, 3, or 4;
n is 1, 2, 3, or 4;
x is 0, 1, 2, 3, 4, or 5; and
y is 0, 1, 2, 3, or 4.

US Pat. No. 10,392,348

2-OXO-3,4-DIHYDROQUINOLINE COMPOUNDS AS PLANT GROWTH REGULATORS

Syngenta Participations A...

1. A compound of formula (I)
wherein:
R1 is selected from the group consisting of C1-C7 alkyl, C1-C7 haloalkyl, C3-C5 cycloalkyl-C1-C7 alkyl, C3-C7alkenyl, C3-C7 alkynyl, (3-6 membered heterocycloalkyl)-C1-C7 alkyl, C3-C5 cycloalkyl and a 4-6 membered heterocycloalkyl, each optionally substituted with one to three Rx;
R2 is selected from the group consisting of hydrogen, cyano, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4haloalkoxy and C3-C4 cycloalkyl;
R3, R7 and R8 are independently selected from the group consisting of hydrogen, halogen, cyano, C1-C4alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C1-C4 alkoxy, C1-C4haloalkyl, C1-C4 haloalkoxy and C3-C4 cycloalkyl;
R4 and R5 are independently selected from the group consisting of hydrogen, C1-C4 alkyl, C1-C4 haloalkyl and C3-C4 cycloalkyl;
or R4 and R5 can form, together with the atom or atoms they are directly attached to, a C3-C4 cycloalkyl or C4heterocyclyl;
R6 is selected from the group consisting of hydrogen, C1-C4 alkyl, C3-C4 alkenyl, C3-C4 alkynyl, and C1-C3alkoxy-C1-C4-alkyl;
L is selected from the group consisting of a bond, a linear —C1-C4-alkyl chain, a linear —C2-C4-alkenyl chain, a linear —C2-C4-alkynyl chain, a linear —C1-C4-alkoxy chain whereby the oxygen atom is attached to A, a linear -amino-C1-C4-alkyl-chain whereby the nitrogen atom is attached to A, and a linear C1-C2alkyl-oxy-C1-C2alkyl, chain each optionally substituted with one to three halogen, cyano, C1-C4 alkyl, C1-C4 haloalkyl or C1-C4 alkoxy;
A is hydrogen, C1-C7 alkyl, C3-C5 cycloalkyl, 3-10 membered heterocyclyl or aryl, each optionally substituted with one to three Ry;
Rx is, independently of each other, selected from the group consisting of halogen, cyano, C1-C4 alkyl, C1-C4haloalkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4alkylcarbonyl, C1-C4 alkoxycarbonyl, carboxylic acid, aminocarbonyl, C1-C4 aminocarbonyl and C3-C4cycloalkyl;
Ry is, independently of each other, selected from the group consisting of halogen, cyano, nitro, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkyloxy, C1-C4alkylsulfanyl, C1-C4 haloalkylsulfanyl, C1-C4 alkylsulfinyl, C1-C4 haloalkylsulfinyl, C1-C4 alkylsulfonyl, C1-C4haloalkylsulfonyl, C1-C4 alkylcarbonyl, C1-C4alkoxycarbonyl, carboxylic acid, aminocarbonyl, C1-C4aminocarbonyl and C3-C4 cycloalkyl which cycloalkyl is unsubstituted or substituted by one or more Rz;
Rz is independently selected from the group consisting of halogen, C1-C4-alkyl and C1-C4-haloalkyl;
wherein A is not butyl when either R4 or R5 is methyl;
and wherein R1 is not methyl when R2, R3, R4, R5, R6, R7 and R8 are each hydrogen;
or salts or N-oxides thereof.

US Pat. No. 10,392,347

2,4-DIHYDROXY-NICOTINAMIDES AS APJ AGONISTS

Bristol-Myers Squibb Comp...

1. A compound having Formula (II):
or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein:
ring B is independently selected from:

 and 6-membered heteroaryl;
R1 is independently selected from: F, Cl, Br, NO2, —(CH2)nORb, —(CH2)nC(?O)Rb, —(CH2)nNRaRa, —(CH2)nCN, —(CH2)nC(?O)NRaRa, —(CH2)nNRaC(?O)Rb, C1-4 alkyl substituted with 0-3 Re and C3-6 cycloalkyl substituted with 0-3 Re;
R2 is independently selected from: C1-5 alkyl substituted with 0-3 Re; C2-5 alkenyl substituted with 0-3 Re, aryl substituted with 0-3 Re, heterocyclyl substituted with 0-3 Re, and C3-6 cycloalkyl substituted with 0-3 Re; provided when R2 is C1-5 alkyl, the methylene unit except the one attached to the pyridine ring may be replaced by O, NH, and S;
R3 and R4 together with the nitrogen atom to which they are both attached form a heterocyclic ring or a spiro heterocyclic ring selected from:

R5 is independently at each occurrence, selected from: OH, —(CH2)n-aryl, —(CH2)n—C3-6 cycloalkyl and —(CH2)n-heterocycle, each substituted with 0-3 R6;
R5a is independently at each occurrence, selected from: —(CR7R7)n—C3-10 carbocycle and —(CR7R7)n-heterocycle, —C(?O)—C3-10 carbocycle, each substituted with 0-3 R6;
R6 is independently selected from: H, F, Cl, Br, —ORb, ?O, —(CH2)nC(?O)Rb, —(CH2)nC(?O)ORb, —(CH2)nNRaRa, CN, —(CH2)nC(?O)NRaRa, —NHC(?O)ORb, C1-4 alkyl substituted with 0-3 Re, (CH2)n—C3-6 carbocyclyl substituted with 0-3 Re, and —(CH2)n-heterocyclyl substituted with 0-3 Re;
R7 is, independently at each occurrence, selected from: H, C1-4 alkyl, and (CH2)n—C3-12 carbocyclyl substituted with 0-3 Re;
Ra, at each occurrence, is independently selected from H, C1-6 alkyl substituted with 0-5 Re, —(CH2)n—C3-10carbocyclyl substituted with 0-5 Re, and —(CH2)n-heterocyclyl substituted with 0-5 Re; or Ra and Ra together with the nitrogen atom to which they are both attached form a heterocyclic ring substituted with 0-5 Re;
Rb, at each occurrence, is independently selected from H, C1-6 alkyl substituted with 0-5 Re, C2-6 alkenyl substituted with 0-5 Re, C2-6 alkynyl substituted with 0-5 Re, —(CH2)n—C3-10carbocyclyl substituted with 0-5 Re, and —(CH2)n-heterocyclyl substituted with 0-5 Re;
Re, at each occurrence, is independently selected from C1-6 alkyl (optionally substituted with F and Cl), OH, OCH3, OCF3, —(CH2)n—C3-6 cycloalkyl, —(CH2)n—C4-6 heterocyclyl, —(CH2)n-aryl, —(CH2)n-heteroaryl, F, Cl, Br, CN, NO2, ?O, CO2H;
Rg, at each occurrence, is independently selected from H, F, Cl, Br, CN, OH, C1-5alkyl (optimally substituted with halogen and OH);
n is independently selected from zero, 1, 2, 3, and 4; and
p, at each occurrence, is independently selected from zero, 1, and 2.

US Pat. No. 10,392,346

KINASE INHIBITORS

Topivert Pharma Limited, ...

1. A compound of formula IIb,
wherein:
LG1 represents imidazolyl, chloro, or aryloxy; and
Z1 represents a structural fragment of formula V:

wherein:
R2 and R3, together with the C-atoms to which they are attached, form a fused phenyl ring;
X1, X2 and X3 all represent CH;
L represents a direct bond;
R5a represents methoxy; and
R4 represents —CO2H,
or a salt or protected derivative thereof, wherein said protected derivative is a compound in which the carboxyl moiety of R4 is protected as a C1-8 alkyl ester.

US Pat. No. 10,392,345

CRYSTAL OF SALT OF NOVEL 3-AZABICYCLO[3.1.0]HEXANE DERIVATIVE AND PHARMACEUTICAL USE THEREOF

SANWA KAGAKU KENKYUSHO CO...

1. A crystal of a salt comprising: a compound represented by a formula (I)
wherein R2 is a hydrogen atom or a halogen atom, and R1 is a group selected from the group consisting of

and an acid selected from the group consisting of hydrochloric acid, hydrobromic acid, and oxalic acid.

US Pat. No. 10,392,344

METHOD FOR PREPARING FLUORINE-18 ELUENT WITH ADJUSTED PH, AND METHOD FOR LABELLING FLUORINE-18 USING SAME

THE ASAN FOUNDATION, Seo...

1. A method for preparing an organic [18F]fluoro compound, the method comprising the steps of:(a) preparing an eluent by a method comprising reacting compounds represented by Formula 1 and Formula 2 as shown in Scheme 1:

wherein R1 is a C1-C10 primary or secondary alkyl group or aryl group;
MX  [Formula 2]
wherein M is lithium, sodium, potassium, cesium, or rubidium, and X is a hydroxyl ion, a carbonate ion, a bicarbonate ion, a phosphate ion, a diphosphate ion, a triphosphate ion, or t-butoxide;

wherein R1, M, and X are as defined in Formulas 1 and 2, and wherein the pH of the eluent is adjusted to 6.0 to 8.0;
(b) eluting an [18F]fluoride adsorbed on a quaternary ammonium support into a reactor using the eluent;
(c) removing the eluent in the reactor after the elution; and
(d) reacting an alkyl halide or alkyl sulfonate with the eluted [18F]fluoride in the presence of a reaction solvent,
wherein the alkyl halide or alkyl sulfonate is selected from the group consisting of N-(3-methanesulfonyloxypropyl)-2?-carbomethoxy-3-?-(4-iodophenyl)tropane, N-(3-toluenesulfonyloxypropyl)-2?-carbomethoxy-3-?-(4-iodophenyl)tropane, 3-(2-nitroimidazol-1-yl)-2-O-tetrahydropyranyl-1-O-toluenesulfonyl propanediol, (5?-O-DMTr-2?-deoxy-3?-O-nosyl-?-D-threo-pentofuranosyl)-3-N-BOC-thymine, (E)-2-(2-(2-(4-(4-(tert-butoxycarbonyl (methyl)amino)styryl)phenoxy)ethoxy)ethoxy)ethyl methanesulfonate and (E)-2-(2-(2-(5-(4-(tert-butoxycarbonyl(methyl)amino)styryl)pyridin-2-yloxy)ethoxy)ethoxy)ethyl methanesulfonate.

US Pat. No. 10,392,343

POLYMERIZABLE COMPOUND, POLYMERIZABLE COMPOSITION, POLYMER, AND OPTICALLY ANISOTROPIC PRODUCT

ZEON CORPORATION, Chiyod...

1. A polymerizable compound represented by a general formula (I),
wherein each of Q1 to Q4 independently represents a hydrogen atom, or a substituted or unsubstituted alkyl group having 1 to 6 carbon atoms,
X represents a substituted or unsubstituted divalent aromatic group having 4 to 12 carbon atoms,
Ax represents a group represented by a general formula (II),

wherein “*” indicates a bonding position,
each of Y1x to Y6xindependently represents a single bond, —O—, —S—, —O—C(?O )—, —C(?O )—O—, —O—C(?O)—O—, —NR1—C(?O)—, —C(?O)—NR1—, —O —C(?O)—NR1—, —NR1—C(?O)—O—, —NR1—C(?O)—NR1—, —O —NR1—, or —NR1—O —, R1 represents a hydrogen atom or an alkyl group having 1 to 6 carbon atoms, each of G1x and G2x independently represents a substituted or unsubstituted divalent aliphatic group having 1 to 20 carbon atoms that optionally includes —O—, —S—, —O—C(?O)—, —C(?O)—O —, —O—C(?O)—O—, —NR2—C(?O)—, —C(?O)—NR2—, —NR2—, or —C(?O)—, provided that a case where the aliphatic group includes two or more contiguous —O— or —S—is excluded,
R2 represents a hydrogen atom or an alkyl group having 1 to 6 carbon atoms,
each of Z1x and Z2x independently represents an alkenyl group having 2 to 10 carbon atoms that is substituted with a halogen atom, or unsubstituted,
A1x represents a substituted or unsubstituted trivalent aromatic group, and
each of A2x and A3x independently represents a substituted or unsubstituted divalent aromatic group having 4 to 30 carbon atoms,
Ay represents a group represented by a general formula (III),

wherein each of Y1y to Y8y independently represents a single bond, —O—, —S—, —O—C(?O)—, —C(?O)—O—, —O—C(?O)—O—, —NR3—C(?O)—, —C(?O)—NR3—, —O—C(?O)—NR3—, —NR3—C(?O)—O—, —NR3—C(?O)—NR3—, —O—NR3—, or —NR3—O—, R3 represents a hydrogen atom or an alkyl group having 1 to 6 carbon atoms,
each of G1y and G2y independently represents a substituted or unsubstituted divalent aliphatic group having 1 to 20 carbon atoms that optionally includes —O—, —S—, —O—C(?O)—, —C(?O)—O—, —O—C(?O)—O—, —NR4—C(?O)—, —C(?O)—NR4—, —NR4—, or —C(?O)—, provided that a case where the aliphatic group includes two or more contiguous —O—or —S—is excluded,
R4 represents a hydrogen atom or an alkyl group having 1 to 6 carbon atoms,
each of Z1y and Z2y independently represents an alkenyl group having 2 to 10 carbon atoms that is substituted with a halogen atom, or unsubstituted,
A1y represents a substituted or unsubstituted trivalent aromatic group,
each of A2y and A3yindependently represents a substituted or unsubstituted divalent alicyclic hydrocarbon group having 3 to 30 carbon atoms, and
each of A4yand A5yindependently represents a substituted or unsubstituted aromatic group having 4 to 30 carbon atoms, and
n represents 0 or 1.

US Pat. No. 10,392,342

USE OF AGGREGATION-INDUCED EMISSION COMPOUNDS IN DISPERSION DETECTING OF NANOPARTICLES

BOE TECHNOLOGY GROUP CO.,...

1. A use of aggregation-induced emission compounds in dispersion detecting of nanoparticles, wherein the dispersion detecting of nanoparticles comprises:modifying the aggregation-induced emission compounds on surfaces of the nanoparticles to obtain a modified nanoparticles solution; and
exciting the modified nanoparticles solution and determining dispersion of the nanoparticles by a luminescence intensity of the modified nanoparticles solution, wherein
in response to determining the luminescence intensity of the modified nanoparticles solution after being excited is lower than a first luminescence intensity, the nanoparticles are determined to be in a dispersed state; and
in response to determining that the luminescence intensity of the modified nanoparticles solution after being excited is above a second luminescence intensity, the nanoparticles are determined to be in an aggregated state or a coagulated state.

US Pat. No. 10,392,341

COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS

ModernaTX, Inc., Cambrid...

1. A compound of Formula (I):or its N-oxide,or a salt thereof, wherein
R1 is selected from the group consisting of C5-30 alkyl, C5-20 alkenyl, —R*YR?, —YR?, and —R?M?R?;
R2 and R3 are independently selected from the group consisting of H, C1-14 alkyl, C2-14 alkenyl, —R*YR?, —YR?, and —R*OR?, or R2 and R3, together with the atom to which they are attached, form a heterocycle or carbocycle;
each R5 is independently selected from the group consisting of C1-3 alkyl, C2-3 alkenyl, and H;
each R6 is independently selected from the group consisting of C1-3 alkyl, C2-3 alkenyl, and H;
M and M? are independently selected from —C(O)O—, —OC(O)—, —OC(O)-M?-C(O)O—, —C(O)N(R?)—, —N(R?)C(O)—, —C(O)—, —C(S)—, —C(S)S—, —SC(S)—, —CH(OH)—, —P(O)(OR?)O—, —S(O)2—, —S—S—, an aryl group, and a heteroaryl group, in which M? is a bond, C1-13 alkyl or C2-13 alkenyl;
R7 is selected from the group consisting of C1-3 alkyl, C2-3 alkenyl, and H;
each R is independently selected from the group consisting of H, C1-3 alkyl, and C2-3 alkenyl;
each R? is independently selected from the group consisting of C1-18 alkyl, C2-18 alkenyl, —R*YR?, —YR?, and H;
each R? is independently selected from the group consisting of C3-15 alkyl and C3-15 alkenyl;
each R* is independently selected from the group consisting of C1-12 alkyl and C2-12 alkenyl;
each Y is independently a C3-6 carbocycle;
each X is independently selected from the group consisting of F, Cl, Br, and I;
R10 is selected from the group consisting of alkylamino and dialkylamino;
m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13; and
n is selected from 1, 2, 3, 4, and 5.

US Pat. No. 10,392,340

PURIFICATION OF CRUDE ISOPHORONEDIAMINE BY PARTIAL CONDENSATION IN SERIES WITH TOTAL CONDENSATION

Evonik Degussa GmbH, Ess...

1. A process for fine purification of isophoronediamine from the production of isophoronediamine by aminating hydrogenation of isophorone nitrile in the presence of at least ammonia, hydrogen, a hydrogenation catalyst and optionally further additions and in the presence or absence of organic solvents to obtain a crude isophoronediamine I,wherein the crude isophoronediamine I is subjected to a fine purification by means of two vacuum distillation columns, wherein
I. in the first vacuum distillation column K I low-boiling by-products still present are removed, and a crude IPDA II is transferred from the bottom of K I into the vacuum distillation column K II,
II. and in the second vacuum distillation column K II the isophoronediamine is obtained in pure form overhead and separated from the organic residues, with two condensers being mounted at the top of the second vacuum distillation column,
wherein the first condenser is a partial condenser and the pure IPDA is removed therein,
and wherein the second condenser is a total condenser and the residual portion of the vapour stream from K II is completely condensed therein and recycled as return stream into the first vacuum distillation column K I.

US Pat. No. 10,392,339

POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY ELEMENT

JNC CORPORATION, Tokyo (...

1. A compound, represented by formula (1):wherein, in formula (1),R1 is alkyl having 1 to 15 carbons, and in the alkyl, at least one —CH2— may be replaced by —O— or —S—, and at least one piece of —(CH2)2— may be replaced by —CH?CH— or —C?C, and in the groups, at least one hydrogen may be replaced by halogen;
MES is a mesogen group having at least one ring;
Sp1 is a single bond or alkylene having 1 to 10 carbons, and in the alkylene, at least one —CH2— may be replaced by —O—, —CO—, —COO—, —OCO— or —OCOO—, and at least one (CH2)2— may be replaced by —CH?CH— or —C?C—, and in the groups, at least one hydrogen may be replaced by halogen;
M1 and M2 are independently hydrogen, halogen, alkyl having 1 to 5 carbons, or alkyl having 1 to 5 carbons in which at least one hydrogen is replaced by halogen; and
R2 is a group represented by formula (1a), formula (1b) or formula (1c):
wherein, in formula (1a), formula (1b) and formula (1c),Sp2 and Sp3 are independently a single bond or alkylene having 1 to 10 carbons, and in the alkylene, at least one —CH2— may be replaced by —O—, —NH—, —CO—, —COO—, —OCO— or —OCOO—, and at least one —(CH2)2— may be replaced by —CH?CH— or —C?C— and in the groups, at least one hydrogen may be replaced by halogen;
S1 is >CH— or >N—;
S2 is >C< or >Si<; and
X1 is a group represented by —OH, —NH2, —OR3, —N(R3)2, formula (x1), —COOH, —SH, —B(OH)2 or —Si(R3)3, in which R3 is hydrogen or alkyl having 1 to 10 carbons, and in the alkyl, at least one CH2— may be replaced by —O—, and at least one —(CH2)2— may be replaced by —CH?CH—, and in the groups, at least one hydrogen may be replaced by halogen, and w in formula (x1) is 1, 2, 3 or 4:

US Pat. No. 10,392,338

SPIROFURANONE COMPOUNDS, DERIVATIVES THEREOF AND PROCESSES FOR THEIR PREPARATION

YISSUM RESEARCH DEVELOPME...

1. A composition comprising a compound of general formula (XIV):
wherein
Ring A is optionally a saturated or unsaturated ring having optionally at least one heteroatom; and is optionally substituted by at least one group selected from straight or branched C1-C10 alkyl,-straight or branched C2-C10 alkenyl, straight or branched C2-C10 alkynyl, CN, —OR4, —NR5R6, —C(?O)R7, halogen;
R4, R5 and R6 are each independently selected from H, halogen, straight or branched C1-C10 alkyl, straight or branched C2-C10 alkenyl, straight or branched C2-C10 alkynyl;
R7 is selected from H, straight or branched C1-C10 alkyl, straight or branched C2-C10 alkenyl, straight or branched C2-C10 alkynyl, halogen, OH, O(C1-C10)alkyl, NH2, amine;
n is an integer selected from 1-4;
—C(n)— is selected from a straight or branched alkylene, straight or branched alkenylene, straight or branched alkynylene;
m is an integer selected from 1-4;
—C(m)— is selected from a straight or branched alkylene, straight or branched alkenylene, straight or branched alkynylene;
l is an integer selected from 1-4;
—C(l)— is selected from a straight or branched alkylene, straight or branched alkenylene, straight or branched alkynylene;
R3 and R3? are each independently selected from C(?O)R20, OR21, C(?O)OR22, CF3SO3, straight or branched C1-C10 alkyl, straight or branched C2-C10 alkenyl, straight or branched C2-C10 alkynyl;
each of alkyl, alkenyl or alkylnyl groups are optionally substituted by at least one group selected from C(?O)R23, OR24, halogen, CF3SO3;
each of R20, R21, R22, R23 and R24 is independently selected from H, OH, halogen, straight or branched C1-C10 alkyl, straight or branched C1-C10 alkoxy, NH2, amine.

US Pat. No. 10,392,337

PROCESS FOR PURIFICATION OF METHYL METHACRYLATE

Dow Global Technologies L...

1. A process for purifying methyl methacrylate; said method comprising: (a) feeding a product mixture comprising methyl methacrylate, methanol, water and oligomers of methyl methacrylate to a divided section of a distillation column comprising a dividing wall; (b) removing an overhead stream and a bottoms stream from the distillation column, and removing a middle side draw stream from the distillation column; wherein the crude product enters the dividing wall distillation column in a divided section on an opposing side of the dividing wall from the middle side draw stream; and (c) removing an upper side draw stream from a point above the dividing wall and below the top of the distillation column, separating a portion of water from the upper side draw stream to produce a dewatered upper side draw stream and returning the dewatered upper side draw stream to the distillation column.

US Pat. No. 10,392,335

METHOD FOR PRODUCING HYDROXYPIVALALDEHYDE

Mitsubishi Gas Chemical C...

1. A method for producing hydroxypivalaldehyde, the method comprisingreacting isobutyraldehyde with formaldehyde to obtain a reaction solution containing hydroxypivalaldehyde,
subsequently extracting the reaction solution with an aldehyde solvent represented by formula (1) under basicity to obtain an extract containing hydroxypivalaldehyde, and
subsequently distilling the extract and then collecting hydroxypivalaldehyde from a still residue:

wherein R represents a saturated alkyl group having 3 or more and 7 or less carbon atoms,
wherein said distilling occurs in the presence of water, and an amount of water which is subjected to said distilling is 100 parts by mass or more and 2,000 parts by mass or less with respect to a total amount, 100 parts by mass, of isobutyraldehyde derived from a raw material and an aldehyde solvent represented by the formula (1) in the extract which is subjected to said distilling.

US Pat. No. 10,392,332

FLUORINATED TENSIDES

MERCK PATENT GmbH, Darms...

1. A compound of formula (I)
where
R is equal to H, alkyl, —OH or —CH2—O-A?-Rf?,
Rf, Rf? and Rf? are each, independently of one another, equal to CF3—CF2—CF2—O—CF(CF3)—CH2— or CF3—(CF2)n—(CH2)m—,
n is equal to 1-2,
m is equal to 1,
R1-R4 are each, independently of one another, equal to hydrogen or a C1-C4 alkyl group,
o and p are each, independently of one another, 0-4, wherein o+p?2, q?1,
A, A? and A? are each, independently of one another, equal to (O—(CR5R6)r—(CR7R8)s)t,
R5-R8 are each, independently of one another, equal to hydrogen or a C1-C4 alkyl group,
r and s are each, independently of one another, 0-4,
t is equal to 0 or 1,
B is equal to (CH2)0-1—O or (CH2)0-1—NR?,
R? is equal to H or linear or branched alkyl, and
X is equal to H or linear or branched alkyl.

US Pat. No. 10,392,326

METHOD FOR PRODUCING FLUORINE-CONTAINING COMPOUND

DAIKIN INDUSTRIES, LTD., ...

1. A method for producing a fluorine-containing compound of Formula (3):CF3CFYCH2Z, wherein n is 0 or 1, one of Y and Z is H, and the other is F or Cl, by successively reacting at least one chlorine-containing compound selected from the group consisting of chlorine-containing fluoroalkane of Formula (1): CX3CHClCH2Cl, wherein X is independently F or Cl, with the proviso that at least one X is F; and chlorine-containing fluoroolefin of Formula (2): CX3CC?CH2, wherein X is independently F or Cl, with the proviso that at least one X is F, with anhydrous hydrogen fluoride in the presence of a fluorination catalyst, wherein a reactor inlet gas comprises hydrogen chloride in a concentration of not less than 0.15 vol % and not more than 10 vol %.

US Pat. No. 10,392,325

METHOD FOR PRODUCING FLUORINATED ALKANE, METHOD FOR SEPARATING AND RECOVERING AMIDINE BASE, AND METHOD FOR USING RECOVERED AMIDINE BASE

Kanto Denka Kogyo Co., Lt...

1. A method for producing a fluorinated alkane represented by the formula (2): R2—F (R2 represents an alkyl group having 3 to 5 carbon atoms), wherein an alcohol having 3 to 5 carbon atoms is fluorinated by a fluorinating agent represented by the formula (1): R1SO2F (R1 represents a methyl group, an ethyl group or an aromatic group) in the absence of a solvent, and in the presence of an amidine base, and wherein the base is the amidine base represented by the following formula (4):(in the formula, n is 0 or 2).

US Pat. No. 10,392,324

XYLENE SEPARATION PROCESS

EXXONMOBIL CHEMICAL PATEN...

1. A process for separating paraxylene and at least one other C8 aromatic from a mixture of paraxylene (PX), metaxylene (MX), orthoxylene (OX), and ethylbenzene (EB) in a simulated moving bed adsorption apparatus having 24 adsorbent beds in two columns, wherein each column contains 12 adsorbent beds, and wherein the 24 absorbent beds comprise a first absorption zone containing 8 to 16 absorbent beds and a second absorption zone containing the balance of the 24 adsorbent beds, wherein each adsorption zone performs a different separation and contained in a single column or span both columns;wherein PX is separated from the mixture in the first adsorption zone to produce a raffinate comprising MX, OX, and EB, and separating at least one of MX, OX, and EB from the raffinate in the second adsorption zone;
wherein a first feed stream and a first desorbent stream are introduced into the first adsorption zone,
wherein a first extract stream and a first raffinate stream are withdrawn from the first adsorption zone,
wherein a second feed stream and a second desorbent stream are introduced into the second adsorption zone,
wherein a second extract stream and a second raffinate stream are withdrawn from the second adsorption zone,
wherein the second feed stream comprises at least a portion of the first raffinate; and
wherein the flow rate of at least one of the streams introduced into or withdrawn from the first adsorption zone is varied during a step time of interval X.

US Pat. No. 10,392,323

APPARATUS AND METHOD FOR PURIFYING CUMENE

LG CHEM, LTD., Seoul (KR...

1. A method for purifying cumene, the method comprising:a light material removal process in which a stream from an alkylation reaction unit is introduced to a lights cut column to be removed of lights and water, wherein the lights cut column includes a first output stream and a second output stream, wherein the first output stream discharges lights and water and is located at a higher position than the second output stream;
a benzene separation process in which a stream from a transalkylation reaction unit and the second output stream of the lights cut column are introduced to a benzene column to be separated into a benzene stream and a first cumene stream, wherein the benzene stream is located at a higher position than the first cumene stream;
a cumene separation process in which the first cumene stream is introduced to a cumene column to be separated into a second cumene stream and a first polyisopropylbenzene stream, wherein the second cumene stream is located at a higher position than the first polyisopropylbenzene stream;
a polyisopropylbenzene separation process in which the first polyisopropylbenzene stream is introduced to a polyisopropyl column to be separated into a second polyisopropylbenzene stream and a heavy materials stream; and
a process of passing the second cumene stream discharged from the cumene column through a heat exchanger of the benzene column.

US Pat. No. 10,392,322

PROCESS AND APPARATUS FOR RECOVERING AROMATIC HYDROCARBONS

ExxonMobil Chemical Paten...

1. A process for recovering aromatic hydrocarbons comprising benzene, toluene, and/or xylenes from a naphtha stream comprising aromatic and non-aromatic hydrocarbons, the process comprising:(a) providing a naphtha stream comprising aromatic and non-aromatic hydrocarbons and C9+ hydrocarbons to a first stage hydrofiner to remove dienes and styrenes and to produce a first stage hydrofiner effluent stream;
(b) passing said first stage hydrofiner effluent stream to a divided wall column to recover a C6+ hydrocarbon stream, wherein the divided-wall column has a dividing wall that allows liquid to pass through in the bottom portion thereof;
(c) passing said C6+ hydrocarbon stream through a second stage hydrofiner to produce a second stage hydrofiner effluent stream;
(d) recycling said second stage hydrofiner effluent stream back to said divided wall column;
(e) recovering a twice hydrofined C6+ hydrocarbon stream from a side location above the bottom portion of said divided wall column;
(f) passing said twice hydrofined C6+ hydrocarbon stream to an extractive distillation unit to recover a product comprising benzene, toluene and/or xylenes; and
(g) obtaining a gas oil stream from the bottom portion of the divided wall column.

US Pat. No. 10,392,321

PROCESSES FOR TRANSALKYLATING AROMATIC HYDROCARBONS

UOP LLC, Des Plaines, IL...

1. A process for transalkylating aromatic hydrocarbon compounds, the process comprising:introducing a heavy alkylbenzene rich stream and a benzene rich stream to a transalkylation zone;
introducing a water source to the transalkylation zone, the water source being in an amount to provide 80 to 120 wppm of water based upon the mass of the feed stream;
contacting the heavy alkylbenzene stream and the benzene stream with a transalkylation catalyst in the transalkylation zone under transalkylation conditions comprising a transalkylation temperature of greater than 130° C. to less than 230° C. in the presence of the water to provide a transalkylation reaction effluent; and
wherein the deactivation rate of the transalkylation catalyst is less than 0.2 wt. %/hr and the conversion of heavy alkylbenzene is greater than 50 wt. %.

US Pat. No. 10,392,316

PROCESS FOR MINIMIZING BENZENE, TOLUENE, AND A RECYCLE LOOP IN A ZERO BENZENE AROMATICS COMPLEX

UOP LLC, Des Plaines, IL...

1. A process for reducing benzene production in an aromatics complex, the process comprising:passing an aromatics stream having a methyl to phenyl ratio below about 1.5 to a benzene column to produce a benzene column overhead stream comprising benzene and a benzene column bottoms stream comprising toluene and aromatics having 9+ carbons;
passing a first portion of the benzene column overhead stream to a transalkylation unit and transalkylating aromatics having 9+ carbons with benzene to produce a trans-alkylation product stream comprising xylenes;
passing the benzene column bottoms stream to a toluene column to produce a toluene column overhead stream comprising toluene and a toluene column bottoms stream comprising aromatics having 9+ carbons;
passing a second portion of the benzene column overhead stream and the toluene column overhead stream to a methylation unit to produce a methylation product stream comprising xylenes;
passing the toluene column bottoms stream to a fractionation zone to produce an overhead stream comprising xylenes, a bottoms stream comprising heavy aromatics, and a middle boiling fraction comprising aromatics having 9-10 carbons;
passing the middle boiling fraction to the trans-alkylation unit;
recycling the trans-alkylation product stream to the benzene column; and,
recycling the methylation product stream to the benzene column.

US Pat. No. 10,392,314

MATERIAL AND METHOD OF MANUFACTURE FOR ENGINEERED REACTIVE MATRIX COMPOSITES

Powdermet, Inc., Euclid,...

32. A reactive matrix composite comprising a plurality of porous preformed particles that are dispersed in a metal material, each of said porous preformed particles formed of a plurality of coated particles that have been sintered together, each of said coated particles are formed of a primary core unit and a reactive binder coated on said primary core unit, said primary core unit and said reactive binder formed of different materials, said coating thickness of said reactive binder is less than 50% of a particle diameter of said primary core unit, said primary core unit including carbon, said primary core unit constitutes about 30-90% by volume of said coated particle, said primary core unit has an average particle diameter of about 1-50 microns, said primary core unit constituting 30-90 vol. % of said coated particle, said reactive binder having a coating thickness of 0.1-3 microns prior to formation of each of said porous preformed particles, each of said porous preformed particles has 10-50% open porosity, said metal material selected from the group consisting of aluminum, magnesium, magnesium alloy, zinc alloy, aluminum-magnesium alloy, said reactive matrix composite having a dissolution rate of about 0.1-5mm /hour in a brine solution, said reactive matrix composite having a strength that is greater than 8000 psig.

US Pat. No. 10,392,313

METHOD FOR APPLICATION OF BIOCHAR IN TURF GRASS AND LANDSCAPING ENVIRONMENTS

Cool Planet Energy System...

25. A method for applying biochar to an area of soil prior to installing turf grass seed in order to improve survivability and decrease water use, where the method comprises the step of adding the biochar to the top 1-4 inches of the soil prior to the installation of turf such that the average concentration of biochar in the top 1-4 inches of soil by volume is greater than 0.01% and less than 60%.

US Pat. No. 10,392,312

SILICON OXYCARBIDE ENVIRONMENTAL BARRIER COATING

United Technologies Corpo...

1. An article comprising:a ceramic-based substrate;
a barrier layer on the ceramic-based substrate, the barrier layer including a matrix of barium-magnesium alumino-silicate or SiO2, a dispersion of silicon oxycarbide particles in the matrix, the silicon oxycarbide particles having Si, O, and C in a covalently bonded network, and a dispersion of particles, of the other of barium-magnesium alumino-silicate or SiO2, in the matrix; and
a distinct intermediate layer between the barrier layer and the ceramic-based substrate, the distinct intermediate layer including an intermediate layer matrix of SiO2 and a dispersion of intermediate layer silicon oxycarbide particles in the intermediate layer matrix.

US Pat. No. 10,392,311

COMPOSITE CERAMICS AND CERAMIC PARTICLES AND METHOD FOR PRODUCING CERAMIC PARTICLES AND BULK CERAMIC PARTICLES

Dynamic Material Systems,...

1. A polymer derived ceramic (PDC) particle, wherein the particle material is derived from at least one of a binary PDC system, a ternary PDC system or a quaternary PDC system formed in a spraying process for producing bulk ceramic components from an agglomeration of partially cured polymer ceramic precursor resin material, the final PDC particle consisting of:a plurality of liquid pre-catalyzed polymeric ceramic precursor resin droplets that are injected into a drop tower heated by radiant energy and as the liquid resin droplets fall from the top portion of a drop tower, a plurality of non-porous partially-cured globules of polymer ceramic precursor material is formed, and
a plurality of powder particles that are functional material fillers is sprayed onto the structure of the partially-cured globules of polymer ceramic precursor material that is subsequently fully cured, chemically bonded together, then fired to produce a uniform, fully-dense, solid, single, continuous ceramic part having a particle size of approximately 2.1 mm to approximately 300 mm in diameter.

US Pat. No. 10,392,310

POROUS PLATE-SHAPED FILLER AGGREGATE, PRODUCING METHOD THEREFOR, AND HEAT-INSULATION FILM CONTAINING POROUS PLATE-SHAPED FILLER AGGREGATE

NGK Insulators, Ltd., Na...

1. A heat-insulation film comprising a plurality of porous plate-shaped fillers, wherein the fillers are arranged as adjacent layers of fillers in the film, the porous plate-shaped fillers have a uniform plate shape with an aspect ratio of 3 or more, a thickness of 0.1 to 50 ?m, a porosity of 20 to 99%, and a deviation of a length among a plurality of the porous plate-shaped fillers, obtained by the following formula, is 10% or less:Deviation of the length (%)=standard deviation of the length/average value of the length×100.

US Pat. No. 10,392,308

FIRE RETARDANT CONSTRUCTION MATERIALS

1. A method for making magnesium oxychloride boards, comprising:mixing a magnesium oxychloride slurry, comprising:
directing magnesium chloride, magnesium oxide, at least one phosphate, at least one inorganic salt, and water into a mixer; and
mixing the magnesium chloride, magnesium oxide, phosphate, inorganic salt and water to form a slurry in the mixer;
mixing at least one filler with the slurry;
directing the slurry to a mold and filling the mold with the slurry to form a magnesium oxychloride board;
curing the magnesium oxychloride board;
directing the slurry to a second mold and filling the mold with the slurry to form a second magnesium oxychloride board;
curing the second magnesium oxychloride board; and
combining the first magnesium oxychloride board with the second magnesium oxychloride board to make a multiple-layered board.

US Pat. No. 10,392,305

ADDITION OF CARBON DIOXIDE TO CONCRETE MIXTURES

The Board of Trustees of ...

1. A method for manufacturing concrete comprising:(a) contacting a first slurry comprising a calcium-rich cementitious material in water with a carbon dioxide-rich gas to form a second slurry; and
(b) adding ordinary Portland cement to the second slurry without reducing the amount of water present in the second slurry from step (a),
wherein the concrete comprises calcite nanoparticles produced in situ and exhibits an increase in compressive strength of at least 10% compared to an identical concrete formed without the carbon dioxide-rich gas.

US Pat. No. 10,392,303

CEMENT CLINKER LINE AND A METHOD FOR OPERATING A CEMENT CLINKER LINE

1. A method for manufacturing clinker, the method comprising:sintering raw meal in a kiln to clinker,
preheating raw meal in a preheater using a main flue gas stream from the kiln as a heat source,
dedusting the main flue gas stream downstream from the preheater at a temperature below the boiling point of mercury to produce mercury-loaded dust,
branching off an auxiliary flue gas stream from the main flue gas stream at an auxiliary flue gas stream branch prior to cooling the main flue gas stream to the temperature below the boiling point of mercury, wherein said branching is carried out either at a location downstream from the preheater or at an intermediate gas exit of the preheater,
dedusting the auxiliary flue gas stream to obtain at least essentially mercury-free dust and dedusted auxiliary flue gas stream,
binding mercury of the auxiliary flue gas stream to an adsorbent, wherein the binding comprises injecting the adsorbent into the dedusted auxiliary flue gas stream and cooling the auxiliary flue gas stream, and
removing the adsorbent from the dedusted auxiliary flue gas stream to form removed adsorbent and further processing the dedusted auxiliary flue gas stream.

US Pat. No. 10,392,302

CEMENT CLINKER LINE AND A METHOD FOR OPERATING A CEMENT CLINKER LINE

1. A method for manufacturing clinker, the method comprising:sintering raw meal in a kiln to clinker,
preheating the raw meal in a preheater with the use of a main flue gas stream from the kiln as a heat source,
dedusting the main flue gas stream at a location downstream from the preheater at a temperature below the boiling point of mercury, to obtain dedusted flue gas and mercury-loaded dust,
withdrawing a bypass flue gas stream from the kiln,
vaporizing at least one of mercury and a mercury compound in the bypass flue gas by injecting at least one of (i) a fraction of the mercury-loaded dust and (ii) a fraction of mercury-loaded waste-products into the bypass flue gas stream,
dedusting the bypass flue gas stream,
cooling the bypass flue gas stream to form a cooled bypass flues gas stream and binding at least one of the mercury and the mercury compound to an adsorbent, said adsorbent being injected into the cooled bypass flue gas stream,
removing the adsorbent from the cooled bypass flue gas to form removed adsorbent and further processing the cooled bypass flue gas,
wherein the method further comprises at least injecting, into the bypass flue gas stream, a reductant prior to said dedusting the bypass flue gas stream, and
wherein said dedusting the bypass flue gas stream is carried out with the use of catalytic hot gas filter, to oxidize mercury atoms in the bypass flue gas stream and to convert nitrogen oxides into nitrogen in the same processing step.

US Pat. No. 10,392,301

INTEGRATION OF ELECTROCHROMIC FILMS ON A SUBSTRATE

Furcifer Inc., Fremont, ...

1. A method for forming a structure having an electrochromic device therein, the method comprising:interposing an electrochromic device between a first adhesive interlayer and a second adhesive interlayer, wherein the first adhesive interlayer is interposed between the electrochromic device and a first substrate, and the second adhesive interlayer is interposed between the electrochromic device and a second substrate, wherein the electrochromic device comprises an electrochromic material, a solid state electrolyte, and a charge storage layer; and
bonding the electrochromic device to the first substrate via the first adhesive interlayer, and to the second substrate via the second adhesive interlayer, to form a laminated structure having the electrochromic device therein,
wherein the solid state electrolyte comprises:
an electrolyte salt selected from the group of LiTFSI, LiPF6, LiBF4, LiClO4, LiCF3SO3, LiN(CF3SO2)2, LiSbFg, LiAsF6, LiN(CF3CF2SO2)2, (C2H5)4NBF4, (C2H5)3CH3NBF4, and LiI; and
a polymer matrix including one or more polar polymers crosslinked to form a network, wherein the one or more polar polymers have a semi-crystalline or crystalline microstructure.

US Pat. No. 10,392,300

HEAT TREATABLE COATED ARTICLE HAVING TITANIUM NITRIDE AND ITO BASED IR REFLECTING LAYERS

GUARDIAN GLASS, LLC, Aub...

1. A coated article including a coating supported by a glass substrate, the coating comprising:a first dielectric layer comprising silicon nitride on the glass substrate;
a first infrared (IR) reflecting layer comprising ITO on the glass substrate, wherein the first dielectric layer comprising silicon nitride is located between at least the glass substrate and the first IR reflecting layer comprising ITO;
a second dielectric layer comprising silicon nitride on the glass substrate over at least the first IR reflecting layer comprising ITO;
a second layer IR reflecting layer comprising a nitride of titanium on the glass substrate over at least the first and second dielectric layers comprising silicon nitride, so that the second dielectric layer comprising silicon nitride is located between and directly contacting the first IR reflecting layer comprising ITO and the second IR reflecting layer comprising the nitride of titanium;
a third dielectric layer comprising silicon nitride on the glass substrate over at least the second IR reflecting layer comprising the nitride of titanium;
wherein the first IR reflecting layer comprising ITO is from 250-450 A thick, and the second IR reflecting layer comprising the nitride of titanium is from 130-300 A thick;
wherein the coating contains no IR reflecting layer based on silver, and contains only two IR reflecting layers;
wherein the coating has a normal emittance (En) value of no greater than 0.30; and
wherein the coated article measured monolithically has: a visible transmission from about 15-80%, a film side visible reflectance no greater than 10%, a glass side visible reflectance no greater than about 30%, a glass side reflective a* value of from ?10.0 to +1.6, and a light-to-solar gain ratio (LSG) of at least 1.10.

US Pat. No. 10,392,299

GLAZING PROVIDED WITH A THIN-LAYER STACK FOR SOLAR PROTECTION

SAINT-GOBAIN GLASS FRANCE...

1. A solar protection glazing comprising a substrate, provided with a stack of thin layers which act on solar radiation, in which said stack consists of the succession of the following layers, starting from the surface of the glass:an underlayer or a set of underlayers, said underlayer(s) each consisting of a dielectric material;
a layer comprising titanium oxide and silicon and having an overall Si/Ti atomic ratio from 0.01 and 0.25, wherein Si and Ti represent at least 90% of the atoms other than oxygen, and wherein the layer has a thickness between 20 and 70 nm; and
an overlayer or a set of overlayers, said overlayer(s) each consisting of a dielectric material,
wherein the dielectric material constituting the underlayers is at least one selected from the group consisting of a zinc oxide, a silicon oxide, a tin oxide, a zinc tin oxide, a silicon nitride, an aluminum nitride, a silicon aluminum nitride, a silicon oxynitride, an aluminum oxynitride, and a silicon aluminum oxynitride, and
wherein the dielectric material constituting the overlayers is at least one selected from the group consisting of a zinc oxide, a silicon oxide, a tin oxide, a zinc tin oxide, a silicon nitride, an aluminum nitride, a silicon aluminum nitride, a silicon oxynitride, an aluminum oxynitride, and a silicon aluminum oxynitride or a titanium oxide having formula TiOx.

US Pat. No. 10,392,297

METHOD FOR MANUFACTURING SUBSTRATE

SHENZHEN CHINA STAR OPTOE...

1. A method for manufacturing a substrate, comprising:depositing are amorphous silicon layer on a base material;
depositing a silicon dioxide layer with a first thickness on the amorphous silicon layer;
an etching step comprising etching the silicon dioxide layer until a thickness of the silicon dioxide layer is reduced to a second thickness; and
washing the substrate and performing excimer laser annealing to change the amorphous silicon layer into a polysilicon layer.

US Pat. No. 10,392,296

SEALED STRUCTURAL BODY AND METHOD FOR MANUFACTURING THE SAME

HITACHI, LTD., Tokyo (JP...

1. A sealed structural body including an internal space and made of glass, wherein:at least a part of a boundary between the internal space of the sealed structural body and an outside is separated by a sealing material containing a metal material and a lead-free oxide glass, the lead-free oxide glass containing Te, V, and at least one of element Ag or P,
the metal material has a lower melting point than a softening point at which the lead-free oxide glass begins to flow,
the metal material has a crystalline structure,
the lead-free oxide glass has a non-crystalline structure, the metal material maintains an original particle shape,
a particle diameter of the metal material is 0.5 to 1 times the thickness of the internal space, and
the internal space has a thickness of 70 ?m or greater.

US Pat. No. 10,392,295

COMPOSITE MATERIAL

Alusid Limited, Preston ...

1. A composite material comprising a fused mixture of:a glass component; and
a non-glass mineral component;
wherein the composite material comprises less than 5 wt % synthetic binding agents, and at least 20 wt % non-glass mineral component;
wherein the non-glass mineral component comprises at least 60 wt % ceramics;
wherein:
the glass component comprises glass particles and the non-glass mineral component comprises non-glass mineral particles that include ceramics particles; and
the ceramics are vitrified ceramics;
wherein the components of the composite material are bound together within a fused-glass matrix.

US Pat. No. 10,392,294

BOROSILICATE GLASS WITH LOW BRITTLENESS AND HIGH INTRINSIC STRENGTH, THE PRODUCTION THEREOF, AND THE USE THEREOF

SCHOTT AG, Mainz (DE)

as well as a total of 0-5.0 wt % of further components,wherein the proportions of the components are chosen in such a way that a weighted crosslinking index, that is, the mean number n of constraints per atom, given by
has a value greater than 2.9,wherein N is a total number of constraints per mole and NA is Avogadro's number and c(SiO2), c(Al2O3), and c(B2O3) refer to the molar concentrations of SiO2, Al2O3, and B2O3, the c(Mi2O) values refer to the molar concentrations of the alkali oxides Mi2O present, and the c(MiO) values refer to the molar proportions of the alkaline earth oxides present, and wherein the ratio

where the K(M-O), M=Si, Al, B are the degrees of covalence of the respective M-O bonds of the components SiO2, Al2O3, B2O3, where:
a degree of covalence of 0.5527 for SiO2,
a degree of covalence of 0.6126 for B2O3, and
a degree of covalence of 0.4329 for Al2O3, and wherein the ed(M-O) values are the respective, cation-related dissociation energies of the components SiO2, Al2O3, B2O3 and are given as: 1864 kJ/mol for SiO2, 1572.5 kJ/mol for B2O3, and 1537 kJ/mol for Al2O3.

US Pat. No. 10,392,293

HIGH-TRANSPARENCY GLASS

AGC Inc., Chiyoda-ku (JP...

1. A glass comprising 1 to 30 ppm of a total iron oxide (t-Fe2O3) in terms of Fe2O3, comprising, as expressed by mass percentage based on oxides:SiO2 50 to 81%,
Al2O3 1 to 12.9%,
MgO 0 to 5%,
CaO 0 to 5.0%,
B2O3 0 to 5%, and
Li2O+Na2O+K2O 5 to 20%,
wherein when a bubble density B is defined as that in a glass body obtained by melting glass raw materials at a temperature of 1550° C., followed by forming into a sheet and then annealing, the bubble density B of the glass is 10 pieces/kg or less, and
the glass has a minimum value of an inner transmittance in a wavelength range of 400 to 700 nm under a condition of a light path length of 200 mm being 80% or more, and
a difference between a maximum value and the minimum value of the inner transmittance being 15% or less.

US Pat. No. 10,392,291

METHOD OF MAKING AN OPTICAL FIBER PREFORM AND HANDLE FOR USE IN MAKING OF OPTICAL FIBER PREFORM

CORNING INCORPORATED, Co...

1. A method for forming an optical fiber preform, the method comprising:inserting a glass core cane into a glass sleeve such that the glass sleeve surrounds a portion of the glass core cane and such that there is a gap between the glass sleeve and the portion of the glass core surrounded by the glass sleeve, the glass sleeve having an inner diameter that is greater than an outer diameter of the glass core cane;
inserting a removable insert in the gap between the glass sleeve and the portion of the glass core cane surrounded by the glass sleeve, the removable insert having a length at least equal to the length of the glass sleeve,
depositing silica soot onto at least a portion of the glass core cane and at least a portion of the glass sleeve to form a silica soot preform; and
flowing gas through the gap during processing of the silica soot preform.

US Pat. No. 10,392,290

PROCESSING 3D SHAPED TRANSPARENT BRITTLE SUBSTRATE

Corning Incorporated, Co...

1. A glass article having a 3D surface, the glass article having at least one edge having a plurality of defect lines extending at least 250 microns, the defect lines each having a diameter less than or equal to about 5 microns.

US Pat. No. 10,392,289

METHOD FOR MANUFACTURING FLOAT GLASS, AND FLOAT GLASS

AGC INC., Tokyo (JP)

1. A method for manufacturing a float glass, comprising: supplying molten glass to a liquid surface of a molten metal bath placed in a float bath, thereby forming into a glass ribbon; lifting the glass ribbon from the liquid surface of the molten metal bath, followed by annealing and cutting to obtain a float glass, whereinthe float glass is alkali-free glass,
the molten metal bath is a tin alloy bath for a float bath, which comprises 1 mass % or more and 40 mass % or less of copper with the remainder being unavoidable impurities and tin,
a proportion of SO3 in the molten glass is 0.1 mass % or less, and
a temperature of a region at which the glass ribbon is lifted from the liquid surface of the molten metal bath in the float bath is 700° C. or higher.

US Pat. No. 10,392,288

METHOD AND APPARATUS FOR REDUCING SHEET WIDTH ATTENUATION OF SHEET GLASS

Corning Incorporated, Co...

22. An apparatus for longitudinally drawing a viscous glass ribbon having a first side and an opposing second side, a first edge and an opposing second edge, and a width defined by a distance between the first and second edges, comprising:a first pair of edge rolls configured to contact the viscous glass ribbon along the first and second sides near the first edge; and
a second pair of edge rolls configured to contact the viscous glass ribbon along the first and second sides near the second edge,
wherein the first and second pair of edge rolls maintain a substantially consistent longitudinal velocity increase of the viscous glass ribbon in a substantially parallel manner across the width of the viscous glass ribbon downstream of the first and second pair of edge rolls.

US Pat. No. 10,392,287

MACHINE FOR MANUFACTURING A HOLLOW ARTICLE MADE OF THIN GLASS

Pochet du Courval, Paris...

1. A machine for manufacturing a hollow glass article comprising at least one thin side wall, said machine comprising:at least one molten glass parison distributor,
a blank mold comprising a cavity designed to successively receive at least one parison of molten glass,
a first blowing nozzle connected to a source of pressurized gas for forming a blank of said article in the blank mold,
a finishing mold,
a handling arm for transferring the blank into a cavity of the finishing mold,
a second blowing nozzle connected to a source of pressurized gas for forming the article in the finishing mold,
wherein the cavity of the finishing mold comprises at least one side part provided with a concave cavity to form, on the side wall of the article, a convex bulge directed towards the exterior of said article, wherein the cavity is adapted to form a planar inner face on the side wall of the article,
wherein the machine comprises a cutter to remove the bulge to give the side wall of the article a substantially constant thickness, said
cutter configured to cut the bulge so as to form an exterior face of the side wall of the article, and
a polisher configured to polish the exterior face.

US Pat. No. 10,392,286

VITRIFIED MATERIAL CONTROL SYSTEM AND METHOD

Plasma Tech Holdings, LLC...

1. A method for controlling the flow of hot vitrified material in a manufacturing process that uses a heating device comprising a heat source, a melt chamber, and a control plate extending into the hot vitrified material, the method comprising the following:operating the heat source to create hot vitrified material in the melt chamber;
applying a vacuum to an upper surface of the hot vitrified material to directly regulate a flow of the hot vitrified material from the melt chamber and out of the heating device; and
adjusting how far the control plate extends into the hot vitrified material.

US Pat. No. 10,392,285

SUBMERGED COMBUSTION MELTERS HAVING AN EXTENDED TREATMENT ZONE AND METHODS OF PRODUCING MOLTEN GLASS

Johns Manville, Denver, ...

1. A submerged combustion melter comprising:a floor, a roof, and a sidewall structure connecting the floor and roof defining an internal space, a first portion of the internal space comprising a melting zone, a second portion of the internal space defining a fining zone downstream of the melting zone, and a third portion of the internal space comprising a treating zone downstream of the melting zone and upstream of the fining zone, the treating zone comprising one or more apparatus configured to inject a treating composition into a molten mass of glass containing bubbles in the treating zone, the treating zone and the fining zone devoid of submerged combustion burners and other apparatus that would increase turbulence above that in the melting zone;
one or more combustion burners in either the floor, the roof, the sidewall structure, or any two or more of these, producing combustion gases and configured to emit the combustion gases from a position under a level of, and positioned to transfer heat to and produce, a turbulent molten mass of glass containing bubbles in the melting zone;
a skimmer having distal end adapted to extend to a point just above a level of molten mass of glass exiting the fining zone to hold back a portion of foam floating on the molten mass of glass flowing out of the fining zone;
the submerged combustion melter comprising a geometry whereby the level of the molten glass is substantially equivalent in the melting zone, the treatment zone, and the fining zone, wherein the floor in the melting zone is substantially horizontal and the floor in the fining zone is angled upward at an angle ? with respect to the substantially horizontal floor in the melting zone so that the floor in the fining zone is angled upward relative to horizontal beginning at an entrance to the fining zone and extending to an exit of the fining zone and rises uniformly from the depth of the substantially horizontal floor in the melting zone to a final depth that is at least 10 percent less than the depth of the substantially horizontal floor in the melting zone.

US Pat. No. 10,392,284

COMBUSTION METHOD FOR LOW VELOCITY REACTANT STREAMS

PRAXAIR TECHNOLOGY, INC.,...

1. A method of carrying out combustion in a furnace, comprising(A) combusting fuel in a furnace to produce gaseous combustion products; and
(B) alternately
(1) (i) passing a portion of the gaseous combustion products into and through a cooled first regenerator to heat the first regenerator and cool said portion of the gaseous combustion products,
(ii) passing at least part of said cooled portion of gaseous combustion products from said first regenerator, and fuel, into a heated second regenerator and, in the second regenerator, reacting the gaseous combustion products and the fuel in an endothermic reaction in the second regenerator to form syngas comprising hydrogen and CO,
(iii) passing said syngas formed in the second regenerator at a velocity less than 50 feet per second into a first duct having an outlet that is connected to the interior of the furnace,
(iv) injecting at least one stream of motive gas having a velocity of at least 100 feet per second from a nozzle in the first duct having an internal diameter D into the syngas in the first duct at an upstream distance L from the interior wall of the furnace wherein the mass flow rate of the motive gas injected into the syngas is less than 60% of the mass flow rate of the syngas into which the motive gas is injected,
under conditions such that the value of (L/D)×(N/R) is from 4 to 25, wherein N is the number of streams of motive gas injected into the syngas in the first duct and R is the ratio of the total mass flow rate of syngas passed into the first duct to the total mass flow rate of the stream, or all of the streams, of motive gas injected into the first duct, thereby entraining the syngas into the motive gas stream in the first duct and forming in the first duct at least one mixed stream comprising a mixture of the syngas and the motive gas and having a velocity greater than 50 feet per second, and
(v) passing said mixed stream at a velocity of greater than 50 feet per second from said first duct into said furnace and combusting the mixed stream with one or more oxidant streams injected into said furnace; and
(2) (i) passing a portion of the gaseous combustion products into and through a cooled second regenerator to heat the second regenerator and cool said portion of the gaseous combustion products,
(ii) passing at least part of said cooled portion of gaseous combustion products from said second regenerator, and fuel, into a heated first regenerator and, in the first regenerator, reacting the gaseous combustion products and the fuel in an endothermic reaction in the first regenerator to form syngas comprising hydrogen and CO,
(iii) passing said syngas formed in the first regenerator at a velocity less than 50 feet per second into a second duct having an outlet that is connected to the interior of the furnace,
(iv) injecting at least one stream of motive gas having a velocity of at least 100 feet per second from a nozzle in the duct having an internal diameter D into the syngas in the second duct at an upstream distance L from the interior wall of the furnace wherein the mass flow rate of the motive gas injected into the syngas is less than 60% of the mass flow rate of the syngas into which the motive gas is injected,
under conditions such that the value of (L/D)×(N/R) is from 4 to 25, wherein N is the number of streams of motive gas injected into the syngas in the second duct and R is the ratio of the total mass flow rate of syngas passed into the second duct to the total mass flow rate of the stream, or all of the streams, of motive gas injected into the second duct, thereby entraining the syngas into the motive gas stream in the second duct and forming in the second duct at least one mixed stream comprising a mixture of the syngas and the motive gas and having a velocity greater than 50 feet per second, and
(v) passing said mixed stream at a velocity of greater than 50 feet per second from said second duct into said furnace and combusting the mixed stream with one or more oxidant streams injected into said furnace.

US Pat. No. 10,392,283

METHOD AND APPARATUS FOR TREATING ACCOMPANIED WATER FROM A WELL

JFE ENGINEERING CORPORATI...

1. A method of treating accompanied water containing calcium ion, soluble silica, 10-1,000 mg/L carbonates, and sulfate ion produced from a well, the method comprising:a magnesium salt adding process, including adding a magnesium salt to mix with the accompanied water under alkaline conditions to precipitate insoluble silica, calcium carbonate, calcium sulfate, and produce a supernatant from which said insoluble silica and calcium sulfate have been precipitated having a pH of 10.5-11, in a first reaction solution;
a microfiltration membrane treatment process, including filtering said first reaction solution with a microfiltration membrane to separate the insoluble silica, calcium carbonate, and calcium sulfate, to generate a filtrate, and wherein carbonate ion concentration of the filtrate is 1 mg/L or less;
an acid adding process, including adding an acid to and mixing with said filtrate to render a pH value of said filtrate in the range from 5 to 9 and a negative Langeliar saturation index, to generate a second reaction solution; and
a reverse osmosis membrane treatment process, including treating said second reaction solution with a reverse osmosis membrane to obtain fresh water and reverse osmosis membrane concentrates.

US Pat. No. 10,392,282

METHOD AND APPARATUS FOR ELECTROCOAGULATION

1. An electrocoagulation apparatus for removing contaminants from water, the apparatus comprising:a tank having a first end, a second end and side walls extending between the first end and the second end;
a first plurality of electrolytic cells provided in the tank, the first plurality of electrolytic cells forming a first stage;
a second plurality of electrolytic cells provided in the tank, the second plurality of electrolytic cells forming a second stage;
a first baffle provided between the first end of the tank and the first plurality of electrolytic cells in the first stage, the first baffle positioned in the tank to direct water introduced into the tank at the first end through the electrolytic cells in the first stage;
a second baffle provided between the first plurality of electrolytic cells in the first stage and the second plurality of electrolytic cells in the second stage, the second baffle positioned to prevent water in the first stage that has not passed through at least one of the first plurality of electrolytic cells in the first stage from entering the second plurality of electrolytic cells in the second stage;
a voltage supply connected to each electrolytic cell, and
a blanketing system operative to monitor the amount of oxygen in the tank and injecting an inert gas into the tank when the oxygen reaches a predetermined level;
wherein each electrolytic cell comprises:
an enclosure; and
a plurality of substantially parallel spaced-apart electrode plates provided in the enclosure, each electrode plate oriented substantially parallel to the side walls,
wherein the enclosure surrounds the plurality of substantially parallel spaced apart electrode plates, and wherein an opening is provided in a bottom of each enclosure, the opening positioned above a bottom of the tank, and wherein a top of each enclosure is open,
wherein the voltage supply is connected across adjacent electrode plates to form anode/cathode electrode pairs,
wherein each electrode plate has a main body and a tab extending above a portion of the main body, and
wherein water entering the electrocoagulation apparatus at the first end will pass through the first baffle before passing through the first stage, then through the second baffle and then through the second stage before exiting the electrocoagulation apparatus at the second end.

US Pat. No. 10,392,281

MEANDER SEPTIC TANK

Orenco Systems Incorporat...

1. A septic tank for treatment of wastewater comprising:a. a substantially cylindrical enclosure including a curved wall defining an interior space;
b. a single baffle in said space, said baffle substantially dividing said space into first and second elongate chambers, each of said first and second chambers including a first end and a second end substantially defined by said baffle and said wall, said baffle further including a portal near said second end of said first chamber to permit wastewater to pass between said first chamber and said second chamber;
c. a wastewater inlet to said tank located near said first end of said first chamber;
d. a wastewater outlet from said tank in said second chamber;
e. wherein said enclosure has a substantially circular floor.

US Pat. No. 10,392,279

EDUCTOR-BASED MEMBRANE BIOREACTOR

Scientific Associates, G...

1. A process for treating domestic wastewater comprising:directing wastewater into a tank containing a membrane filter and mixed liquor;
recirculating wastewater and mixed liquor from a top end of the tank into a bottom end of the tank via a recirculation conduit;
introducing a flow of recirculated wastewater and mixed liquor from the top end of the tank into a mixing channel of an aeration device disposed in the tank via the recirculation conduit;
drawing ambient air into the mixing channel of the aeration device using the flow of recirculated wastewater and mixed liquor from the recirculation conduit;
drawing wastewater and mixed liquor proximately surrounding the aeration device into the mixing channel of the aeration device using the flow of recirculated wastewater and mixed liquor from the recirculation conduit; and
generating bubbles in the mixing channel with the drawn wastewater, the recirculated wastewater, the drawn mixed liquor, and the drawn ambient air below the membrane filter.

US Pat. No. 10,392,278

LEACH FIELD SYSTEM

33. A wastewater system comprising:a first set of high aspect ratio channels, each of the channels in the first set of high aspect ratio channels comprising an infiltrative side, an upper boundary, an infiltrative bottom, and having a height and a width;
a first separation spacer having a length and engaged to a first anchor, the first anchor securing the first separation spacer to a first high aspect ratio channel of the first set of high aspect ratio channels, at least a portion of the length of the first separation spacer spanning a distance between a first pair of high aspect ratio channels of the first set of high aspect ratio channels;
a second separation spacer having a length and engaged to a second anchor, the second anchor securing the second separation spacer to a second high aspect ratio channel of the first set of high aspect ratio channels, at least a portion of the length of the second separation spacer spanning a distance between a second pair of high aspect ratio channels of the first set of high aspect ratio channels; and
a distribution conduit positioned and configured to dispense wastewater effluent to each of the high aspect ratio channels in the first set of high aspect ratio channels,
wherein the distribution conduit does not cover the entirety of the upper boundary of three or more high aspect ratio channels in the first set of high aspect ratio channels,
wherein each of the high aspect ratio channels in the first set of high aspect ratio channels is parallel or substantially parallel to each other and has a height to width aspect ratio of 96 or 3 or between 96 and 3,
wherein three or more adjacent high aspect ratio channels in the first set of high aspect ratio channels are spaced two inches or more apart,
wherein the first separation spacer is positioned a distance apart from the second separation spacer,
and wherein the first anchor engages the infiltrative side of the first high aspect ratio channel and the second anchor engages the infiltrative side of the second high aspect ratio channel.